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I 
ZUSAMMENFASSUNG 
Influenza Viren stellen eine große Bedrohung der öffentlichen Gesundheit dar, die mit hoher 
Morbidität und Mortalität besonders in Kindern und älteren Menschen assoziiert ist. Zudem 
verursacht die Erkrankung beträchtliche sozio-ökonomische Kosten. Die saisonale 
Grippeschutzimpfung induziert eine neutralisierende Antikörperantwort, welche sich gegen 
antigene Bereiche im Kopfbereich des viralen Oberflächenproteins Hämagglutinin (HA) richtet. 
In diesen Bereichen tritt jedoch verstärkt Antigendrift auf, wodurch die Effektivität der saisonalen 
Grippeimpfung auf den Impfstamm beschränkt wird, während keine ausreichende Schutzwirkung 
gegenüber viralen Driftvarianten oder neu entstehenden pandemischen und zoonotischen Viren 
besteht. Eine effektivere und breit reaktive oder sogar universelle Grippeimpfung wird daher 
dringend benötigt. 
Die Entdeckung breit reaktiver Antikörper gegen konservierte Bereiche, wie dem HA-
Stammbereich, hat die Erforschung von Impfstrategien vorangetrieben, mit deren Hilfe gezielt 
breit reaktive Antikörper induziert werden können. Chimären HA oder Headless HA erzielten in 
diesem Zusammenhang bereits vielversprechende Ergebnisse. Beide Antigenkonzepte beruhen 
dabei auf dem Prinzip des Ausschlusses der immundominanten, jedoch hoch variablen Regionen 
im HA-Kopfbereich, um eine Fokussierung der Immunantwort auf immunsubdominante, aber 
konservierte Bereiche im HA-Stammbereich zu erzielen. Zudem bergen innovative 
Impfstoffplattformen, wie zum Beispiel Adeno-assoziierte Virus (AAV)-Vektoren, ein immenses 
Potenzial. AAV-Vektoren können in Zellkultur hergestellt werden, sie können ohne die 
Verwendung von Nadeln intranasal verabreicht werden und sind für die Verwendung im 
Menschen zugelassen. Zudem wird die Immunogenität des Antigens durch die AAV-Vektor 
vermittelte Expression, welche der Antigenexpression im Verlauf einer natürlichen Influenza 
Virus Infektion gleicht, positiv beeinflusst. 
In der vorliegenden Arbeit führte die Immunisierung mit AAV-Vektoren, die wildtypisches 
HA, Chimäre HA oder Nukleoprotein exprimieren, zur Induktion breit reaktiver Antikörper in 
Mäusen, nicht aber die Immunisierung mit Headless HA exprimierenden AAV-Vektoren oder 
inaktiviertem Grippeimpfstoff. Die Schutzwirkung ging einher mit der Fähigkeit der AAV-Vektor 
Impfstoffe FcγR-aktivierende Antikörper zu induzieren, wodurch in der Maus vermutlich FcyR-
vermittelte Effektormechanismen wie zum Beispiel Antikörper vermittelte zelluläre Zytotoxizität 
ausgelöst wurden, die zum Schutz der Tiere gegenüber einer Influenza führten. Interessanterweise 
löste nicht nur die AAV-vektor vermittelte Impfung mit Chimären HA, sondern auch mit 
wildtypischem HA eine Antikörperantwort gegen den HA-Stammbereich aus. Dies deutet darauf 
hin, dass die Immundominanz des HA-Kopfbereiches allein durch die AAV-Vektor vermittelt 
Expression des Antigens abgemildert werden konnte. Abschließend konnte zum ersten Mal die 
Schutzwirkung einer AAV-Vektor Immunisierung gegen HA im Frettchen demonstriert werden. 
Die in dieser Arbeit beschriebenen Ergebnisse zeigen somit das große Potenzial von AAV-
Vektoren als Impfvehikel für eine breit reaktive Grippeschutzimpfung auf. 
II 
SUMMARY 
Influenza viruses represent a severe threat to public health, associated with high morbidity and 
mortality especially in children and the elderly. Moreover, the disease is associated with 
substantial socio-economic costs. A seasonal vaccine is available, which readily leads to the 
induction of neutralizing antibodies against antigenic sites in the head domain of the viral surface 
protein hemagglutinin (HA). These antigenic sites are, however, prone to antigenic drift. 
Therefore, seasonal vaccination induces only strain specific protection, while it is not effective 
against drifted seasonal virus strains and emerging pandemic or zoonotic viruses. Hence, there is 
an urgent need for a more effective and broader reactive or even universal influenza vaccine. 
The discovery of broadly reactive antibodies against highly conserver regions such as the HA-
stalk domain has prompted a great interest into research on vaccination strategies to induce 
broadly protective HA antibodies. Concepts such as chimeric HA and headless HA have been 
developed, which show promising results with respect to the induction of protective HA-stalk 
antibodies. Both antigen concepts rely on the principle of avoiding immunodominant but strain 
specific epitopes to re-focus immunity towards conserved but immunosubdominant epitopes in 
the HA-stalk. Aside from rational antigen development, also innovative vaccine delivery platforms 
such as Adeno-associated virus (AAV)-vectors offer an attractive developmental perspective. 
AAV-vectors can be readily manufactured in cell culture, they can be applied without needles into 
the nose, and the vector system is licensed for use in humans. Furthermore, AAV-vectored 
antigen expression, which resembles antigen processing as it occurs during natural infection with 
influenza virus, will likely positively influence the immunogenicity of the antigen. 
In this thesis, it could be shown that only immunization with AAV-vectors expressing wildtype 
HA, chimeric HA or nucleoprotein induced broad protection in mice, but not vaccination with 
AAV-vectors expressing headless HA or an inactivated influenza vaccine. Intriguingly, protection 
was associated with the ability of the AAV-vectored vaccines to potently induce FcγR-activating 
antibodies, indicating that protection is mediated by FcγR-mediated effector mechanisms such as 
antibody-dependent cellular cytotoxicity. Surprisingly, not only chimeric HA but also wildtype 
HA induced antibodies against the HA-stalk when expressed from an AAV-vector, suggesting 
that AAV-vectored antigen expression can mitigate the immunodominance of virus strain-
specific epitopes in the HA-head. Importantly, for the first time a protective effect AAV-vectored 
immunization towards HA could be shown in ferrets. Thus, results described in this thesis suggest 
a large potential for the development of AAV-vectors as carriers for a broadly protective influenza 
vaccine. 
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1. INTRODUCTION
 INFLUENZA VIRUSES  1.1.
 GENERAL INTRODUCTION 1.1.1.
Influenza viruses are negative sensed, single stranded 
RNA viruses with a segmented genome, which belong to 
the family of Orthomyxoviridae (1). Within the influenza 
viruses, only the genera A, B and C are able to infect 
humans. A fourth genus, influenza D viruses, is 
connected to infections in cattle and pigs (2). Influenza A 
viruses show a very broad host range, covering several 
avian and mammalian species, while influenza B virus 
infections are mainly restricted to humans with 
occasional outbreaks in marine mammals (3, 4). 
Influenza A viruses are further subtyped according to the 
combination of their surface proteins hemagglutinin 
(HA) and neuraminidase (NA) (e.g. H1N1). To date, 18 
HA (H1 – H18) and 11 NA (N1 – N11) subtypes have 
been antigenically differentiated, with intra- and 
intersubtype sequence variations of HA of up to 20 % or 
30 – 70 %, respectively (5-7) (Figure 1). However, only 
the subtypes H1N1, H2N2, H3N2, H5N1, H5N6, H6N1, H7N7, H7N9, H9N2, and H10N7 have 
been reported to infect humans (8, 9) (Figure 2). Additionally, influenza A viruses are divided into 
group 1 and group 2 viruses based on the HA amino acid sequence (Figure 1). Influenza B viruses 
are sub-classified into lineages, whereas viruses circulating in humans belong to the Yamagata or 
Victoria lineage that diverged from each other in the 1920s. 
Influenza A and B viruses cause recurrent epidemics of respiratory illness in humans, i.e. 
the “flu season”, whereas influenza C virus infections generally occur during childhood and cause 
only mild disease (10). For temperate climate areas the epidemic season starts in November and 
ends in March. Seasonal influenza viruses are directly transmitted from person to person via 
aerosols produced during coughing and sneezing or by contact with contaminated surfaces and 
fomites (9). Replication of seasonal influenza viruses takes place mainly in ciliated cells of trachea 
and bronchi, but attachment to alveolar type II pneumocytes, alveolar macrophages and dendritic 
cells in the lower respiratory tract may occur (11, 12). After an incubation period of one to two 
days, typical influenza disease, i.e. “the flu”, is characterized by a sudden onset of high fever in 
combination with cough, head- and general aches, chills, fatigue, sore throat or sneezing (13). 
Usually, symptoms last no longer than one to two weeks before people recover without need for 
medical attendance (9). However, complications such as pneumonia, bronchitis, sinusitis and 
otitis may occur, which can be life-threatening. 
Figure 1: Phylogenetic tree of Influenza A 
virus HA 
Influenza A virus HA are divided into two 
groups based on their amino acid sequences 
(Group 1 and Group 2). Influenza A virus 
subtypes that have been circulating in 
humans (filled rectangles) and such with 
pandemic potential (empty rectangles) are 
marked. (modified from Wu et al., Trends 
Microbiol (2014)) 
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The annual global attack rate is estimated to be 5 – 10 % in adults and 20 – 30 % in children. 
The viral infection causes annually three to five million cases of severe illness, 290 000 to 650 000 
of which become fatal. Persons at highest risk for complications are pregnant women, children at 
the age of 6 – 59 months, the elderly (≥69 years) and health care workers. Additionally, influenza 
can exacerbate chronic health conditions such as asthma, immune deficiencies or chronic 
cardiopulmonary diseases (9). The resulting economic costs for health systems and due to loss of 
productivity in the population are substantial (14). 
Morbidity and mortality can even increase dramatically in case of pandemics, which occur in 
non-predictable, irregular intervals when a virus undergoes major antigenic changes and is 
introduced into a population which is immunologically naïve to it (15, 16). One of the most 
prominent examples is the 1918 H1N1 pandemic, the so called “Spanish flu”, which is estimated 
to have caused up to 50 million deaths worldwide (17) (Figure 2). A related virus caused the most 
recent pandemic in 2009 (“Swine Flu”) (15). 
Since the end of the last century an increasing number of direct zoonotic transmissions of 
avian influenza viruses to humans have been reported (18). The severity of the disease ranges from 
mild to very aggressive depending on the infecting virus subtype (8). With H5N1 viruses for 
instance a mortality rate of about 50 % is reported, which is much higher than for seasonal 
influenza viruses (18). Although being hardly transmissible from human to human, there is 
potential for avian influenza viruses to acquire mutations enabling them for direct human to 
human transmission which increases their pandemic potential (19-21). The constant threat of 
seasonal and pandemic influenza viruses as well as emerging zoonotic strains emphasizes the 
urgent need for more effective prophylactic and therapeutic countermeasures, which is 
antagonized by the ever changing nature of the virus. 
Figure 2: Influenza A viruses circulating in the human population 
Viruses of three HA (H1, H2 and H3) and two NA (N1 and N2) subtypes circulated in humans during the last century. 
Four pandemic viruses emerged, replacing the by that time circulating subtypes: The H1N1 pandemic virus in 1918-
1919 (“Spanish Flu”, 50 million deaths), the H2N2 pandemic virus in 1957 (“Asian Flu”, 1.1 million deaths), the H3N2 
pandemic virus in 1968 (“Hong Kong flu”, 1.0 million deaths) and most recently, the H1N1 pandemic virus in 2009 
(“Swine flu”, 0.5 million deaths). In 1977 a virus related to the H1N1 virus from 1950 re-emerged (“Russian flu”). At the 
moment, viruses of the subtypes H3N2 and H1N1 are circulating in humans. (modified from Palese, Nat Med (2004)) 
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 MORPHOLOGY 1.1.2.
Influenza A virions are spherical or pleomorphic particles with diameters of 80 – 120 nm 
(spherical) to more than 300 nm (filamentous). The virion envelope is derived from the host cell 
lipid membrane and harbors three viral membrane proteins (22): Hemagglutinin (HA) and 
neuraminidase (NA), which form characteristic spikes that project about 10 – 14 nm from the 
membrane, and matrix protein 2 (M2) (Figure 3). HA is the most abundant of the membrane 
proteins, being 4–times more abundant than NA and 10–100 – times more than M2 (23). 
The interior of the envelope is lined by matrix protein 1 (M1) and contains the 
ribonucleoprotein (RNP) complexes (24). These comprise the viral (v)RNA segments, the 
nucleoprotein (NP), and the viral RNA-dependent-RNA-polymerase (RdRp) complex, which 
consists of the subunits polymerase acid (PA), polymerase basic 1 (PB1) and polymerase basic 2 
(PB2) (25). 
Figure 3: Morphology of influenza A virus particles 
(A) Schematic drawing of an influenza A virus particle. Hemagglutinin (HA), Neuraminidase (NA) and M2 protein are
embedded into the host cell derived lipid membrane. The Matrix protein (M1) lines the inner side of the envelope.
Within the particle, accessory proteins NS1 and NEP/NS2 as well as the viral RNP complexes are located. The RNP
complexes consist of one of the eight viral RNA segments, the Nucleoprotein (NP) and the RdRp-complex (PB1, PB2
and PA). (B) Negative stain transmission electron micrograph of A/California/7/2009 (H1N1)pdm influenza virus.
(Courtesy of Gudrun Holland and Norbert Bannert (RKI), 85.000 x magnifications, false color) 
Table 1: Proteome of influenza A viruses 
Proteins are categorized as membrane, internal or non-structural virion protein. Not all of the accessory proteins are 
expressed by all influenza isolates and the function or existence of some has yet to be determined. (modified from 
Vasin et al., Virus Res (2014)) 
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Also, the accessory nonstructural protein 1 (NS1) and nuclear export protein/nonstructural 
protein 2 (NEP/NS2) were shown to be part of the virion (26) (Figure 3). The individual RNP 
display double-helical rod-like structures of about 50 – 150 nm in length (24, 27). The eight vRNA 
are approximately 890-2350 nucleotides in length, whereas the coding region is flanked by non-
coding regions that contain the regulatory sequences needed for transcription and replication (28-
31). Influenza A viruses increase their coding capacity by ribosomal leaky scanning and open 
reading frame shifting (e.g. PB1 or PA segment) or alternative splicing (e.g. M1, M2 and NS 
segment), which eventually results in the expression of a minimum of ten proteins (32-37) (Table 
1). 
 REPLICATION 1.1.3.
Attachment of influenza viruses to the host 
cell is mediated by binding of HA on the viral 
surface to its receptor on the cell membrane: 
glycoproteins or glycolipids that carry a terminal 
N-acetylneuraminic (sialic) acid (38-41). Hence,
the receptor is ubiquitously expressed in many
animal species. Avian and human influenza
viruses preferentially target sialic acid that is
linked to a penultimate galactose residue either
via α(2,3)-linkage or α(2,6)-linkage, respectively
(42-46). Corresponding to the fact that influenza 
is a respiratory or enteric infection in humans or 
avian species, respectively, in humans α(2,6)-
linked sialic acid predominate the respiratory 
tract, while α(2,3)-linkage is most common in 
the avian intestine (11). The receptor-specificity 
depends on amino acids at several positions within the receptor binding site (RBS) of HA (47-50) 
(Figure 4). The preference for different conformations of the receptor contributes to the species 
specificity of human and avian influenza viruses. An increased relative abundance of α(2,3)-linked 
sialic acid in the human lower respiratory tract can partially explain the ability of avian viruses to 
infect humans with very low efficiency, but cause high lung pathology at the same time (51). 
However, amino acid changes in the RBS that alter the receptor-specificity may be a prerequisite 
for efficient infection and spread of avian viruses after transmission to humans (52, 53).  
After attachment of HA to the receptor, clathrin-mediated endocytosis is triggered and the 
virus is taken up into the cell (54). Also, HA is responsible for fusion of the viral and host cell 
membrane resulting in escape of the RNP complexes from the endosome into the cytoplasm. To 
become fusogenic each monomer of the trimeric HA has to be cleaved from the precursor protein 
HA0 into the subunits HA1 and HA2 (Figure 5, A and B). Although leaving the overall HA 
conformation quite unchanged, cleavage generates a metastable state of HA, with the newly 
formed positively charged N-terminus of HA2, the so called fusion peptide, being buried in a 
Figure 4: Structure of trimeric HA and the receptor
binding site 
(A) Three dimensional structure of HA. Glycan residues
(green) on HA1 (red) and HA2 (blue) are depicted. 
Position of the head and stalk domain is indicated (B) 
Magnification of the RBS with main structural features 
130 loop, 190 helix and 220 loop. The receptor analogue 
LSTc is depicted (yellow). (PDB: 3UBE) 
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cavity within the HA monomer (55) (Figure 5B). Acidification to a pH of about 5 - 6 triggers an 
irreversible conformational change (56): Re-folding of HA results in exposition of the fusion 
peptide and its approximation towards the endosomal membrane, in which it is ultimately 
inserted (Figure 5C). HA, now being anchored via HA2 into both the viral and the cellular 
membrane, undergoes further rearrangement steps that bend the molecule in half and allow the 
two membranes to come into close proximity and eventually fuse, resulting in formation of a pore 
through which the RNP complexes escape into the cytoplasm (57-60) (Figure 5, C and D). 
Before release of the RNP into the cytoplasm, protons have to enter the viral particle through 
the pH-gated M2 ion channel, which results in the disruption of interactions of M1 with the RNP 
(61, 62). For transcription and replication, the RNP complexes are transported into the nucleus 
through interactions of cellular importins with the nuclear localization signals within NP and the 
RdRp (63). Within the nucleus, the RdRp transcribes mRNA carrying a 5’–cap and a Poly(A) tail 
from the vRNA segments. Transcription is initiated on a 5’–capped primer which is cleaved from 
cellular pre-mRNA (so called “cap snatching”) (64, 65). Unlike cellular mRNA, influenza viral 
mRNA are polyadenylated by reiterative copying of a polyuracil stretch within the vRNA (66, 67). 
Hereafter, mRNA are exported from the nucleus and translated by the cellular translation 
machinery (68). Proteins harboring nuclear localization signals (e.g. NP or polymerase subunits) 
are subsequently transported into the nucleus (69). Membrane proteins are translated at the rough 
endoplasmic reticulum, trafficked to the Golgi apparatus and sorted to cholesterol-rich lipid rafts 
at the apical plasma membrane (70). 
Figure 5: Conformations of HA 
during the fusion process 
(A) Structure of the uncleaved HA
precursor, HA0 (only one
monomer is shown). The position
of the C- and N-terminus is
indicated (blue/red circles). In the
uncleaved molecule, the cleavage
site (yellow) is projecting from
surface of the structure forming a 
loop between HA1 (red) and HA2
(blue). (B) Matured HA with
cleaved HA1 and HA2 subunit.
The newly generated C- and N-
termini are indicated (circels: N1 
and C1 of HA1 red; N2 and C2 of
HA2 blue). The fusion peptide is
located at the N-terminus of HA2
(N2). (C) At fusion pH,
conformational changes in HA2
lead to repositioning of the fusion 
peptide towards the cellular
membrane while the RBS domain
in HA1 is preserved. (D) Schematic 
representation of the
conformational changes during
fusion. HA2 alone is shown in the 
right three panels (PDB structures: 
1RD8, 1RU7, 1HTM, 2VIR).
(modified from Hughson, Curr Biol 
(1997); Bullogh, Nat (1994)) 
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During this process, the proteins are correctly folded and monomers are assembled to their 
oligomeric forms, e.g. three HA monomers form a trimer (Table 1) (71). Additionally, post-
translational modifications occur, such as addition of several glycosylations and palmitoylations to 
HA (Figure 4) (72-74). 
Eventually, a switch from transcription to synthesis of full length complementary (c)RNA 
occurs, which in turn serve as templates for the replication of the genomic vRNA segments (75-
77). The newly formed RNP complexes are exported from the nucleus through an interaction with 
M1 and NEP/NS2 and transported to the apical site of the cell (69, 78, 79). The viral components 
assemble at the lipid raft domains and the virus particles bud from the plasma membrane (80). 
During this process, a selective packaging mechanism ensures that particles contain all eight RNP 
complexes (81). Because HA binds to sialic acids on the host cell surface also during budding, 
NA’s sialidase activity is needed to finally release the progeny virions from the cell surface (82-84). 
For the virus to become infective, HA0 has to be cleaved into HA1 and HA2, as mentioned above. 
For most HA subtypes that contain a single arginine in their cleavage site (Q/E-X-R), this process 
is mediated by proteases expressed by influenza viruses target cells in the human respiratory tract 
such as Clara, HAT or TMPRSS2 (85-87). However, some HA of the subtypes H5 and H7 contain 
a polybasic cleavage site (R-X-R/K-R) (88). The proteases responsible for cleavage of these HA, i.e. 
subtilisin-like proteases such as furin, show very wide tissue distribution, which might be related 
to the systemic and highly virulent courses of infection seen with these viruses (89, 90) (see 1.1.1). 
 IMMUNITY TO INFLUENZA VIRUSES 1.2.
 GENERALITIES ON CELLS AND MECHANISMS INVOLVED IN AN IMMUNE RESPONSE 1.2.1.
Breathing not only enables gas exchange which is vital for life, but also constantly exposes the 
respiratory tract to a large number of pathogens. To fight intruders, the human body is equipped 
with sophisticated defense mechanisms: the immune system.  
The first physical barrier to pathogens is the mucociliary epithelium of the respiratory tract. If 
viruses circumvent this barrier, epithelial and endothelial cells as well as lung resident innate 
immune cells including dendritic cells (DC) and alveolar macrophages represent the first line of 
defense (91). Influenza virus triggers an intrinsic response by activation of pattern recognition 
receptors, i.e. Toll-like-, RIG-I-like-, and NOD-like-receptors, which recognize “non-self” 
pathogen-associated molecular patterns, such as viral single stranded RNA (92). This response 
induces the production of antiviral and inflammatory cytokines, including type I interferon (IFN) 
and TNFα, leading to recruitment and activation of further innate immune effector cells (91). The 
production of IFN-stimulated gene products counteracts the infection by establishment of an 
antiviral state in infected as well as neighboring non-infected cells. Also, damage-associated 
molecular patterns, e.g. extracellular mitochondrial DNA, can activate innate cells (93). The 
complement system can inhibit influenza virus through direct lysis or activation of innate cells as 
well (94). Alveolar macrophages as well as monocytes and neutrophils which enter the site of 
infection from the blood stream become activated and phagocytose pathogens as well as debris of 
infected cells, or produce antimicrobial molecules (e.g. reactive oxygen species) (95, 96). Natural 
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killer cells (NK cells) are able to recognize infected cells and are equipped with several 
mechanisms to eliminate them (perforin/granzyme pathway or FasL/Fas interaction) (97).  
By bridging innate and adaptive immunity, DC represent the most important professional 
antigen presenting cells (APC) besides macrophages and B-cells (98). APC, like all other nucleated 
cells, present endogenously produced peptide antigen on MHC class I molecules (MHCI) on their 
surface. In addition, they express MHC class II molecules (MHCII) allowing them to present 
exogenously acquired peptide antigens, too (99). Moreover, some APC are able to present 
exogenous antigen on MHCI, so called ‘cross presentation’, and vice versa, also presentation of 
endogenous antigen on MHCII plays a role during influenza virus infection (100, 101). DC take 
up antigen via endocytosis of viral products or debris of infected cells, by direct infection or by 
trogocytosis (102). The abundance, accessibility and mode of presentation of the antigen will 
likely define the outcome of the immune response (103). After antigen uptake, DC home to 
draining lymph nodes where they present the antigen to naïve, antigen-specific T-cells. Following 
engagement of the antigen-MHC complex with the T-cell receptor in the presence of co-
stimulatory signals, T-cells clonally expand, acquire a specific set of effector functions and migrate 
to the site of infection (99). Different subsets of lung resident DC (CD103+, CD11b+, pDC) were 
shown to preferentially activate different T-cell subsets during influenza infection (97, 102). 
CD8+ T-cells differentiate into cytotoxic T lymphocytes (CTL) after recognition of antigen-
MHCI complexes. CTL are the primary cell type eliminating influenza virus infected cells via 
induction of apoptosis (perforin/granzyme pathway; FasL/Fas interaction, TRAIL mediated) and 
secretion of pro-inflammatory cytokines (104). Interestingly, CD8+ T-cells also play a role in 
regulating the immune response at the end of the infection (105). Influenza virus-specific CTL can 
be found in all individuals older than 15 years of age, with the dominant proportion being specific 
for epitopes in internal virion proteins such as NP and M1 (106, 107).  
Recognition of antigen-MHCII complexes by CD4+ T-cells induces their differentiation into 
several functionally different effector cell types. These stimulate, modulate or regulate the immune 
response (“helper cells”). Among these, TH1 cells bias the immune response towards inflammation 
and stimulate the maturation of CTL (99). Influenza virus infection is generally associated with a 
strong TH1-type response. Though being non-essential for their primary activation, the 
establishment of an efficient CTL memory is also strongly dependent on CD4+ T-cell help (108). 
Interestingly, cytotoxic CD4+ T-cell can also directly eliminate influenza virus infected lung 
epithelial cells (109). In contrast to that, TH2 cells and particularly T follicular helper (TFH) cells in 
the lymphoid organs promote the production of antibodies by inducing maturation of B-cells and 
antibody class switch (110). Another helper cell subset, TH17 cells, can promote clearing of the 
infection by enhancing CTL and B-cell responses, while TReg cells where shown to limit CD8+ T-
cell effector functions, thus, preventing immunopathology (109, 111).  
After clearance of the infection, the effector T-cell pools contract and long lived memory T-
cells remain. Memory cells re-activate their effector functions more rapidly and potently 
compared to naïve cells (112). Moreover, their localization not only to lymphoid organs (central 
memory T-cell, TCM) but to the site of infection (effector memory T-cells, TEM; resident memory 
Introduction 
8 
T-cell, TRM) accelerates their response. Particularly lung TRM cells were found to confer long lasting
protection against influenza virus infection (113).
B-cells can recognize not only peptide-MHC complexes but also linear or conformational
epitopes in proteins (99). Interestingly, while influenza virus surface antigens, e.g. HA, are 
considered to be primary inducers of a humoral response, also antibodies against internal antigens 
such as NP can be induced during infection (114, 115). Upon recognition, B-cells endocytose their 
antigen and present peptide-MHCII complexes to antigen specific, activated CD4+ T-cells (i.e. TFH 
cells) in the draining lymph nodes. The interaction of B and T-cell leads to proliferation of the B-
cell and differentiation into antibody secreting plasma cells that leave the lymphoid organ. Some 
B-cells reside in the lymphoid tissue and, promoted by TFH cells, increase their effectivity and
functionality by affinity maturation and antibody class switch (see 1.2.2) (116). As with T-cells, a
B-cell memory is established after clearance of the infection which can be recalled within hours
after second exposure (116). For influenza virus infections also CD4+ T-cell independent
activation of B-cells was described, although efficient B-cell memory relies on CD4+ T-cell help
(117).
Adequately balanced cellular and humoral immune responses can efficiently clear the 
infection. However, a misregulated response may lead to immunopathology (118). Furthermore, 
though establishment of a memory T and B-cell response makes vaccination possible in the first 
place, it can also lead to immunopathology if not considered cautiously during a vaccine’s design 
process (118, 119).  
 STRUCTURE AND FUNCTIONS OF ANTIBODY MOLECULES 1.2.2.
To react and adapt to the immense number of different pathogens which infect the organism 
during life time, the immune system is able to generate a nearly unlimited, highly variable 
repertoire of antigen specific antibody molecules. The antibody molecule (ca. 150 kDa) consists of 
two identical heavy (50 kDa) and two identical light (25 kDa) chains, which are linked to each 
other via disulfide bonds (99) (Figure 6). The heavy and light chains consist of four or two 
immunoglobulin (Ig) domains, respectively. Each Ig domain is composed of several β-sheets 
arranged in a characteristic β-barrel. Antigen binding occurs at a highly variable region in the first 
Ig domain of the molecule (variable region: VH or VL). Due to the β-barrel arrangement, the 
antigen binding site is formed by highly variable loops at the tip of the antibody molecule, the so 
called complementarity determining regions (CDR). Each antibody molecule contains three CDR 
loops of the light (CDRL1-3) and three of the heavy chain (CDRH1-3). The adjacent Ig domains are 
more conserved (constant region: CH1-3 or CL). A second function of antibodies besides antigen 
binding is the activation of other cells and mediators of the immune system. Activation of these 
effector functions is mediated by the C-terminal Fc region of the antibody. Whereas the VL / VH, 
CL / CH1 and CH3 / CH3 are associated with each other, there is no such connection due to the 
presence of carbohydrates moieties at the interface of the two CH2 domains (120). 
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The human immune system produces about 1011 antibody specificities at a given time, which 
might be an underestimate being limited by the absolute number of B-cells. This immense 
diversity is achieved through several mechanisms such as i) random joining of V(D)J segments 
during B-cell maturation via somatic recombination within the genome loci coding for the 
variable region, ii) unspecific insertion of nucleotides during this process (i.e. junctional 
diversity), iii) random combination of heavy and light chains with different variable regions in 
one antibody molecule and iv) somatic hypermutation of the variable region after B-cell activation 
and selection for high affinity antibodies (affinity maturation) (121-124). In addition to 
mechanisms affecting the binding specificity, also the constant region of the heavy chain is 
variable: A recombination event within the activated B-cell switches the expressed heavy chain 
constant region gene segment (µ, δ, γ, ε  or α) and thereby the antibody’s isotype (IgM, IgD, IgG, 
IgE or IgA) (99). Antibody isotypes show differential spatial and temporal appearance: after 
primary infection IgM molecules dominate the immune response. Later, IgG molecules are 
produced and become the most abundant isotype in the serum. Furthermore, IgA play a pivotal 
role during infections with respiratory pathogens like influenza virus due to presence in the 
mucosa of the respiratory tract (125). The antibody isotypes are specialized in different effector 
functions such as neutralization, opsonization, complement activation as well as activation of 
other immune effector cells. In part, these differences are accounted for by varying affinities of the 
antibody isotype’s Fc region for Fc-gamma receptors (FcγR) on immune cells. 
 FC-GAMMA RECEPTORS 1.2.3.
FcγR are expressed on a variety of leukocyte populations, including NK cells, macrophages, 
monocytes, neutrophils, basophils and mast cells (126). Interestingly, DC and B-cells do express 
FcγR, indicating their role in shaping adaptive cellular and humoral immunity as well (120). Based 
on the stoichiometry and mode of binding, FcγR are classified into type I and type II receptors 
(Figure 7) (127). Type I FcγR vary with respect to their potential to activate different downstream 
signaling cascades and their affinity for IgG isotypes (Figure 7A). They are, therefore, categorized 
into activating (human: FcγRI, IIA, IIC, IIIA, IIIB; mouse: FcγRI, III, IV) and inhibitory 
Figure 6: Structure of a classical antibody molecule 
(A) Three dimensional structure of an IgG2a molecule showing Ig domains of light (green and red) and heavy (grey
and blue) chains (PDB: 1IGT). (B) Schematic drawing of an Ig molecule. The position of the antigen binding site within 
the variable region of the antibody (VL and VH) is indicated. The constant region (CL and CH1-3) makes up the ‘stalk’ of 
the Y-shaped antibody, which is also called the Fc region (CH2 and 3) (color coding as in (a)). 
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(human/mouse: FcγRIIB) type I FcγR (128). While most cells co-express activating and inhibitory 
type I FcγR, NK cells and B-cells express only one activating or inhibitory receptor at a time, 
respectively. Although type I FcγR subclass members were shown to bind several IgG isotypes in 
vitro, there is evidence that in vivo binding is more restricted to individual IgG isotypes (120). 
The type I receptor molecule consists of two or three IgG-like domains (D1-D3) (Figure 7A). 
Type I FcγR signaling is, with the exception of the GPI-linked FcγRIIIB, initiated at ITAM 
(activating) or ITIM (inhibitory) domains within the ligand-binding domain (FcγRIIA, FcγRIIC 
and FcγRIIB) or within the associated adaptor molecule (e.g. FcR γ chain, FcγRI, FcγRIIIA) (126) 
(Figure 7A). Phosphorylation of ITAM or ITIM domains triggers Ca2+-dependent or MAP-
kinase-signal transduction cascades, eventually resulting in activation of a multitude of cellular 
effector functions, resulting in activation, regulation, and modulation of immune responses (see 
below) (120). 
Signaling triggered by type II FcγR is less well defined compared to type I receptor signaling, 
but results in activation of several effector functions, too, interestingly including upregulation of 
type I FcγR surface expression (129). Intriguingly, structural analysis revealed that type I FcγR 
bind to the interface between the two heavy chains of the Fc part, thereby precluding binding of a 
second FcγR to the same antibody molecule (Figure 7C) (130, 131). Thus, only immune 
complexes in which multiple antibody molecules are present can efficiently crosslink and activate 
type I FcγR (132). In contrast, type II FcyR bind a region between CH2 and CH3 on each heavy 
chain, thus allowing binding of two receptor molecules to one antibody molecule at a time (Figure 
7C) (127). The Fc region can adapt two conformations depending on the glycosylation status of 
CH2, rendering the binding of type I and type II receptors to on antibody molecule mutually 
exclusive (Figure 7C) (133). In fact, it was shown that Fc glycosylation patterns change 
dynamically after immunization with an inactivated influenza vaccine (129). Selection of high 
affinity B-cell receptors (BCR) was augmented after engagement of type II FcγR on B-cells, 
Figure 7: Human type I and type II Fcγ-receptors 
(A) Type I FcγR are related to the Ig-receptor superfamily and categorized into activating and inhibitory receptors
according to the signaling cascades they initiate. (B) Type II FcγR belong to the C-type lectin receptor family. (C) 
Binding of type I and type II receptors to the Fc region is mutually exclusive and regulated by differential
glycosylation of CH2, altering the conformation of the Fc region. Thereby, further diversification of the functional
effector response is enabled. (adapted from Pincetic et al., Nat Rev Immunol (2014); Bruhns, Blood (2012)) 
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followed by upregulation and engagement of the inhibitory type I FcγRIIB, which eventually 
raised the threshold for BCR activation (129). Thus, further diversification and regulation of the 
effector immune response is enabled (129, 134). Also, Fc glycoengineering, i.e. the targeted 
manipulation of the antibody molecule’s glycosylation pattern, has been employed to enhance or 
augment cytotoxic activity of therapeutic antibodies, including anti-tumor antibodies (135). 
Another example for the important role of FcγR during establishment of adaptive immune 
responses is their regulation of T-cell activation. Here, relative abundance of activating and 
inhibitory type I FcγR on DC regulates antigen uptake and inflammatory cytokine secretion, and 
thus T-cell activation (135). Two major innate effector mechanisms triggered via Fc-FcγR 
interactions are antibody-dependent phagocytosis (ADP) and antibody-dependent cellular 
cytotoxicity (ADCC) (95, 96, 136). ADCC and ADP are mediated mainly by NK cells, monocytes, 
macrophages and neutrophils (126). In NK cells, FcγR engagement leads to activation of 
perforin/granzyme or FasL/Fas pathways (137). Neutrophils where shown to produce reactive 
oxygen species upon stimulation of FcγR (96). However, the exact mechanism underlying 
neutrophil-mediated cytotoxicity remains elusive and might involve extracellular trap formation 
(136, 138, 139). Recently, it was shown that ADP is induced in alveolar macrophages during 
murine influenza (95). In fact, Fc-FcγR interactions confer specificity to these otherwise non-
adaptive innate effector mechanisms. 
 NATURAL INFECTION AND SEASONAL INFLUENZA VACCINATION INDUCE STRAIN SPECIFIC 1.2.4.
ANTIBODIES 
As influenza viruses replicate at high rates, complete prevention of infection, i.e. sterile 
immunity, represents the most efficient defense mechanism for the organism (140). Accordingly, 
natural infection or seasonal vaccination induces mainly antibodies which are directed against the 
attachment and fusion mediating HA. Antibodies against the other viral surface proteins NA or 
M2e play minor roles as they interfere with later steps of the influenza virus life cycle (141, 142). 
As mentioned above, also antibodies against internal proteins such as NP may be involved in 
protection (143). 
Sterile immunity is conferred via sterical hindrance of neutralizing antibodies that bind near 
the RBS within the membrane proximal HA globular head, and thereby block the interaction of 
HA with its receptor (Figure 4). Additionally, antibodies can mimic the receptor and prevent 
attachment by inserting a single CDR loop into the narrow cavity at the RBS (144). Although 
neutralizing antibodies against the HA-head can confer lifelong protection against the same virus, 
they are considered to have only narrow or strain-specific reactivity (145). Major antigenic sites 
surrounding the RBS in the HA-head have been mapped in early studies, which show very high 
sequence variability enabling rapid emergence of viral immune escape mutants (146-149). The 
main mechanisms driving these variations are i) the insertion of point mutations into the 
influenza virus genome by the error-prone RdRp (‘antigenic drift’), which generates amino acid 
changes along with variations in the glycosylation pattern of the protein, and ii) the re-assortment 
of genome segments during co-infection of different influenza viruses (‘antigenic shift’). Antigenic 
drift thus leads to a more gradual change of the antigenicity. This, however, can generate escape 
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mutants also within one flu season. Antigenic shift can lead to the emergence of new viruses that 
are introduced into an immunologically naïve population (1.1.1) (150). 
The seasonal inactivated vaccine induces neutralizing antibodies against the HA-head, which 
show only narrow binding breadth. Rapid and unpredictable antigenic changes of the viruses pose 
the major obstacle to the production of an efficient influenza vaccine: A mismatch between the 
viruses circulating throughout the season and the viruses that are contained in the vaccine will 
result in a dramatic reduction of the effectiveness of the seasonal influenza vaccine. 
 VACCINATION AGAINST INFLUENZA VIRUSES 1.3.
 CURRENT INFLUENZA VACCINES 1.3.1.
First historical reports on outbreaks of influenza date back more than 400 years before Christ 
(151). Since then, numerous severe influenza pandemics were documented, with the most 
devastating being the H1N1 pandemic in 1918, and the most recent the H1N1 pandemic in 2009 
(Figure 2). The etiology of the disease was resolved only in 1933, with the isolation of influenza A 
virus from nasal secretions of an infected patient (152). The discovery of the virus quickly 
prompted research on influenza vaccines and antivirals, which was propelled by the appearance of 
new virus subtypes during the last century (Figure 2) (153, 154). Three classes of antivirals are 
currently available for prophylactic and therapeutic treatment of influenza: blockers of the M2 ion 
channel (e.g. Amantadine), inhibitors of NA activity (e.g. Oseltamivir), and inhibitors of PA 
endonuclease activity (e.g. Boloxavir). M2 inhibitors are, however, not recommended anymore 
due to the rapid induction of viral resistance mutations during treatment (155). Oseltamivir, 
although being no longer listed on the ‘core list’ of the ‘WHO Model Lists of Essential Medicines’ 
(156), is still considered to be an effective influenza therapeutic, though alternatives would be 
desirable (157). The recently licensed PA inhibitor Boloxavir showed promising results in a 
clinical trial compared to Oseltamivir (158). However, the emergence of a resistance mutation 
which decreased susceptibility was noted during treatment (158). Therefore, and because the 
aforementioned antivirals are almost exclusively limited to therapeutic use, vaccination is the 
most effective countermeasure against influenza. Consequently, influenza vaccination is 
recommended for all people at high risk for severe influenza, i.e. persons at the extremities of age, 
pregnant women or persons suffering from underlying chronic health conditions as well as those 
at elevated risk for infection, e.g. health care workers (159) (see 1.1.1). 
The current seasonal influenza vaccine is tri- or quadrivalent (TIV or QIV), thus containing 
antigen from two circulating influenza A strains (i.e. H1N1 and H3N2) and from either one or 
both influenza B lineages. In Germany, the use of QIV is recommended by the Standing 
Committee on Vaccination (Ständige Impfkomission, STIKO) since 2018, thus minimizing the risk 
for a vaccine mismatch with the influenza B components (160). While originally composed of 
whole inactivated virus (WIV), the inactivated vaccine currently includes either split virus or viral 
subunits (surface proteins HA and NA), showing lower reactogenicity and adverse effects than 
WIV (154, 161). Though used less commonly recombinant HA and virosomal vaccines are 
available as well (162, 163). Most commonly, vaccine preparations are applied intramuscularly but 
also formulations for intradermal application are available (164). In addition to inactivated 
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vaccines, live-attenuated influenza vaccines (LAIV) are used as an intranasal administration (165). 
Mimicking natural infection LAIV triggers a protective mucosal humoral and cellular immune 
response being superior to inactivated vaccines in children (166). Nevertheless, reduced efficiency 
of LAIV in non-naïve adults and concerns as to possible genetic reversion of the attenuated 
viruses restricts their more general use (167, 168). Aside from seasonal vaccines, monovalent 
preparations containing pandemic viruses (H1N1)pdm and such with pandemic potential (H5N1) 
are available as measures for preparedness for an unforeseen pandemic (169). 
Since influenza viruses evolve constantly, also the vaccine components have to be adapted 
permanently to match the circulating viruses. To this end, the WHO collects influenza virus 
surveillance data globally throughout the year resulting in recommendations regarding the viral 
strains which should be included in the vaccine (February/March, Northern hemisphere) (170). 
Usually, national public health and legal authorities follow these recommendations and 
commission private manufacturers to produce the vaccine (171). Bulk manufacturing is most 
frequently done in embryonated chicken eggs (until September, Northern hemisphere) (172). 
Beforehand, most human influenza viruses have to be adapted to high-yield egg-based production 
either by repeated passaging or classical re-assortment (until April, Northern hemisphere) (170). 
This can, however, lead to undesirable changes of their antigenicity (173). Additionally, the 
limited availability of vaccine-quality eggs restricts vaccine supply for the world’s population. On 
the contrary, cell culture-based production platforms are readily up scalable and yield high 
amounts of virus progeny (174). Several cell cultures have been evaluated and licensed for vaccine 
production, among them MDCK cells (canine) and Vero cells (simian) (175, 176). Although 
adaption of vaccine viruses to (non-human) cell culture might be necessary, too, their versatility 
make them particularly useful for the preparation of (pre-) pandemic vaccines, i.e. when time is 
limited (177, 178). 
Following growth, the virus is concentrated, purified, chemically inactivated and fragmented 
(until October/November, Northern hemisphere) (170). In parallel, reference reagents for testing 
the vaccine products are produced which are used for quality control of the vaccine before its 
release and distribution (170). The vaccine is standardized to contain 15 µg of each HA antigen 
component. It is administered shortly before the start of the seasonal epidemic, e.g. for the 
Northern hemisphere from October/November on (159). Persons such as the elderly, for whom 
seasonal vaccination is particularly recommended, generally respond poorly to immunologic 
stimuli (159, 179). To increase the immunogenicity of the seasonal vaccine, thus, licensed in some 
EU countries is the use of higher antigen doses (up to 60 µg per HA component), intradermal 
administration, or the addition of immuno-stimulatory compounds, i.e. adjuvants like the oil-in-
water emulsions MF59 or AS03 (165, 169, 180). Additionally, innovative delivery systems and 
adjuvants are under investigation to complement the inactivated seasonal vaccine (181, 182). 
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Due to the complexity of the recommendation process and the long manufacturing period 
there is a risk for the vaccine components to not match the actually seasonally circulating strains. 
Vaccine mismatches occur quite often and are associated with a reduced effectiveness of the 
vaccine against the mismatched component especially in the vulnerable group of person >65-years 
of age (Table 2) (183, 184). Aside from mismatched components, the vaccine’s efficacy is mainly 
influenced by the status of the immune system of the vaccine recipient, which is in turn mainly 
dependent on age and health status. Thus, the approximate overall influenza seasonal vaccine 
effectiveness rate is only 40 – 60 % even in case of a good vaccine match, while apparently vaccine 
effectiveness varies for each subtype (Table 2) (185). The relatively low vaccine effectiveness can 
lead to individual mistrust and hesitancy towards influenza vaccination (186). In fact, this is 
reflected by low overall vaccination coverage rates in most European countries (187). To improve 
protective efficacy and thus trust in influenza vaccination and vaccine coverage, research on 
innovative vaccine platforms and broadly reactive antigens, so called ‘universal influenza 
vaccines’, is essential (188-191). 
  BROADLY REACTIVE ANTIBODIES AGAINST INFLUENZA VIRUSES 1.3.2.
In the early 1980’s, Graves et al. discovered that cross reactive antibodies could be induced 
when influenza virus particles where treated with acid and the detergent DTT before 
immunization of rabbits (192). This treatment removed the HA1 subunit from the virion, 
resulting in the induction of a cross-reactive HA2-specific antibody response. As mentioned 
above, the membrane distal globular head domain of HA which consists of the internal part of 
HA1 is highly variable (Figure 8; see 1.2.4). On the contrary, the membrane proximal part of HA, 
the so called ‘stalk domain’, which is comprised of HA2 and the terminal parts of HA1, is highly 
conserved among influenza viruses (150). The cross-reactive antibodies identified by Graves et al. 
where likely directed against conserved epitopes in the HA-stalk domain (192). 
In fact, one decade later the first broadly reactive HA-stalk binding antibody, C179, was 
obtained from mice immunized with an H2N2 virus, which reacted with various group 1 
influenza A viruses (193, 194). The importance of this finding remained unappreciated until other 
broadly reactive HA-stalk binding antibodies were extracted from human PBMC several years 
later (195, 196). 
Table 2: Vaccine effectiveness against influenza virus subtypes 
Left: Pooled vaccine effectiveness in the seasons 2010 – 2015 (with 95 % confidence interval thereof in brackets) is 
reduced in case of a H3N2 mismatch especially in the vulnerable group of people of 65-years of age and older 
(adapted from Rondy et al., J Infect (2017)). Right: Pooled vaccine effectiveness in the seasons 2004 - 2015 varies for 
the individual vaccine components (adapted from Belongia et al., Lancet Infect Dis (2016)). 
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Although targeting similar regions within the HA-stalk, the antibodies differ in their binding 
breadth (197) (Figure 8). Like C179, antibodies CR6261 or F10 bind only to the HA of group 1 
influenza A viruses (198, 199), while antibody CR8020 binds to group 2 viruses only (200). In 
contrast, antibody FI6v3 shows promiscuous binding to almost all influenza A virus HA (201). 
Remarkably, binding to influenza A and B viruses was demonstrated for antibody CR9114 (202). 
Interestingly, most HA-stalk binding antibodies recognize conformational epitopes and do not 
bind to the post-fusion HA conformation (196, 200, 203). 
The discovery of broadly reactive HA antibodies has not been restricted to antibodies targeting 
epitopes within the HA-stalk domain (Figure 8C): as certain residues in the RBS are functionally 
highly conserved, several RBS-targeting broadly reactive antibodies such as S139/1 were isolated 
(204, 205). Most, if not all of them reach into the receptor binding pocket with one of their CDRH 
loops and mimic the receptor (196). However, the high variability of the residues surrounding the 
RBS limits their affinity and reactivity breadth (204). Other antibodies like H5M9 target highly 
conserved epitopes in other parts of the HA-head domain, including the vestigial esterase domain 
of influenza B viruses (206) (Figure 8C). Eventually, in addition to the classical highly variable 
antigenic sites, six different conserved antigenic sites were defined so far in the HA-head or -stalk 
domain of group 1 and 2 influenza A and of influenza B viruses (Figure 8C) (207). 
Figure 8: Conserved epitopes within HA 
(A) Schematic representation of HA1 and HA2 domain of HA (TM: transmembrane domain). In the three dimensional
molecule the head domain is comprised of the internal part of HA1 (light grey) while the HA-stalk domain consists of 
parts of HA1 and HA2 (dark grey). (B) Cumulative number of amino acid substitutions in H3 HA from 1968 – 2015 for
HA1 including or excluding the RBS (dark red or light red, respectively) or for HA2 (blue) (adapted from Wu et al., J Mol 
Biol (2017)). (C) Three dimensional structure of HA together with Fab fragments of broadly binding antibodies.
Although antibodies C179 (red, PDB: 4HLZ), CR8020 (blue, PDB: 3SDY) and CR9114 (orange, PDB: 4FQI) bind similar
sites within the HA-stalk they show different binding breadth. Broadly reactive antibodies against the HA-head can 
bind the RBS, i.e. S139/1 (cyan, PDB: 4GMS), or other regions, i.e. H5M9 (green, PDB: 4MHH). All antibody structures
were mapped onto the H2N2 HA of PDB 4HLZ (adapted from Lee et al., Curr Top Microbiol Immunol (2017)).
Accordingly, two conserved epitopes in the head have been identified (A (RBS): in influenza A and influenza B viruses; 
B (vestigial esterase): in influenza B virus). Four conserved epitopes were defined in the HA-stalk domain (#1 (α-helix): 
influenza A virus group 1; #2 (upper long α-helix) and #3 (fusion peptide): influenza A virus group 2; #4 (HA1 c-
terminus): influenza B virus). (adapted from Neu et al., Curr Opin Immunol (2016))
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 EFFECTOR MECHANISMS OF BROADLY REACTIVE ANTIBODIES AGAINST INFLUENZA VIRUSES 1.3.3.
 Since non-RBS targeting antibodies cannot block the attachment of the virus to the host cell, 
they may interfere with later steps of the viral replication cycle (Figure 9). As described in section 
1.1.3, the HA-stalk domain plays an important role during fusion of the viral and endosomal 
membranes (Figure 5). In fact, antibodies were identified that interfere with this step by blocking 
the conformational changes of HA during acidification of the endosome (200, 203, 208) (Figure 9 
B). HA-stalk antibodies, furthermore, interfere with budding and egress of the virus or maturation 
of HA (209, 210) (Figure 9, C and D). Intriguingly, even sterical inhibition of NA activity by an 
HA-stalk binding antibody was described (211). 
Aside from direct inhibition of steps in the replication cycle, the viral particle can be lysed by 
the complement system, which is potently activated by HA-stalk antibodies (94, 212) (Figure 9F). 
Interestingly, also FcγR-mediated effector mechanisms such as ADCC seem to be of major 
importance for non-RBS binding antibody-mediated protection (95, 96, 136) (Figure 9E, see 
1.2.3). Broadly-reactive ADCC-activating antibodies against H7N9 and H5N1 subtype viruses 
were found in individuals who were not exposed to these viruses before (213). The absence of 
neutralizing antibodies against these novel viruses indicates that the ADCC-activating antibodies 
are not directed against the RBS (213). Likewise, broadly protective, but non-neutralizing 
antibodies against (H1N1)pdm were found before the first pandemic wave in 2009 in children, 
who were not exposed to the same or structurally related H1N1 viruses before (214). ADCC-
activating antibody titers were shown to rise with age, likely due to repeated influenza infection or 
vaccination (213, 215). However, in non-human primates vaccination with human TIV did not 
prime ADCC-activating antibodies, while infection with H1N1 or H3N2 virus did (216). 
Nevertheless, pre-existing ADCC-activating antibody titers could be boosted in humans by 
inactivated vaccine, indicating that efficient priming (e.g. by natural infection or LAIV 
immunization) of an ADCC-activating antibody response is imperative (217-221). 
Figure 9: Interference of antibodies with 
the influenza virus life cycle 
Antibodies against HA can interfere with 
different steps during the influenza virus 
life cycle. Head binding antibodies (blue) 
can inhibit attachment of the virus to the 
host cell receptor (A). HA-stalk binding 
antibodies (green) inhibit later steps in the 
replication cycle like fusion/uncoating (B), 
budding/egress (C) or maturation of HA 
(D). Additionally, HA-stalk antibodies can 
activate other cells of the immune system 
by FcR interactions (E) or the complement 
system (F). (adapted from Krammer et al., 
Curr Opin Virol (2013)) 
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The protective potency of ADCC-activating monoclonal HA-stalk antibodies was proven in 
vivo employing FcγR-KO mice or antibody variants no longer able to activate FcγR (222-225). 
Effector functions of neutrophils and alveolar macrophages seem to be critical in this regard (95, 
96). While initially it was apparent that only HA-stalk antibodies mediate FcγR activation, it is 
now evident that any broadly reactive non-RBS binding antibody can elicit FcγR activity (222, 
223). Intriguingly, this holds also true for broadly reactive antibodies against NA (223). 
Furthermore, intrinsically poorly FcγR-activating NA-inhibiting (NAIpos) antibodies can co-
operate with HA-specific antibodies and enhance their FcγR-activation potency (226). On the 
contrary, HAIpos-antibodies which bind to the sialic acid binding pocket in the RBS are no potent 
inducers of FcγR activity (227). In fact, it was demonstrated that HAIpos antibodies can inhibit 
FcγR-activation by HA-stalk antibodies although they do not prevent their binding to the HA-
stalk (226). Therefore, in addition to Fc-FcγR interaction, also the accessibility and functionality of 
the sialic acid binding pocket in the RBS is necessary for activation of FcγR-mediated effector 
functions (224, 227-229). A model is proposed, according to which two concomitant interactions 
are required to potently activate effector functions: i) interaction of HAIneg antibodies with FcγR 
and ii) interaction of the RBS with sialic acid on the immune cell (227). However, it is unclear 
whether the RBS-sialic acid interaction only stabilizes the HA or acts as a co-receptor (136). 
Recent finding of an exceptional influenza B HA antibody which can block receptor attachment 
(HAIpos) and mediated ADCC indicate that more research is needed to define the ultimate 
requirements for HA-specific FcγR-activating antibodies (230, 231). 
Moreover, FcγR-activating antibodies against the internal proteins NP and M1 were readily 
found in humans and also could mediate protection after passive transfer in mice (143, 232, 233). 
Although the presence of NP and M1 on the surface of infected cells was described, further 
investigation on their in vivo significance and contribution to protection of ADCC-activating 
antibodies against internal influenza virus proteins seems to be necessary (114, 234). 
In a pig vaccination model antibody-dependent enhancement of disease (ADE) associated with 
HA-stalk antibodies was described (235). Here, HA-stalk antibodies potentially cross-linked the 
viral fusion peptide with the cellular membrane and rather promoted infection then prevented it. 
Other studies in pigs linked ADE to intradermal delivery only while vaccination of mice would 
not induce ADE antibodies (236, 237). Furthermore, non-neutralizing but FcγR-activating 
antibodies occasional can enhance disease by increasing uptake and replication of virus in FcγR-
expressing cells (e.g. macrophages) (127). This has also been shown for influenza viruses (238, 
239). Also, pathologic deposition of immune complexes in the tissue can result in increased FcγR-
mediated cytotoxicity and inflammation (127). Though the exact reason for ADE might not be 
well understood, the phenomenon must be carefully considered when designing a vaccine which 
particularly aims at the induction of non-neutralizing antibodies.  
Although functionally constrained, epitopes in the HA-stalk are under selective pressure as 
well, and immune escape virus mutants can arise (240, 241). Interestingly, viruses seem to escape 
either via complete abolishment of antibody binding or by increase of the fusion activity of the 
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HA, allowing fusion even in the presence of the antibody (240). However, immune escape is 
associated with a loss of viral fitness (240). 
 HA-STALK ANTIBODIES ARE RARELY INDUCED IN NATURE 1.3.4.
Most HA-stalk antibodies show a similar mode of binding as they use hydrophobic residues of 
their CDRH to contact a highly conserved pocket within the HA-stalk (124, 196) (Figure 6, Figure 
8). Some antibodies quiet untypically use solely their heavy chain to interact with HA (201, 242). 
A great number of HA-stalk antibodies employs the VH1-69 antibody germline gene locus (243, 
244). However, non-VH1-69 HA-stalk antibodies have been described which sometimes emulate 
the binding modalities of VH1-69 (196, 201, 245). VH1-69 codes for important hydrophobic 
anchor residues at the apices of the CDRH loops that directly contact the HA-stalk (124, 246). A 
genetic polymorphism in humans at these positions can diminish the HA-stalk antibody response 
(247). The development of high-affinity VH1-69 HA-stalk antibodies does apparently not rely on 
the extensive acquisition of somatic mutations, indicating their general potential to rapidly be 
induced (121, 246). However, HA-stalk antibodies are rare in the human population (248). The 
impaired induction of HA-stalk antibodies by natural infection or seasonal vaccination could be 
explained by the immunodominance of epitopes in the HA-head. According to Angeletti and 
Yewdell, factors mainly influencing antibody immunodominance include antigen quantity and 
accessibility, the frequency and affinity of B-cell precursors, T-cell help, and the immunization 
conditions, besides minor factors including genetic background, age, and environment (249). In 
fact, poor accessibility of stalk epitopes by BCR was shown to occasionally occur and result in a 
HA-head-biased response (250, 251). Also, the above mentioned restricted VH-germline gene 
usage and increased poly-/auto-reactivity (e.g. DNA cross-reactivity) of stalk-reactive B-cells can 
further result in a reduced number of available HA-stalk specific naïve B-cells (244, 252). 
Interestingly, the form of antigen and route of administration also was shown to critically 
influence the immunodominance hierarchy, whereas intranasal infection with an active virus 
mounted antibodies covering more antigenic sites on HA as compared to intramuscular or 
intraperitoneal administration of inactivated virus (253). 
Nevertheless, antibodies against conserved epitopes within HA are able to broadly protect 
humans against influenza (254). In fact, the extinction of the seasonal H1N1 strain circulating 
before 2009 was attributed to an increase of HA-stalk antibodies following infection or 
vaccination with the 2009 pandemic influenza virus, which was also supported in a mouse model 
(243, 255, 256). Li et al. describe a model, in which broadly reactive but otherwise 
immunosubdominant memory B-cells against conserved epitopes in HA become predominantly 
reactivated during infection with a divergent influenza strain due to the lack of memory B-cells 
against the divergent HA-head (257). This phenomenon, a specific case of original antigenic sin, 
might generally be responsible for the extinction of seasonal viruses by an emerging pandemic 
strain (258, 259). Indeed, during a period of only minor antigenic drift, i.e. when HA-head 
domains of circulating viruses were closely related to each other, substantial increase over time 
could only by detected for antibodies against the immunodominant HA-head, while HA-stalk 
antibody levels increased only modestly (260). Stronger induction of HA-stalk antibodies was 
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seen, however, in individuals being seropositive for more divergent influenza virus subtypes 
harboring more variable HA-head domains (260). Similarly, the induction of HA-stalk antibodies 
by a (H1N1)pdm vaccine was impaired in presence of pre-existing HA-head specific antibodies 
against the pandemic virus (252). Not only antigenic shift but also periods of marked antigenic 
drift can lead to an increase of HA-stalk antibodies and older people who have longer histories of 
exposure to divergent influenza viruses also tend to have higher levels of HA-stalk antibodies 
(261-263). Interestingly, also the extent polyclonality and isotype distribution of the HA-stalk 
antibody response seems to influence the potency of protection (264). 
Although induction of HA-stalk antibodies seems to be more frequent after natural infection, 
also their induction after vaccination was described (250, 265-269). However, due to 
immunodominance of epitopes in the HA-head, efficient induction of HA-stalk antibodies by 
vaccination requires development of innovative antigens and delivery concepts. 
 VACCINE CONCEPTS TO INDUCE BROADLY REACTIVE ANTIBODIES AGAINST HA 1.3.5.
Several antigen concepts were described in the literature that aim at the induction of antibodies 
against conserved regions in the HA, such as the stalk domain. These include i) sequential 
vaccination with diverse antigens, ii) vaccination with minimal antigens, iii) vaccination with 
consensus antigens and iv) vaccination with glycan-modified antigens (259).  
i) Diverse antigens: Chimeric HA (cHA) contain the stalk domain of one influenza virus
subtype but the head domain of other exotic subtypes (e.g. H1 stalk and H13 head), which are 
currently not circulating in humans, and are thus expected to lack pre-existing immunity in the 
population (270, 271) (Figure 10). Hence, vaccination with cHA resembles the immunologic 
phenomenon described above (see 1.3.4): after repetitive exposure to different cHA which all 
contain an identical HA-stalk, the immune response towards broadly reactive epitopes is boosted. 
The immune response against variable epitopes in the divergent exotic HA-heads is inferior 
because it would have to be induced de novo against each cHA (272). cHA were used to induce 
broadly protective HA-stalk reactive antibodies in mice and ferrets (273-281) (Figure 10). 
Furthermore, a formulation of inactivated split influenza virus carrying a cHA on its surface is 
evaluated in a phase I/II clinical trial underlining the potential of the approach (282). 
Figure 10: Chimeric and headless HA can be used to boost HA-stalk reactive antibodies 
(A) Sequential immunization with chimeric HA (cHA) that contain the identical stalk domain (e.g. H1) but exotic head 
domains (e.g. H13, H2 or H10) induces re-focussing of the immune response from dominant head epitopes (red) to
conserved stalk epitopes (grey). (B) Headless-HA lack dominant epitopes in the head completely and therefore
induce antibodies to conserved stalk epitopes (grey). Antibodies against regions not exposed in the wildtype HA
(black) might also be induced. (adapted from Krammer, Curr Opin Virol (2016)) 
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ii) Minimal antigens: Minimal antigens represent either epitopes, structural features (e.g. long
α-helix) or specific domains of HA (e.g. stalk) which lack unwanted epitopes (e.g. in the head) 
(259). Although strategies using epitopes coupled to immunogenic carrier particles and the 
display of HA-stalk epitopes embedded in the HA-head were evaluated, the majority of research 
focusses on so called headless HA (283, 284). Headless HA completely lack the HA-head domain 
due to deletion of the respective region in the open reading frame of HA (285) (Figure 10). As 
mentioned above, most HA-stalk antibodies recognize conformational epitopes (196). Since the 
HA-stalk is metastable, removal of the complete head can readily lead to misfolding into 
undesired antigenic conformation, i.e. the post fusion conformation (Figure 5) (286). This is, 
however, not the case for most cHA, where the exotic head seems to stabilize the HA-stalk 
conformation (271). In fact, early headless HA versions, in which the HA-head was substituted 
with a short linker did not display the correct conformation of the stalk as evidenced by the lack of 
binding of well characterized conformational HA-stalk antibodies (287-289). Nevertheless, 
broadened protection in mice and rabbits was achieved. To improve antigenicity, more recent 
headless HA versions contained additional mutations to stabilize the neutral pH conformation of 
the HA-stalk, including removal of newly generated hydrophobic surfaces as well as removal of 
the HA cleavage site or alterations of disulfide bonds (290-293). Moreover, the addition of 
trimerization motifs to the membrane proximal part of the headless HA resulted in a significantly 
improved conformation and antigenicity (236, 289, 294-296). Recently, two very advanced 
headless HA have been reported by Yassine et al. and Impagliazzo et al., in which the membrane 
distal end was stabilized as well and/or the headless HA was fused to a carrier particle (297, 298). 
Exceptional broad protection was demonstrated in mice, ferrets and non-human primates and 
was associated with a rise in ADCC-activating antibody titers (297, 298). Although recent headless 
HA seem to have overcome issues regarding the HA-stalk conformation, the addition of 
heterologous stabilizing elements (trimerization motifs, carrier particles) may result in a skewed 
immune response towards these highly immunogenic elements (285). 
iii) Optimized/centralized antigens: Broad protection in several animal models including mice
and ferrets could be induced with consensus or computationally optimized broadly reactive (e.g. 
COBRA) HA antigens containing at each position the most prevalent, i.e. conserved, amino acid 
(299, 300). Also, ancestral HA sequences can be used to induce broadly protective antibodies 
(301). Furthermore, conserved epitopes of different HA variants can be combined in one 
construct (mosaic antigen) (302, 303). 
iv) Glycan-modified antigens: Influenza viruses use the addition or removal of surface glycans
to escape the immune response (304). However, this can be harnessed to modulate and broaden 
the immune response by unmasking otherwise hidden epitopes (259). Two strategies were 
successfully used to induce broadly protective antibodies against the HA-stalk: i) removal of 
glycans on the HA-stalk that interfere with recognition of these moderately immunogenic 
epitopes or ii) addition of glycans to the HA-head to shield the immunodominant epitopes (304-
306). 
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 OTHER ANTIGENS TO INDUCE BROAD PROTECTION AGAINST INFLUENZA 1.3.6.
Aside from HA, research on universal influenza vaccines mainly focusses on the target 
antigens NP, the highly conserved extracellular domain of M2 (M2e), and to a lower extent also 
M1, while recently NA was described as highly promising broadly reactive antigen candidate (307, 
308). While M2e and NA vaccine candidates aim at the induction of an antibody response, NP 
and M1 mainly focus on eliciting a strong cellular immune response (309). Vaccination with 
complete proteins, as well as T-cell and B-cell epitope vaccines are under evaluation in a multitude 
of studies. Furthermore, some concepts include linking of the antigen to an immune stimulatory 
carrier such as bacterial or viral subunits (cholera toxin subunit A, Hepatitis B virus core protein), 
or receptors and agonist of the host immune system (TLR5, CD11c), or virus like particles (237, 
310, 311). The feasibility of new production methods, e.g. in plants, and new adjuvants is tested 
(182, 312). Additionally, innovative delivery platforms such DNA and RNA vaccines and viral 
vectors are under intensive investigation (307, 313, 314).  
 VIRAL VECTORS AS CARRIERS FOR INFLUENZA VACCINES 1.3.7.
The use of viral vectors as carriers for influenza vaccines is appealing, since they offer possible 
solutions to some of the problems associated with the vaccine manufacturing cycle as discussed in 
section 1.3.1. For example, it is possible with viral vectors to express genes in vivo without the 
need for production and purification of antigen in chicken eggs. Moreover, antigens are expressed 
in situ in their desired conformation. Comparable to the antigen expression during natural 
infection, vectored antigens are subjected to cognate antigen processing pathways, which is likely 
positively modulating the immune response (313). Hence, different vectors (Poxvirus, Alphavirus, 
Herpesvirus, Vesicular stomatitis virus (VSV), Newcastle disease virus, Baculovirus, Parainfluenza 
virus, Adenovirus (AdV), Adeno-associated virus) were tested for the induction of strain-specific 
or broadly protective immunity with different native (HA, NA, NP, M1, M2, PB2) and modified 
antigens (HA-stalk, M2e) in several animal species including mice, ferrets, pigs and non-human 
primates, as well as avian species (313). Intriguingly, cHA immunization also induced protective 
HA-stalk antibodies in a virus vectored vaccine approach in mice and ferrets, albeit the 
immunization regimen required change of the vectors (VSV pseudotypes to AdV to influenza B 
virus) (276, 278, 279). Modified vaccine virus Ankara (MVA) virus vectors which express a 
headless HA alone or in combination with other antigens (NP, M2e) were used as well (315). 
Interestingly, MVA-vectored headless HA only afforded protection when it was co-expressed 
together with NP, indicating some limitations to a virus vectored headless HA approach (315). 
Nevertheless, production of high amount of virus vectors according to good manufacturing 
production criteria is still costly (316). Also, inherent pathogenicity of some virus vectors raises 
concerns regarding their safety in humans (317, 318). Pre-existing immunity in humans against 
viral vectors poses a challenge to development of a virus vector vaccine (319-321). Thus, the 
choice of the right viral vector system might be critical for the success of an influenza vaccine 
approach. Adeno-associated virus vectors seem to be well suited for this purpose. 
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 AAV-VECTORS 1.4.
Adeno-associated viruses (AAV) where identified as contamination in an Adenovirus 
preparation in 1965 (322). Belonging to the family of Parvoviridae, AAV is a non-enveloped virus 
with icosahedral capsid symmetry (ca. 20 nm in diameter) (323). The encapsidated single stranded 
DNA genome is about 4.7 kb in length and either of negative or positive polarity. The genome is 
flanked by non-coding cis-active sequences, the inverted terminal repeats (ITR), which have 
important functions during replication and potential integration of the genome (324) (Figure 11). 
Two open reading frames (rep and cap) code for seven major proteins: Rep78, Rep68, Rep52 and 
Rep40 are important factors for replication and integration of the genome, while capsid proteins 
VP1, VP2 and VP3 are structural parts of the virion. The expression of these proteins is initiated 
from three different promotors (p5, p19 and p40) (324). Additionally, mRNA splicing and also 
antisense transcription and translation can increase the coding capacity, and further accessory 
proteins were described to play a role during AAV life cycle (324, 325). As members of the genus 
Dependovirus, AAV relies on co-infection with helper viruses such as Adenovirus or Herpes 
Simplex virus for efficient replication (326). Also, Hepatitis B virus and Bocavirus 1 can act as 
helper viruses underlining that a multitude of viral and host factors are being exploited by AAV, 
including proteins and RNA, but that the minimum which is absolutely required may still yet be 
ill-defined (327, 328). 
Vectors based on AAV are ‘gutless’, meaning they completely lack viral genes and only contain 
the ITR between which the transgene and regulatory elements for its expression are placed (326) 
(Figure 11B). Rep and Cap genes as well as helper genes required for production of AAV-vector 
particles have to be provided in trans (329). AAV-vectors, thus, can be produced from a three-
plasmid system (transgene / AAV genes / helper genes) without contaminations of wildtype AAV 
and helper viruses. Interestingly, AAV-vector genomes (containing AAV2 ITR) can be 
transencapsidated in heterologous capsids of various subtypes with e.g. other tissue specificities 
(330). 
Figure 11: Capsid and genome structure of AAV 
(A) 3D structure model of an AAV capsid (PDB: 1LP3, color-gradient: b-factor) with inset showing negative stain
electron microscopic picture of purified AAV capsids. (B) schematic drawing of a wildtype AAV genome (top) with
inverted terminal repeats (ITR), Rep and Cap genes and position of promotors (p5, p19, p40). The AAV-vector (bottom) 
completely lacks rep and cap genes but contains an expression cassette comprised of a promotor (P), an irrelevant
intron, the transgene, a V5-tag and a polyadenylation/termination signal (pA). 
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AAV genomes persist predominantly as episomal circular concatemers (331). Impressively, 
expression is extremely durable (1 year and longer) and persisting genomes are apparently neither 
cleared from the cells nor epigenetically silenced (332, 333). Most likely signals or higher order 
structures in the ITR regulate persistence of AAV-vectors (325). Furthermore, integration was 
described for AAV with an integration hotspot being the chromosomal region 19q13.4. This is 
due to the presence of an AAV Rep protein binding element in this region, which eventually leads 
to recruitment of the host non-homologous recombination machinery in a Rep-dependent 
manner (334, 335). Along the same lines, Nault et al. reported that AAV integration caused 
hepatic cell carcinoma in humans (336). However, the conclusions drawn by Nault et al. were 
argued by other groups, thus, the true impact of AAV-associated oncogenicity remains elusive 
(318, 337). In fact, also protection from cervical cancer in AAV infected women was demonstrated 
(338). Since AAV-vectors completely lack rep gene integration is extremely unlikely (339) (Figure 
11). Also, toxicity was seen only after administration of high vector doses or with specific cell lines 
(embryonic stem cells) (340, 341). The licensure of AAV-vectors for gene therapy for the 
treatment of familial lipoprotein lipase deficiency (alipogene tiparvovec (Glybera®)) and retinitis 
pigmentosa (voretigene neparvovec (Luxturna®)) in the EU and the USA and its use in over a 
hundred clinical trials definitely underlines their safety (324, 342, 343). 
AAV genomes were extracted from the epithelia of the respiratory tract, tonsils and adenoids 
after co-infection with an AdV but also from other human tissue like muscle, spleen, blood and 
the urogenital tract of women (325). Interestingly, human leucocytes were found recently to be 
positive for AAV at high frequencies indicating that these cells may be a natural reservoir (344). 
Many different AAV serotypes have been isolated from human tissues and from tissues of other 
animal species, including primates but also snakes (321). Serotypes vary regarding their capsid 
identity between 99 % and 50 % while the most widely used serotypes in clinical studies are 
human origin AAV2, AAV1, AAV6, AAV8 and rhesus origin AAVrh.10 (324). AAV serotypes 
show specific tissue tropisms, thus, allowing specific targeting of transgene expression to the 
desired site of the body by selection of a distinct capsid (345). These differences are likely due to 
differential receptors usage of each serotype (345). Hence, attachment of AAV serotypes to a 
variety of specific glycan and/or protein receptors was shown (346). Recently, a putatively 
universal AAV receptor (AAVR) was identified, which seems to be essential for most, including 
AAV2 and AAV9, but not all AAV serotypes (347-349). After attachment, capsids are 
endocytosed in a clathrin-dependent or independent manner and trafficked retrograde to the 
Golgi apparatus (350-352). AAV capsids eventually escape into cytoplasm and accumulate 
perinuclear before they are imported into the nucleus by host importins, and the genome is 
uncoated (353-355). Replication takes place in dedicated foci within the nucleus where the second 
strand of the genome is complemented mediated by Rep proteins and host DNA repair machinery 
(356, 357). As mentioned above, genomes either persist in a concatemerized form (without helper 
functions) or progeny virus is produced (in presence of helper functions) (324). Capsid assembly 
takes place within the nucleus, where also progeny genomes are packed (358). 
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Initial infection with AAV occurs very early in life. Neutralizing antibodies against multiple 
serotypes can be found in humans, indicating the great extent of cross-reactivity of these 
antibodies (359). However, the prevalence varies for each AAV serotype: AAV2 has the highest 
prevalence (30-60 %) of neutralizing antibodies while other serotypes, including AAV9, show only 
moderate prevalence (15-30 %). Neutralizing and total antibodies correlate, thus, 70 % and 45 % 
humans are sero-positive for AAV2 and AAV9, respectively (319, 359). AAV-specific T-cells can 
be found from an early age on but their prevalence is lower compared to AAV antibodies. Cellular 
and humoral responses do not correlate. However, T-cells also show extended cross-reactivity. 
Most prevalent T-cells display a memory phenotype and exert cytotoxic effector functions upon 
activation (359). To circumvent immune responses against AAV and to prevent neutralization of 
the vector, different strategies are being evaluated: isolation of new (non-human) serotypes, 
modification of existing capsids and creation of new capsids by directed evolution. Furthermore, 
improvement of the production methods to yield highly pure virus vector stocks which can be 
administered in lower doses (326, 359). In addition, transgene production can be optimized with 
self-complementary AAV-vectors which package genomes containing both DNA strands and, 
thus, do not require the rate limiting step of second DNA strand synthesis (360).  
Intriguingly, AAV-vectors were also used to actively or passively immunize against several 
viral pathogens including human immunodeficiency virus, human papillomavirus virus, 
respiratory syncytial virus, severe acute respiratory syndrome coronavirus, and influenza virus 
(361). 
 AAV-VECTORS FOR INFLUENZA VACCINATION 1.4.1.
AAV-vectors were used as vehicles for influenza vaccines in very few studies either as active 
immunization (serotypes AAV2, AAV8, AAV rh32.33 or AAV9, expressing HA, NP and M1) 
(362-364) or passive immunization (serotypes AAV8 and AAV9, expressing HA-specific 
antibodies) (365-367). Interestingly, in the passive immunization studies broad protection was 
achieved with AAV-vectors expressing three HA-stalk binding antibodies, namely F10, CR6261, 
FI6, in young, aged and immunodeficient mice, as well as ferrets (365-368). AAV-vectors seem to 
be particularly suited for such passive immunization approaches due to the durable expression of 
the respective antibody (361).  
The first study describing an active AAV-vectored influenza vaccine was published in 2001 
(364). Xin et al. focused on the development of AAV-vectors as carrier for an HIV vaccine. The 
authors, however, also intranasally immunized mice with an AAV2-vector expressing the HA of 
A/Puerto Rico/8/1934(H1N1) (PR8) with or without simultaneous immunization with AAV-IL2. 
This was done to proof that an AAV-vector vaccine was not only immunogenic against HIV, but 
also induced protective immunity, which was shown in a lethal influenza mouse model. Mice were 
partially but significantly protected from homologous influenza virus challenge and AAV-IL2 
further adjuvanted the protective effect which was attributed to an enhancement of cell mediated 
immunity (364). Furthermore, in another study Lin et al. transferred pooled human serum into 
mice before intramuscular immunization with AAVrh32.22 or AAV8 expressing PR8 NP. This 
experiment was intended to analyze pre-existing immunity in humans against AAVrh32.22, a new 
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rhesus monkey AAV-vector serotype (363). AAVrh32.22-NP immunized mice were completely 
and AAV8-NP immunized mice partially protected against homologous influenza challenge, 
which on the one hand proved that human serum does not interfere with AAVrh32.22 but with 
AAV8, and on the other hand represented the first report on an successful AAV-vectored 
influenza vaccine against the internal NP protein (363).  
More recently, Sipo et al. used AAV2/9-vectors (AAV2 ITR and AAV9 capsid) which 
expressed codon-optimized A/Mexico/4603/2009 (H1N1)pdm HA, NP and M1 proteins (362). 
AAV9, which was used in the aforementioned study, has some remarkable features making it 
particularly suited to serve as a vaccine vector against respiratory diseases. The AAV9 capsid 
coding sequence was isolated and reconstructed from human tissue (321). As for most AAV 
serotypes, AAV9 sero-prevalence is quite high in humans (about 45 %) (319). However, 
neutralizing factors not only show lower prevalence (about 30 %) but 70 % of the tested 
individuals present low (1:20) AAV9 neutralizing antibody titers (319). Therefore, AAV9 might 
have an advantage for use in humans in the context of pre-existing immunity over other AAV 
serotypes (319). AAV9 was shown to target alveolar epithelial cells in vivo where it stably 
expressed transgene over month (369-371). Most importantly, AAV9 was re-administrable into 
the respiratory tract of mice due to the lack of neutralizing antibodies in bronchoalveolar lavage 
fluid even in the presence of neutralizing serum antibodies (369). Sipo et al. reported the 
induction of T-cell as well as antibody responses against all antigens after intramuscular 
immunization with a combination of AAV-HA/AAV-NP/AAV-M1, with the strongest T-cell and 
antibody response against NP or HA, respectively (362). As expected, no neutralizing antibodies 
were detected against the heterologous PR8. For homologous (H1N1)pdm challenge, mice were 
vaccinated with each AAV-vector alone or with the trivalent combination. Interestingly, AAV-HA 
as well as AAV-H1/AAV-NP/AAV-M1 induced sterile immunity resulting in complete protection 
without weight loss of the animals (362). AAV-NP also completely protected animals, which was 
most likely mediated by strong cell-mediated immunity. However, these animals did show signs of 
disease due to the lack of neutralizing antibodies. AAV-M1 alone was not able to protect the mice 
(362). Intriguingly, AAV-HA/AAV-NP/AAV-M1 also partially protected animals from challenge 
with the heterologous PR8 which was associated with slightly reduced lung virus loads. The 
authors concluded that heterologous protection is mediated by broadly reactive cell-mediated NP-
specific immunity in absence of cross-neutralizing HA-specific antibodies against PR8 (362). 
However, in a follow up study cross-protection against PR8 after intramuscular immunization 
with an AAV9-vector expressing A/California/7/09(H1N1pdm) (Cal/7/9) NP was only seen after 
introduction of the major CTL epitope (NP366-374) of PR8 into the NP of Cal/7/9 (371). Also, 
immunization with an AAV-vector expressing an epitope chain comprised of the major CTL 
epitope of most influenza A virus NP proteins induced a non-functional T-cell response which 
failed to protect animals (371). These somehow contradictory findings indicate that further 
evaluation of the contribution of cell-mediated and humoral immunity to heterologous protection 
with an AAV-vectored vaccine against influenza is necessary. However, they also underline the 
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enormous potential of AAV9-vectors for the use as vehicles for broadly protective influenza 
vaccines. 
 
 AIM OF STUDY 1.5.
The current seasonal influenza vaccine has unsatisfactory low overall effectiveness especially in 
the population being at high risk for influenza-associated complications (183). Moreover, 
protection is virus strain specific and, thus, the vaccine has little to no effectiveness against non-
vaccine strains, i.e. drifted seasonal and emerging pandemic or zoonotic strains. Hence, a more 
effective and broadly reactive vaccine is highly desirable in view of improvement of public health 
(190, 191). 
Recently, antigens have been described, which in contrast to the current vaccine aim at the 
induction of immunity (humoral and/or cellular) against conserved regions in influenza virus 
antigens, including for instance the HA-stalk domain (272). Furthermore, research and 
development of innovative vaccine delivery platforms such as AAV-vectors is considered 
important (190, 191). These cannot only help to overcome challenges associated with the vaccine 
manufacturing cycle, but also directly influence the immune response and enhance 
immunogenicity of the antigen (314). 
The aim of this thesis was to evaluate the feasibility of AAV-vectors as broadly reactive 
influenza vaccine carriers and identify immunization regimens, i.e. antigens or combinations 
thereof, which would induce broad protection against challenge infection. Therefore, breadth and 
quality of the humoral immune response after vaccination of mice with AAV-vectors expressing 
either wildtype influenza antigens (HA, NP) or antigens particularly aiming at the induction of 
antibodies against the HA-stalk (chimeric HA, headless HA) was assessed. Thereupon it was 
evaluated, whether one of the measured immunological parameters, such as neutralizing 
antibodies or FcγR-activating antibodies, could be correlated with protection of mice against 
homologous or heterologous influenza virus challenge. Finally, the protective effect against 
homologous viral challenge was investigated for the first time in ferrets, which represent the gold-
standard animal model for influenza in humans. A detailed knowledge of the effects of the AAV-
vector on the immunogenicity of influenza virus antigens and their protective efficacy will likely 
facilitate the progression to clinical evaluation of AAV-vectors as carriers for a broadly-reactive 
influenza vaccine as characterized herein. 
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2. MATERIALS
Animals: 
Mice: 
C57BL/6NCrl 
Charles River 
(Sulzfeld, Germany) 
Ferrets 
Mustela putorius furo 
EuroFerret 
(Denmark) 
Immortalized cell lines: 
HEK 293T Homo sapiens embryonic kidney cells, epithelial, adherent, DMEM 
MDCKII Canis familiaris kidney cells, epithelial-like, adherent, MEM 
BW5147 (& derivates) Mus musculus thymus cells, T-cell, suspension, R10 
Chemo-competent bacteria: 
Escherichia coli (DH5α™) subcloning efficiency 
(genotype: F- ϕf80lacZ∆M15 ∆(lacZYA-argF) U169 recA1 endA1 
hsdR17(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λ-) 
2xYT medium, 
Thermo Fisher 
Scientific Inc. 
(Waltham, USA) 
Influenza A viruses: 
A/California/7/2009 (H1N1)pdm 
Mouse infections: NIBSC ref. 39570, 
107.6TCID50/ml, NYMC X-181 (hyH1N1sw); 
5:3 reassortant: HA, NA, PB1 of Cal/7/9 
(H1N1)pdm in the background of A/PR/8/34 
(H1N1) 
All others: virus grown on embryonated 
chicken eggs and purified by 
ultracentrifugation, source: National 
reference center (NRC) at RKI 
A/California/7/2009 (H1N1)pdm 
whole inactivated virus (WIV) 
inactivated and purified X-181 (H1N1)pdm 
virus (charge BII/1/15), source: NIBSC 
A/Mexico/InDRE4487/2009(H1N1)pdm Ferret Infections: 105 TCID50/ml, source: PEI 
A/Puerto Rico/8/1934 (H1N1) 
Mouse infections: NIBSC ref. 39560; 
109.1TCID50/ml 
All others: virus grown on embryonated 
chicken eggs and purified by 
ultracentrifugation, source: FG17 (RKI) 
A/Puerto Rico/8/1934 (H1N1) WIV inactivated and purified A/PR/8/34 (H1N1) virus (charge BII/19/14), source: NIBSC 
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Influenza A viruses: 
HA/NA-1918 x WSN/1933 (H1N1) 
6:2 reassortant: HA and NA of A/Brevik 
Mission/1/1918 (H1N1) in the background of 
A/WSN/1933 (H1N1), source: FG17 (BSL3) 
(RKI) 
A/Widgeon/Denmark/66174/G18/2004 
(H2N3) Source: NRC at RKI 
X31 (H3N2) 
6:2 reassortant: HA and NA of 
A/Aichi/2/1968 (H3N2) in the background of 
A/PR/8/34 (H1N1) 
Mouse infections: NIBSC ref. 39600; 
109.3TCID50/ml 
All others: virus grown on embryonated 
chicken eggs and purified by 
ultracentrifugation, source: FG17 (RKI) 
X31 (H3N2) WIV inactivated and purified X-31 (H3N2) virus (charge BII/21/14), source: NIBSC 
A/Panama/2007/1999 (H3N2) 
virus grown on embryonated chicken eggs 
and purified by ultracentrifugation, source: 
FG17 (RKI) 
A/Viet Nam/1203/2004 (H5N1) 
virus grown on embryonated chicken eggs 
and purified by ultracentrifugation, source: 
FG17 (BSL3) (RKI) 
A/Anhui/1/2013 (H7N9) 
virus grown on embryonated chicken eggs 
and purified by ultracentrifugation, source: 
FG17 (BSL3) (RKI) 
A/Mallard/Nordvorpommern/Wv9417/2004 
(H10N7) 
virus grown on embryonated chicken eggs 
and purified by ultracentrifugation, source: 
NRC at RKI 
A/Gull/Maryland/707/1977 (H13N6) 
virus grown on embryonated chicken eggs 
and purified by ultracentrifugation, source: 
FG17 (RKI) 
Plasmids (not constructed during this work): 
pAAV-MCS 
pHelper 
empty AAV-vector 
Helper plasmid expressing Adenovirus E2A, E4, VA 
genes 
Agilent 
Technologies 
(Santa Clara, USA) 
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Plasmids (not constructed during this work): 
p5E18-VD2/9 
pAAV-HA 
pAAV-NP 
pAAV-GFP 
Helper plasmid expressing AAV2 rep and AAV9 cap 
gene 
HA of Cal/7/9 (H1N1)pdm, 
codon opt. for mus musculus 
NP of Cal/7/9 (H1N1)pdm, 
codon opt. for mus musculus 
Green fluorescent protein of Renilla reniformis, 
humanized 
Isaac Sipo 
(FG18, RKI Berlin, 
(362)) 
Primers and probes: 
AAV insert sequencing fw 5’-CCACCAGACATAATAGCG-3’ 
AAV insert sequencing ref 
(=Sp6 promoter 3’ primer) 5’-ATTTAGGTGACACTATAG-3’ 
AAV qPCR (CMV promoter) fw 5’-TGGAGTTCCGCGTTACATAACTTAC-3’ 
AAV qPCR (CMV promoter) rev 5’-CTATTGGCGTTACTATGGGAACATAC-3’ 
AAV Probe (CMV promoter) 5’-FAM-CCTGGCTGACCGCCCAACGAC-BBQ-3’ 
Enzymes: 
Fast AP Thermosensitive Alkaline Phosphatase 1 U/µl 
Thermo Fisher Scientific 
Inc.  
(Waltham, USA) 
FastDigest® BamHI 
FastDigest® Bsu36I 
FastDigest® HindIII 
FastDigest® HpaI 
FastDigest® SmaI 
Pierce® Universal Nuclease for cell lysis (Benzonase) 250 U/µl 
T4 DNA Ligase 5 U/µl 
Commercial antibodies: 
ADK9 
Anti-AAV9 (intact particle) 
Origin: mouse (monoclonal: ADK9, IgA) 
Progen (Heidelberg, Germany) 
Anti-FluA virion 
Anti-influenza A virion 
Antigen: ‘strain USSR (H1N1)’ 
Origin: goat 
5315-0064 
Bio-Rad (Hercules, USA) 
anti-GAPDH 
Anti-human GAPDH 
Origin: rabbit 
Cell Signaling Technologies (Danvers, USA) 
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Commercial antibodies: 
anti-HA2 
Anti-pdmH1N1 HA2 
Origin: rabbit 
Biorbyt (Cambridge, UK) 
Biotin-IL-2 
Anti-mouse-IL2, biotinylated 
Origin: rat (monoclonal: JES6-5H4, IgG2b) 
BD Biosciences (Franklin Lakes, USA) 
C179 
Anti-HA-stalk domain (conformational) 
Antigen: A/Okuda/57 (H2N2) 
Origin: mouse (monoclonal: M145, IgG2a) 
TaKaRa Bio Inc. (Shiga, Japan) 
donkey-anti-mouse IgG (H&L)-AF488 
goat-anti-mouse-IgA-HRP 
Thermo Fisher Scientific Inc. 
(Waltham, USA) 
IL-2 
Anti-mouse-IL2 
Origin: rat (monoclonal: JES6-1A12, IgG2a) 
BD Biosciences (Franklin Lakes, USA) 
rabbit-anti-goat (H&L)-HRP 
rabbit-anti-mouse (H&L)-HRP 
Agilent Technologies Inc. 
(Santa Clara, USA) 
Streptavidin-HRP 
Streptavidin conjugated to HRP 
016-030-084
Jackson ImmunoResearch Laboratories Inc.
(West Grove, USA)
V5-Tag 
Anti-V5-Tag 
Origin: mouse (monoclonal: SV5-Pk1, IgG2a) 
Bio-Rad (Hercules, USA) 
Kits: 
QIAamp MinElute Virus Spin Kit 
QIAfilter Plasmid Maxi Kit 
QIAquick PCR Purification Kit 
Qiagen 
(Hilden, Germany) 
Invisorb® Spin DNA Extraction Kit 
Invisorb® Spin Plasmid Mini Two 
Stratec Molecular GmbH 
(Berlin, Germany) 
1-Step™ Ultra TMB-ELISA Substrate Solution
Pierce® BCA protein assay kit
Platinum® Taq DNA Polymerase
SuperSignal™ West Dura Extended Duration Substrate
Thermo Fisher Scientific Inc. 
(Waltham, USA) 
Software: 
GraphPad Prism 7.03 GraphPad Software, Inc. 
Adobe Photoshop CS6 v.13 extended Adobe Systems Inc. 
Chemostar Professional Intas Science Imaging Instruments GmbH 
Zen 2012 (blue/black) Carl Zeiss Microscopy GmbH 
Intas GDS Intas Science Imaging Instruments GmbH 
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Software: 
Geneious 10.0.5 Biomatters Ltd. 
Microsoft Office 2010 Microsoft Corporation 
Adobe Illustrator CS6 Adobe Systems Inc. 
Endnote X7.4 Thomson Reuters 
Reader Control Software BMG Labtech 
MARS Data Analysis Software BMG Labtech 
BD Cell Quest Pro BD Biosciences 
PyMol 1.7.2.1 Schrödinger, LLC 
Consumables and Equipment: 
Amicon® Ultra-15 centrifugal filter units Merck KGaA (Darmstadt, Germany) 
Flow cytometer FACSCalibur BD Biosciences (Franklin Lakes, USA) 
Optima™-L 100K ultracentrifuge with 70-Ti 
rotor Beckman coulter 
(Brea, USA) Quick-Seal® (1x3.5 inch) ultracentrifugation 
tubes 
Cell culture incubator Binder GmbH (Tuttlingen, Germany) 
Agarose gel system Mini-Sub® 
BioRad 
(Hercules, USA) 
Mini-Protean® system 
PowerPac™ 300W HC / Basic 
Trans-Blot® SD semi-dry Transfer cell 
Gel dryer Phero-Temp 40 Biotec-Fischer GmbH (Reiskirchen, Germany) 
Micropipettes Research® plus 
Eppendorf 
(Hamburg, Germany) Thermomixer compact 
5417R cooling centrifuge 
Water bath DC10 Thermo Haake GmbH (Karlsruhe, Germany) 
Intas UV transilluminator system Intas 
(Göttingen, Germany) Advanced Fluorscence and ECL Imager 
CKX41 inverse bright field microscope Olympus (Tokio, Japan) 
LightCylcer® 480 II instrument Roche (Basel, Switzerland) 
Orbital shaker Certomat® H Sartorius Stedim Biotech (Göttingen, Germany) 
Shaker Roto-Shake Genie® Scientific Industries Inc 
(Bohemia, USA) Shaker Vortex Genie® 2 
 
Materials 
 
32 
Consumables and Equipment: 
Cell culture plastic consumables 
Sarstedt (Nürnbrecht, Germany) 
Carl Roth (Karlsruhe, Germany) 
GE Healthcare (Little Chalfont, UK) 
TTP AG (Trasadingen, Switzerland) 
Greiner Bio One (Solingen, Germany) 
Brand GmbH+KoKG(Wertheim, 
Germany) 
Thermo Fisher Scientific Inc. (Waltham, 
USA) 
centrifuge Sorvall LYNX 4000 superspeed 
Thermo Fisher Scientific Inc.  
(Waltham, USA) 
ELISA Plates Nunc Maxisorb™ 
Heraeus™ Pico™ 17 microcentrifuge 
NanoDrop™ 8000 UV/Vis Spectrophotometer 
Sterile work bench Herasafe™ KS12 
 
Chemicals & substances: 
Iodixanol, 60 % Axis Shield (Oslo, Norway) 
Bacto-agar 
Tryptone 
Yeast extract 
BD Biosciences 
(Franklin Lakes, USA) 
Bovine serum albumin (BSA), 30% MP Biomedicals (Eschwege, Germany) 
Midori green advanced DNA stain Nippon Genetics Europe (Düren, Germany) 
Polyethylenimine (PEI), molecular weight ca. 25 kDA Polyscience Inc. (Hirschberg, Germany) 
Chicken red blood cells Preclinics (Potsdam, Germany) 
TEMED 
Triton X-100 
SERVA Electrophoresis 
GmbH 
(Heidelberg, Germany) 
Isofluran, 1 ml/ml 
CP-Pharma 
HandelsGmbH 
(Burgdorf, Germany) 
Amersham™ Protran® Premium Western blotting nitrocellulose 
membranes 
Filter paper 
Whatman 
(Maidstone, USA) 
Avicel microcrystalline cellulose FMC Corporation (Philadelphia, USA) 
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Chemicals & substances: 
Agarose NEEO Ultra Quality 
Ammoniumpersulfat (APS) 
Boric acid 
C6H5O7Na3 ∙ 2H2O 
DTT 
Ethanol, ≥99.9 % 
Formaldehyde, 37 % 
Glycerole 
Glycine 
H2O2, 30% 
H2SO4, 2.5 M 
Kanamycin 
KIO4 
L-Gluatmine
Methanol, ≥99.9 % 
MgCl2 
Na2CO3 
NaCl 
Pefabloc® SC-protease-inhibitor 
PFA 
Roti®-Blue 5x concentrate 
Rotiphorese® Gel 30 (37.5:1) 
SDS, 20 % 
Skimmed milk powder 
TRIS 
Tween-20 
β-Mercaptoethanol 
Carl Roth 
(Karlsruhe, Germany) 
1 Kb Plus DNA Ladder 
6x DNA Loading Dye 
DMEM 
KH2PO4 
Lipofectamine™2000 
MEM 
Na2HPO4 
Opti®-MEM 
PageRuler™ Prestained Protein Ladder, 10 to 180 kDa 
PBS 
Penicillin/Streptomycin, 10 000 U/ml 
RPMI 
Thermo Fisher Scientific 
Inc. 
(Waltham, USA) 
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Chemicals & substances: 
Acetone 
Ampicillin 
C6H8O7 ∙ H2O 
CaCl2 
Crystal Violet 
DAPI 
DEAE-dextran 
EDTA 
Fetal bovine serum (FBS) 
KCl 
Na3VO4 
Na-deoxycholat 
NaHCO3 
NaHCO3 
Phenol red 
Ponceau S 
Sodiumpyruvate, 100 mM 
Succrose 
TPCK-treated trypsin 
Merck KGaA 
(Darmstadt, Germany) 
 
Buffers, media and solutions: 
2xYT agar plates 
1.5 % (w/v) bacto-agar 
100 mg/l ampicillin 
in 2xYT medium 
2xYT medium, pH=7.2 
1.6 % (w/v) tryptone 
1.0 % (w/v) yeast extract 
171 mM NaCl 
100 mg/l ampicillin 
in ddH2O 
Acetone, 80 % (v/v) in PBS 
Cell lysis buffer (RIPA) 
10 mM Tris/HCl (pH=8) 
150 mM NaCl 
0.5 mM EDTA (pH=8) 
0.1 % SDS 
1 % Triton X-100 
2 mM Na3VO4 
1 mM Pefablock® 
Chicken red blood cells, 1% (v/v) in PBS 
Coomassie de-staining solution 
10 % (v/v) ethanol 
5 % (v/v) acetic acid 
in ddH2O 
Coomassie fixation solution 
30 % (v/v) ethanol 
10 % (v/v) acetic acid 
in ddH2O 
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Buffers, media and solutions: 
Coomassie staining solution 
20 % Roti®-Blue 5x concentrate 
20 % (v/v) ethanol 
in ddH2O 
Crystal violet solution, 1x 
10 % (v/v) formaldehyde 
10% (v/v) crystal violet stock solution, 10x 
in ddH2O 
Crystal violet stock solution, 10x 
20 % (v/v) ethanol 
1 % (w/v) crystal violet 
in ddH2O 
DEAE-dextran, 1 % in ddH2O 
DMEM 
10 % (v/v) FBS 
2 mM L-glutamine 
100 mg/l penicillin/streptomycin 
in DMEM 
ELISA coating buffer, 50 mM pH=9.6 
71.4 mM NaHCO3 
28.6 mM Na2CO3
in ddH2O 
L-glutamine, 200 mM in ddH2O 
Glycerol, 1 % (v/v) in PBS 
H2O2, 3 % (v/v) in PBS 
KIO4, 0.011 M (w/v) in PBS 
MEM 
10 % (v/v) FBS 
2 mM L-glutamine 
100 mg/l penicillin/streptomycin 
in MEM 
MEM infection 
0.2 % (v/v) BSA 
2 mM L-glutamine 
100 mg/l penicillin/streptomycin 
in MEM 
Na-deoxycholat, 0.5 % (v/v) in PBS 
NaHCO3, 5 % in ddH2O 
PBS 
137 mM NaCl 
2.7 mM KCl 
80.9 mM Na2HPO4 
1.5 mM KH2PO4 
in ddH2O 
PBS++ 
1 mM MgCl2 
1 mM CaCl2 
in PBS 
PBS-MK 
25 mM KCl 
5 mM MgCl2 
in PBS 
PBST0.05%-0.1% 0.05 – 0.1 % (v/v) Tween-20 in PBS 
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Buffers, media and solutions: 
Polyethylenimine (PEI) solution 2.58 g/l (w/v) in ddH2O 
pH solutions, 0.1 M pH=7.2 – 4.4/+DTT 
C6H8O7 ∙ H2O C6H5O7Na3 ∙ H2O 
7.0 0 mM 100 mM 
5.8 16.0 mM 84.0 mM 
5.4 25.5 mM 74.5 mM 
5.0 35.0 mM 65.0 mM 
4.4 49.5 mM 50.5 mM 
4.4+DTT pH=4.4 + 0.1 M DTT 
in ddH2O 
PFA, 4 % in ddH2O 
Phenol red, 0.5 % (w/v) in PBS 
R10 
10 % (v/v) FBS 
2 mM L-glutamine 
100 mg/l penicillin/streptomycin 
1 mM Na-pyruvat 
50 µM β-mercaptoethanol 
in RPMI 
SDS-PAGE running buffer, 10x 
250 mM Tris 
1.92 M glycine 
34 mM SDS 
SDS-PAGE sample buffer, 6x 
500 mM Tris/HCl (pH=6.8) 
12 mM EDTA (pH=8) 
12 % (w/v) SDS 
60 % (v/v) glycerol  
0.6 % (w/v) bromophenol blue 
5 % (v/v) β -mercaptoethanol 
Semi viscous overlay medium (Plaque assay) 
0.2 % (w/v) BSA 
0.05 % (w/v) NaHCO3 
0.01 % (w/v) DEAE-dextran 
2 mM L-glutamine 
100 mg/l penicillin/streptomycin 
1.25 % (w/v) Avicell 
1-2 µg/ml TPCK-treated trypsin
in MEM
Semidry blotting buffer 
40 mM Tris 
30 mM glycine 
1.3 mM SDS 
20 % (v/v) ethanol 
in ddH2O 
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Buffers, media and solutions: 
SOC-medium 
2.0 % (w/v) tryptone 
5 % (w/v) yeast extract 
10 mM NaCl 
2.5 mM KCl 
20 mM MgCl2 
in ddH2O 
Sucrose-NTE, 25 % 
25 % sucrose 
1 M NaCl 
0.1 M Tris 
M EDTA (pH=8.0) 
in ddH2O 
Sulfuric acid, 1M in ddH2O 
TBE buffer, 10x 
0.89 M Tris 
0.89 M boric acid 
10 mM EDTA (pH=8.0) 
in ddH2O 
TBST0.05% 
100 mM Tris/HCl (pH=8.0) 
1.5 M NaCl 
0.05 % (v/v) Tween-20 
in ddH2O 
TPCK-treated trypsin, 1 mg/ml in ddH2O 
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3. METHODS
 CELL CULTURE 3.1.
Cells were maintained at 5 % CO2 and 37°C in a humidified environment in cell line specific 
culture medium. In order to maintain optimal growth, adherent cell cultures were sub-cultured 
when they reached about 90 % confluency. Therefore, cell culture medium was aspirated and the 
cells were washed once with PBS. Trypsin-versene was added to the cell culture vessel which was 
then incubated at 37°C until all cells were detached from the vessel’s surface. Cell culture medium 
was added and a fraction of the cells was transferred into a fresh cell culture vessel. 
Non adherent cell cultures were sub-cultured before pH changes in the cell culture medium were 
indicative. Therefore, the cell culture medium was transferred to 50 ml tubes and centrifuged at 
500 RCF for 5 min. After this, supernatant was aspirated and the cells were resuspended in fresh 
cell culture medium. A fraction of the cell was transferred into a fresh cell culture vessel. 
 TRANSFECTION 3.2.
 LIPOFECTAMINE®-TRANSFECTION 3.2.1.
Transfection of MDCKII cells with Lipofectamine®2000 (Thermo Fisher Scientific) was done as 
indicated by the manufacturer, whereas a 1 µg DNA per 2 µl Lipofectamin®2000 reagent was used. 
 PEI-TRANSFECTION 3.2.2.
Transfection of 293T cells with polyethylenimine (PEI) was done as in Reed et al., 2006 (372). 
Briefly, a 2.58 µg/ml PEI (linear, MW 25 kDa) solution in water was prepared according to the 
publication mentioned above and stored at -20°C until use. For optimal transfection efficiency, 
cells were seeded into cell culture vessels the day before transfection. DNA and PEI were mixed in 
adequate cell culture medium without FBS in a ratio of 1 µg DNA per 2 µl of PEI solution. The 
mixture was incubated at RT for 15 min before it was dropped directly into the cell culture 
supernatant. A change of the cell culture medium before or after the transfection was not 
performed. After 24-48 h of incubation at 5 % CO2 and 37°C, cells were further processed for 
SDS-PAGE, immunofluorescence etc. (see below). 
 PRODUCTION AND QUANTIFICATION OF INFLUENZA VIRUSES 3.3.
 PRODUCTION AND PURIFICATION OF INFLUENZA VIRUS PREPARATIONS 3.3.1.
To produce sufficient amounts of influenza virus, eleven day old embryonated chicken eggs were 
inoculated with 1000 PFU of virus per 100 µl PBS++ per egg and incubated at 37°C for 48 h in a 
humidified environment. Eggs were then refrigerated overnight at 4°C, before the eggshell was 
opened and the allantoic fluid was harvested. Debris was removed by centrifugation at 3000 RPM 
at 4°C. The cleared allantoic fluid was poured on top of a 5 ml 25 %-sucrose cushion and 
centrifuged at 24 000 RMP at 4°C for 1.5 h. The supernatant was aspirated and 1-2 ml PBS was 
added to the pellet before it was left at 4°C overnight. The resuspended pellet was aliquoted and 
stored at -80°C. Protein concentration of the purified influenza virus preparation was determined 
with Pierce™ bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific) according to 
the manufacturer’s instructions. 
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A Hemagglutination assay was performed by serially diluting the virus preparation twofold in 
50 µl PBS in V-bottom shaped 96-well plate. 50 µl of 1 % chicken red blood cells in PBS were 
added to each well and the plate was incubated at 4°C for 20 min. The Hemagglutination titer was 
determined as reciprocate of the last dilution of the virus preparation at which agglutination still 
can be observed. 
 INFLUENZA VIRUS TITRATION BY PLAQUE FORMING ASSAY 3.3.2.
MDCKII cells were seeded in 12-well plates the day before infection. Virus containing samples 
were serially diluted tenfold in 200 µl PBS++ with 0.2 % BSA. The cells were washed once with 
PBS++ before 0.15 ml of the virus dilution was added per well and the plates were incubated at 
room temperature for 45°C with occasional gentle agitation. After inoculation, cells were washed 
once again and semi-viscous overlay-medium containing 1-2 µg/ml TPCK-treated trypsin was 
added to the wells and the plates were incubated at 5 % CO2 and 37°C for 48 h. The overlay-
medium was then removed and cells were washed once with PBS and simultaneously fixed and 
stained with crystal violet solution at room temperature for 15 min. After aspiration of the 
staining solution, the cells were washed once with water and air-dried. Due to the cytolytic effect 
of influenza viruses, infected cells of cell culture monolayers become visible as a so called ‘plaque’ 
and can be counted. Viral titers are expressed as plaque forming units per ml (PFU/ml) and are 
determined by multiplying the number of plaques with the reciprocal dilution factor divided by 
0.15 (with respect to the volume used for inoculation). 
 PRODUCTION, PURIFICATION AND QUANTIFICATION OF RECOMBINANT AAV-VECTORS 3.4.
In principle, the Iodixanol-based purification protocol as suggested by Strobel et al. (373) with 
minor modifications was used for the production of recombinant AAV-vectors (Figure 12). 
Typically, 15-20 15-cm dishes of 293T cells per AAV-vector preparation were seeded the day 
before transfection. Cells were then transfected with the plasmids mentioned below by using PEI 
transfection protocol (see 3.2.2, Table 3). The amount of each plasmid used per 15-cm dish 
corresponds to an equimolar ratio of the plasmids. 
Figure 12: Schematic representation of the AAV-vector production process 
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Table 3: Amount of transfected plasmid DNA 
 for production of recombinant AAV-vectors 
amount per 15-cm dish 
pAAV 9 µg 
p5E18-VD2/9 10 µg 
pHelper 15 µg 
PEI 68 µl 
72 hours after transfection, cell culture medium was aspirated and ca. 10 ml PBS-MK were added. 
Cells were resuspended and centrifuged at 2000 RCF for 10 min. After removal of the supernatant 
5 ml PBS-MK containing 0.5 % Na-deoxycholat and 0.5 µl/ml benzonase were added for lysis of 
the cells and the cell pellet was resuspended by vortexing. The lysate was incubated at 37°C for 1 h 
and vortexed every 15 min. To remove cellular debris from the crude AAV-vector preparation, 
samples were centrifuged at 10 000 RCF for 15 min and supernatant containing the AAV-vectors 
was harvested. To purify the AAV-vectors from cellular components, a discontinuous Iodixanol 
gradient isopycnic centrifugation was performed. To this end, the crude lysate was transferred 
into ultracentrifugation tubes and underlaid with a discontinuous Iodixanol gradient (Table 4). 
Centrifugation was carried out at 300 000 RCF at 18°C for 2.5 h. In order to not disturb to 
gradient acceleration and break were set to low. 
Table 4: Composition of Iodixanol gradient steps 
Final Iodixanol 
concentration 
60% Iodixanol 
(ml) 
PBS-MK 
(ml) 
5 M NaCl 
(ml) 
phenol red 
(µl) 
Vol. in tube 
(ml) 
15 % 2,4 5,3 1,9 14,4 8,0 
25 % 3,0 4,2 - 10,8 6,0 
40 % 6,4 3,2 - - 8,0 
60 % 6,0 - - 3,0 5,0 
Subsequently, the ultracentrifugation tube was punctured with a needle and ca. 5 ml of the AAV-
vector containing 40 %-phase were extracted with the help of a syringe. 25 ml of PBS-MK were 
added and the sample was passed through a 0.45 µm pore size syringe filter. Afterwards, ultra-
centrifugal filter units (molecular weight cutoff 100 000 kDA) were used to concentrate the sample 
to approximately 1-2 ml of pure AAV-vector by centrifugation at ca. 3000 RCF for 30 min. The 
purified product was stored at -80°C. 
 TITRATION OF THE GENOMIC CONTENT OF THE AAV-VECTOR PREPARATIONS 3.4.1.
For titration of the AAV-vector preparation a quantitative real-time PCR (qPCR) was performed 
to measure the amount per microliter of product of viral genomes that are resistant to DNase 
digestion, i.e. the number of intact viral particles that encapsidate an AAV-vector genome. 
First, 10 µl of the purified AAV-vector were digested with 0.5 µl/ml Benzonase at 37°C for 1 h. 
Afterwards, viral genomic DNA was extracted according to the manual of the QIAamp MinElute 
Virus Spin Kit (Qiagen) and eluted in 100 µl water (i.e. 10-1 dilution of original material). The 
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eluate was further serially diluted tenfold with water and the dilutions 10-3 to 10-6 were used in the 
qPCR (Table 5). 
Table 5: Reaction components and conditions of the qPCR for AAV-vector titration 
Component Volume (20 µl reaction)  PCR conditions 
Aqua dest. 10,84 µl  Initially 
denature 
95°C  
10X PCR buffer (minus Mg) 2,00 µl  10 min  
50 mM MgCl2 2,00 µl  denature 
95°C 
40
 cy
cle
s 10 mM dNTPs (each) 1,60 µl  15 sec 
10 µM forward primer 0,60 µl  
anneal 
60°C 
10 µM reverse primer 0,60 µl  20 sec 
10 µM Taqman-probe 0,20 µl  
elongate 
72°C 
5 U/µl Platinum®-Taq DNA polymerase 0,16 µl  10 sec 
Sample (10-3 to 10-6 AAV DNA extraction) 2,00 µl     
 
The PCR was performed in white 96-well plates in a LightCycler®480 (Roche) instrument. 
Fluorescence was red at the beginning of each annealing cycle and quantification was calculated 
with the “Abs Quant/2nd Derivative Max” setting within the LightCycler®480 Software. For this 
purpose, a standard was included on the 96-well plate. The standard was prepared by restriction 
digesting pAAV plasmid DNA with SmaI. After separation of the digested pAAV plasmid DNA in 
an agarose gel, the respective band, i.e. a dsDNA cassette containing the complete AAV genome, 
was cut out and the DNA fragment was purified according to the manual of the Invisorb® Spin 
DNA Extraction Kit (Stratec). The concentration of the dsDNA was measured with a NanoDrop™ 
8000 spectrophotometer (Thermo Fisher Scientific) and set to 1 µg/ml. The absolute number of 
ssDNA molecules in this 1 µg/ml stock solution was calculated with the formula NDNA = NA x (10-
9 / MW), where NDNA is the number of DNA molecules in the stock solution, NA is the Avogadro 
constant and MW the molecular weight of the DNA fragment, which is calculated with the 
formula MW = (An x 313.2) + (Tn x 304.2) + (Cn x 289.2) + (Gn x 329.2) + 79.0, where An, Tn, Cn 
and Gn is the number of each of the respective nucleotides within the DNA fragment (Table 6). 
The standard stock solution was then serially diluted tenfold and the 10-3 to 10-6 dilutions were 
used for qPCR. 
Table 6: Concentration of qPCR standards for AAV-vector titrations 
AAV-vector DNA molecules per µl stock solution 
DNA molecules per µl 
standard dilution 
(10-3 to 10-6) 
HA (used also for cHA) 4.33 x108 4.33 x105 to 4.33 x102 
HL HA (used also for mHL) 5.27 x108 5.27 x105 to 5.27 x102 
NP 4.63 x108 4.63 x105 to 4.63 x102 
GFP 9.00 x108 9.00 x105 to 9.00 x102 
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 ASSESSMENT OF PURITY OF THE AAV-VECTOR PREPARATIONS 3.4.2.
The degree of purity of the AAV-vector preparation was assessed by separation of 10 µl of the 
preparation in a SDS-PAGE (see 3.6.2) followed by Coomassie staining of the gel (see 3.6.4). 
Before SDS-PAGE, samples were mixed 1:1 with 2x sample buffer with β-mercaptoethanol and 
boiled at 95°C for 5 min. 
 MORPHOLOGICAL ANALYSIS OF THE AAV-VECTOR PREPARATIONS 3.4.3.
To confirm integrity and morphology of the AAV-vectors, an ELISA with an AAV9-capsid-
specific antibody (ADK9) was performed, which recognizes its epitope only on the intact capsid 
(374). Additionally, electron micrographs were taken from the AAV preparations. 
 ADK9 CONFORMATIONAL CAPSID ELISA 3.4.3.1.
96-well ELISA plates were coated with 50 µl/well of a twofold dilution of the AAV-vector
preparations in coating buffer at 4°C overnight. The next day, plates were blocked with 3 %
skimmed milk in PBST at 37°C for 1 h. 50 µl of ADK9 diluted 1:250 in blocking buffer were added
to each well and the plates were incubated at 37°C for 1-2 h. After washing the plates three times
with PBST, 50 µl of secondary anti-mouse-IgA HRP conjugated antibody were added in a 1:1000
dilution to each well and the plates were incubated at 37°C for 1 h. 50 µ/well ELISA-substrate were
added to the plates after washing them three times. The color reaction was stopped by the addition
of 50 µl 1M sulfuric acid per well and optical density (OD) was red at 450 nm.
 ELECTRON MICROGRAPHS 3.4.3.2.
Transmission electron microscopy was performed at the RKI by Lars Möller in cooperation with 
the Centre for Biological Threats and Special Pathogens 4 (ZBS4): Advanced Light and Electron 
Microscopy. Briefly, after negative stain of AAV-vector preparations with uranylacetat, samples 
were examined on a JEM-2100 200 kilovolt transmission electron microscope (Jeol). 
 ASSESSMENT OF AAV-VECTORED TRANSGENE EXPRESSION AFTER IN VITRO TRANSDUCTION 3.4.3.3.
Infectivity of the AAV-vectors was assessed on 293T cells, since this cell line represents one of the 
very few being susceptible to AAV9 infection. 293T cells were seeded in 12-well plates the day 
before transduction. 20-40 µl of the AAV-vector preparation were then directly added to the cell 
culture medium. The next day, cell culture medium was exchanged with fresh medium and the 
cells were incubated for another 48 h before they were processed for SDS-PAGE and Western blot, 
immunofluorescence or flow cytometry (see 3.6.1, 3.6.2, 3.6.3, 3.7.1, 3.7.2). 
 CONSTRUCTION OF PAAV-PLASMIDS 3.5.
 PLASMID CONSTRUCTION 3.5.1.
A headless HA version of the A/California/7/09 (H1N1)pdm HA was constructed by exchanging 
the amino acids between cysteine 52 and cysteine 277 in HA1 with a short linker (4x glycine) 
(288). A Bsu36I restriction sites was generated downstream of the linker by introducing a silent 
mutation into the corresponding DNA sequence (C213T  P284P). A HindIII restriction site 
followed by a Kozak sequence (ACCATGA) and a BamHI restriction site were added to the 5’ and 
3’ end of the DNA fragment, respectively. 
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Modified headless (mHL) HA were constructed by adapting the amino acid changes mentioned in 
Yassine et al., 2016 (mHL1) or Impagliazzo et al., 2016 (mHL2) to the A/California/7/09 
(H1N1)pdm HA (297, 298). Of each of the mHL a version with (+TM) and without 
transmembrane domain was designed. Therefore, the terminal 36 amino acids were deleted to 
yield the mHL without transmembrane domain. A HindIII restriction site followed by a Kozak 
sequence and a BamHI restriction site were added to the 5’ and 3’ end of the DNA fragment, 
respectively. 
Figure 13: Schematic representation of the synthesized HA constructs and fragments 
as described in section 3.5.1. 
(A) Head regions (C52-C277) of H2, H10 and H13 HA with flanking (H1N1)pdm sequences and HpaI and Bsu36I restriction sites
(B) headless HA containing an insertion of 4xG linker (in red) between C52-C277. The positions of a HpaI and Bsu36I restriction 
sites upstream and downstream of the two C within HA are marked, the latter was generated by silent mutation (CT, marked 
as red in the sites’ nucleotide sequence). The headless HA sequence is flanked by a HindIII restriction site plus Kozak sequence 
(start codon in blue) and a BamHI restriction site. (C) The sequences of the modified headless (mHL1 and mHL2) are also
flanked by a HindIII restriction site plus Kozak sequence (start codon in blue) and a BamHI restriction site. (D) The pAAV-vector 
contains two long terminal repeat regions (LTR) at both ends, a CMV promoter (p), an irrelevant intron (I), a V5 Tag (V5) which 
is fused to the transgene, a poly adenylation and termination signal (pA) and the transgene, which is in this case HA, that is 
flanked by a HindIII and a BamHI restriction site. 
To generate chimeric HA (cHA) proteins, the head regions of the avian H2N3, H10N7 and 
H13N6 influenza viruses, defined as the region between cysteine 52 and cysteine 277, were used 
(270). 32 and 18 nucleotides of A/California/7/09 (H1N1)pdm HA upstream or downstream of 
cysteine 52 and cysteine 277, respectively, were added to the avian head regions. These additional 
nucleotides included a naturally occurring HpaI restriction site and a Bsu36I restriction site that 
was generated by the silent mutation mentioned above at the 5’ and 3’ end, respectively. All DNA 
fragments were codon-optimized to murine gene expression and synthesized commercially 
(GeneArt, Invitrogen, Thermo Fisher Scientific). 
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Table 7: pAAV plasmid designation and insert 
plasmid HA version comment 
pAAV-HA wildtype HA A/California/7/09 HA (H1N1)pdm 
pAAV-HA1 chimeric HA H2N3 head + (H1N1)pdm stalk 
pAAV-cHA2 chimeric HA H10N7 head + (H1N1)pdm stalk 
pAAV-cHA3 chimeric HA H13N6 head + (H1N1)pdm stalk 
pAAV-HL headless HA protein as in Steel et al., 2010 (288) adapted to (H1N1)pdm 
pAAV-mHL1 mod. headless protein as in Yassine et al., 2016 (297) adapted to (H1N1)pdm 
pAAV-mHL2 mod. headless protein as in Impagliazzo et al., 2016 (298) adapted to (H1N1)pdm 
For the construction of the cHA, headless HA fragment was restriction digested with HpaI and 
Bsu36I, 5’ ends of the DNA fragment were dephosphorylated with alkaline phosphatase and 
ligated through T4 ligase with HpaI / Bsu36I restriction digested H2N3, H10N7 and H13N6 head 
fragments to yield cHA1, cHA2 and cHA3, respectively. Subsequently, to yield the final AAV-
vectors, the headless HA, the mHL and the three cHA were restriction digested with BamHI and 
HindIII and ligated with pAAV-HA (362), which was also restriction digested with these enzymes 
and dephosphorylated (Table 7). All procedures were done according to the manufacturer’s 
instructions. Correctness of the plasmid constructs was analyzed by restriction digestion with 
BamHI and HindIII and sequencing. 
 SEQUENCING 3.5.2.
Sanger DNA sequencing was done according to the manufacturer’s instructions with the BigDye® 
Terminator 3.1 sequencing kit (Applied Biosystems) using the following protocol and insert 
sequencing primers (see section 2) (Table 8). 
Table 8: Protocol for Sanger sequencing PCR 
Component Volume (10 µl reaction) PCR conditions 
Aqua dest. ad 10 µl Initially denature 90°C / 1 min 
5x ABI reaction buffer 1.5 µl denature 96°C / 10 sec 
25
 cy
cle
s 
Primer 10 µM 0.5 µl anneal 40°C / 5 sec 
BigDye® 3.1 mix 1.0 µl elongate 60°C / 4 min 
DNA 200 ng 
 BIOCHEMICAL METHODS 3.6.
 PREPARATION OF CELL LYSATES 3.6.1.
Cell culture medium was aspirated and the cells were washed once with ice cold PBS. Fresh, ice-
cold PBS was added and the cells were detached from the cell culture vessel with a cell scraper. 
After centrifugation at 2 500 RCF at 4°C for 2 min, PBS was aspirated and lysis buffer was added 
in which the cell pellet was resuspended. Subsequently, the lysates were incubated on ice for 
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20 min before they were centrifuged at 10 000 RCF at 4°C for 10 min. Supernatant was harvested 
and stored at -20°C. 
 SDS-PAGE 3.6.2.
Polyacrylamide gels were produced in-house by first casting the separation gel between a short 
and a spacer glass plate with a spacer width of 0.75 mm (gels for Coomassie staining) or 1.5 mm 
(all others) (Table 9). After complete polymerization of the separation gel the stacking gel was 
layered over it and a 10-well comb was inserted. Finally, the gel was transferred into a vertical gel 
chamber and running buffer was added. Generally, protein samples (see 3.6.1) or purified virus 
samples (4 – 8 µg/lane) were prepared for SDS-PAGE by mixing them with 6x sample buffer with 
β-mercaptoethanol and boiling at 95°C for 5 min before they were loaded on the gel and separated 
by applying a constant electric current of 25 mA/gel to it. 
Table 9: Composition of acrylamide gels for SDS-PAGE 
Amounts are sufficient for one 1.5 mm gel. 
component separation gel 10 % 
stacking gel 
5% 
30 % Acrylamide/ Bisacrylamide (29:1) 3.3 ml 0.83 ml 
ddH2O 4.0 ml 2.8 ml 
1.5 M Tris-HCl pH 8.8 2.5 ml - 
0.5 M Tris-HCl pH 6.8 - 1.25 ml
10 % SDS 100 µl 50 µl
10 % APS 100 µl 50 µl 
TEMED 6 µl 6 µl 
 PROTEIN TRANSFER AND WESTERN BLOT 3.6.3.
Proteins were transferred from acrylamide gels to nitrocellulose membrane by stacking three 
layers of Whatman paper, one nitrocellulose membrane, the acrylamide gel and another three 
layers of Whatman paper between the anode and the cathode of a semi-dry blotting apparatus and 
applying a constant electric current of 80 mA/gel to it for 80 min. 
After protein transfer, nitrocellulose membranes were blocked with 5 % skimmed milk in TBST at 
room temperature for 1 h. Primary antibody or mouse serum (1:500) was diluted in 5 % skimmed 
milk in TBST and added to the membrane which was incubated at 4°C overnight. The next day 
HRP-conjugated secondary antibody was added after excessive washing with TBST. After another 
round of excessive washing, SuperSignal™ West Dura Extended Duration Substrate (Thermo 
Fisher Scientific) was added to the nitrocellulose membrane according to the manufacturer’s 
instructions. Chemiluminescence was detected with a ChemiDoc™ imager and the corresponding 
software (BioRad). 
 COOMASSIE STAINING 3.6.4.
After SDS-PAGE acrylamide gels were incubated in Coomassie fixation solution at room 
temperature for 30 min. The fixation solution was replaced with 1x Roti®-Blue (Roth) Coomassie 
staining solution and the gel was incubated at room temperature overnight. The next day 
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Coomassie destaining solution was added and the gel was incubated until areas without sample 
were destained completely. The gel was then rinsed with water and dried in a vacuum gel drying 
apparatus. 
 IMMUNOFLUORESCENCE STAINING 3.7.
 IMMUNOFLUORESCENCE STAINING ON COVERSLIDES 3.7.1.
4 % PFA was added directly to the cell culture medium in a 1:1 ratio (final [PFA]: 2 %) and plates 
were left at 4°C for 15 min. The supernatant was aspirated and 100 % ice-cold methanol was 
added (Note: there was no negative effect of methanol permeabilization on conformation of the 
antigens (as assessed by C179 staining) compared to other methods (e.g. Tween20, Triton x-100, 
saponin) (data not shown)). After 10 min the methanol was removed and the cells were washed 
once with PBST before they were blocked with 5 % skimmed milk and 10 % FBS in PBST at 37°C 
for 1 h. Serum or commercial primary antibodies were added to the cells appropriately diluted in 
50 µl blocking buffer for 1-2 h at 37°C. After washing the cells three times with PBST 50 µl dye-
conjugated secondary antibody (1:1000) and DAPI were added to the cells for 1 h at 37°C before 
the cells were washed again three times with PBST, one time with desalted water, mounted with 
Mowiol, and inspected under a Zeiss Axio Observer D1 inverted epifluorescence microscope or 
Zeiss LSM 780 confocal laser scanning microscope. 
 STAINING FOR ANALYSIS VIA FLOW CYTOMETRY  3.7.2.
Cells expressing transfected proteins were detached from cell culture vessel with trypsin versene 
and transferred to 15 ml centrifugation tubes. After centrifugation (500 RCF, 5 min) 2 % PFA was 
added, cell were resuspended and fixed at 4°C for 20 min. The cells were centrifuged, supernatant 
was aspirated and 100 % ice-cold methanol was added at -20°C for 10 min. After washing the cells 
two times with PBST, the cells were resuspended in 5 % skimmed milk and 10 % FBS in PBST and 
transferred into a 96-well plate (50 µl per well). The plates were centrifuged after 1 h incubation at 
37°C before 50 µl/well serum or primary antibody at an appropriate dilution was added for 1-2 h 
at 37°C. After washing the cells three times with PBST 50 µl dye-conjugated secondary antibody 
(1:1000) were added to the cells for 1 h at 37°C before the cells were washed again three times with 
PBST. Fluorescence was measured with a BD FACSCalibur™ flow cytometer (BD). Analysis was 
done with BD CellQuest™ Pro. 
 SEROLOGICAL METHODS 3.8.
 ELISA 3.8.1.
96-well high-binding ELISA plates were coated with antigen (4-8 µg/ml purified influenza virus or
1:500 dilution of AAV) in 50 µl coating buffer at 4°C overnight. The next day coating buffer was
aspirated and plates were blocked with 100 µl 5 % skimmed milk in PBST at 37°C for 1 h. Blocking
buffer was removed and 50 µl/well serum serially diluted in blocking buffer were added to each
well and the plates were incubated at 37°C for 1-2 h. After washing the plates three times with
PBST, 50 µl of secondary HRP conjugated antibody were added in a 1:1000 dilution to each well
and the plates were incubated at 37°C for 1 h. 50 µ/well ELISA-substrate were added to the plates
after washing them three times. The color reaction was stopped by the addition of 50 µl 1M
sulfuric acid per well and OD was red at 450 nm.
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 CONFORMATIONAL CHANGE ELISA 3.8.2.
96-well ELISA plates were coated with antigen (4-8 µg/ml purified influenza virus) in 50 µl
coating buffer at 4°C overnight. The next day coating buffer was aspirated and plates were
incubated with 50 µl/well of different 0.1 M citric acid – sodium citrate buffer solutions (pH = 7.2,
5.8, 5.4, 5.0, 4.4 or 4.4 + 0.1 DTT) at room temperature for 30 min. Afterwards, the plates were
washed two times with PBST and then blocked and incubated with antibody as indicated above
(see 3.8.1).
 IN-CELL ELISA 3.8.3.
MDCKII cells were seeded in 96-well plates and transfected as described under 3.2.1. 48 h post 
transfection, 4 % PFA was added directly to the cell culture medium in a 1:1 ratio (final [PFA]: 
2 %) and plates were left at 4°C for 15 min. The supernatant was aspirated and 100 µl 100 % ice-
cold methanol were added. After 10 min the methanol was removed and the cells were washed 
once with PBST before they were blocked with 100 µl of 5 % skimmed milk and 10 % FBS in PBST 
at 37°C for 1 h. After quenching of the endogenous peroxidase with 100 µl of 3 % H2O2 at room 
temperature for 30 min, 50 µl of mouse serum or C179 antibody in blocking buffer were added to 
each well at a dilution of 1:250 for 1 h at 37°C. After washing the cells three times with PBST, 50 µl 
HRP-conjugated secondary antibody (1:1000) and was added to the cells for 1 h at 37°C before the 
cells were washed again three times with PBST and 50 µ/well ELISA-substrate were added to the 
plates after washing them three times. The color reaction was stopped by the addition of 50 µl 1M 
sulfuric acid per well and OD was red at 450 nm.  
 INFLUENZA VIRUS MICRONEUTRALIZATION ASSAY (MN) 3.8.4.
MN was performed as outlined in He et al., 2015 (375), which is an extended version of a WHO 
recommended protocol (376) to capture effects of anti-HA (stalk) antibodies on events in the late 
viral replication cycle. MDCKII cells were seeded in 96-well plates one day before the assay. Sera 
were inactivated by heating to 56°C for 30 min and subsequently diluted 1:20 in MEM with 0.2 % 
BSA with 1 µg/ml TPCK-treated trypsin. 1:20 diluted sera were serially diluted twofold in MEM 
with 0.2 % BSA with 1 µg/ml TPCK-treated trypsin. Additionally, two control dilutions (cell ctrl. 
and virus ctrl.) where prepared which did not contain serum. 3.5 x104 PFU influenza virus 
(mouse) or 2 x102 PFU (ferret) in 25 µl MEM with 0.2 % BSA with 1 µg/ml TPCK-treated trypsin 
were added to 25 µl of each serum dilution and the virus ctrl. wells. No virus was added to the cell 
ctrl. wells, instead only MEM 0.2 % BSA with 1 µg/ml TPCK-Treated trypsin was added and all 
plates were incubated at 37°C for 1 h. The final starting serum dilution was now 1:40. MDCKII 
cells were washed once with PBS++ and the serum/virus mixture (50 µl) was transferred to the 
cells. The cells were inoculated at 37°C for 1 h before they were washed once with PBS++ and 50 µl 
serum in the identical dilution as before was added to each well in MEM with 0.2 % BSA with 
1 µg/ml TPCK-treated trypsin.  
After 24 h incubation at 5 % CO2 and 37°C, cell culture medium was aspirated, cells were fixed 
with 80 % ice-cold acetone for 10 min at room temperature, air dried and blocked with 5 % 
skimmed milk in PBST for 45 min at 37°C before endogenous peroxidase was quenched with 
100 µl/well 3 % H2O2 at room temperature for 30 min. Cells were washed once with PBST and 
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50 µl/well primary polyclonal goat anti-influenza antibody (5315-0064, BioRad; 1:1000 in blocking 
buffer) were added for 1-2 h at 37°C. After washing the plates 3-times with PBST, 50 µl secondary 
HRP-conjugated anti-goat antibody were added to the cells diluted 1:1000 in blocking buffer and 
they were incubated at 37°C for 1 h. Cells were washed 3-times and 50 µl ELISA-substrate were 
added. After color development the reaction was stopped with 50 µl 1 M sulfuric acid and OD was 
red at 450 nm. Neutralization was calculated with the following formula, whereas resulting values 
that were above 1 were set to be 1 and values that were below 0 were set to be 0: 
MN (fold)= 1 - ODwell-meanOD all cell ctrl. wells
meanOD all wells of resp. dilution
 
 HEMAGGLUTINATION INHIBITION ASSAY (HAI) 3.8.5.
For inactivation, 1 volume of serum was mixed with 0.5 volumes of 8 µg/ml TPCK-treated trypsin 
and incubated at 56°C for 30 min. Samples were cooled down to room temperature and 3 volumes 
of 0.011 M KIO4 were added before samples were incubated at room temperature for 15 min. 
Afterwards, 3 volumes of 1 % glycerol were added and samples were incubated at room 
temperature for 15 min. Finally, 12.5 volumes of PBS were added to reach a starting dilution of 
1:20. The sera were further diluted twofold in 25 µl PBS in a V-bottom shaped 96-well plate. 
Additionally, two control dilutions (no virus ctrl. and no serum ctrl.) where prepared which did 
not contain serum. 4 HA units of virus in 25 µl PBS were added to each well except for the no 
virus ctrl to which only 25 µl PBS were added (starting dilution of serum 1:40). The plates were 
incubated at 37°C for 1 h. 50 µl of 1 % chicken red blood cells in PBS were added to each well and 
the plate was incubated at 4°C for 20 min. The HAI titer is determined as reciprocate of the last 
dilution of serum at which agglutination is still inhibited. 
 AAV MICRONEUTRALIZATION ASSAY (AAV MN) 3.8.6.
AAV MN was principally performed as described by Meliani et al., 2015 (377). 293T cells were 
seeded in 96-well plates. The next day, serum was pre-diluted 1:50 in FBS and inactivated at 56°C 
for 30 min. Semi-log10 dilutions of the serum were prepared in FBS, starting with the 1:50 pre-
dilution. Additionally, two control dilutions (cell ctrl. and virus ctrl.) where prepared which did 
not contain serum. AAV-GFP was diluted in DMEM with 0 % FBS to 2.22 x1010 GC/ml. 27 µl of 
each serum dilution and virus ctrl. were mixed with 27 µl of AAV GFP dilution (i.e. 6 x108 
GC/well) and incubated at 37°C for 1 h. 27 µl of DMEM with 0 % FBS were added to the cell ctrl. . 
20 µl of the serum/virus mixture were added directly to the cell culture medium of the 293T 96-
well plate and cells were incubated at 5 % CO2 and 37°C for 48 h. 
Cell culture medium was aspirated and cells were washed once with PBS before trypsin-versene 
was added and the cells were left at 37°C until a single cell suspension was established. Cell culture 
medium was added to the cells and the plates were centrifuged at 500 RCF for 5 min. Supernatant 
was aspirated and 0.5 % PFA was added at room temperature for 15 min. Finally, PBS was added 
and the plates were centrifuged again before fresh PBS was added, cells were resuspended and 
green fluorescence was measured with a BD FACSCalibur™ flow cytometer (BD). Analysis was 
done with BD CellQuest™ Pro. 
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 FC-GAMMA RECEPTOR ASSAY (INFECTION & TRANSFECTION BASED) 3.8.7.
The FcγR assay (courtesy of Prof. Dr. med. Hartmut Hengel, Universitätsklinikum Freiburg) is 
based on the protocols described in Corrales-Aguilar et al., 2013 and Van den Hoecke et al., 2017 
(225, 378). BW 5147 reporter cell lines that stably express chimeric surface receptors comprising 
the extracellular domain of the murine FcγRI, -IIB, -III or -IV and the intracellular signaling 
module of the murine CD3-ζ chain were produced by lentiviral transduction as described in (225, 
378, 379). Upon activation of the FcγR by immune complexes IL-2 is produced which is quantified 
by ELISA. MDCKII cells were seeded into 96-well plates one day before they were washed once 
with PBS++ and infected with 1 x104 PFU/100 µl per well influenza virus in MEM with 0.2 % BSA 
without TPCK-treated trypsin, or mock infected. No washing was performed after infection. 
Alternatively, MDCKII cells were seeded into 96-well plates one day before they were transfected 
with 0.4 µg plasmid DNA using the Lipofectamine™ protocol mentioned above (see 3.2.2) or mock 
transfected. On the following day, cell culture medium was exchanged with fresh medium. The 
next day, serum was inactivated at 56°C for 30 min and twofold dilutions were prepared in 50 µl 
R10 medium starting with a dilution of 1:50. Cell culture medium was aspirated and 50 µl/well of 
the serum dilution were added for 1 h at 37°C. 50 µl of only the 1:50 dilution were added to mock 
infected or transfected wells. During the incubation period, FcγR cells were counted and 
concentration was set to 1-2 x105 cells per 200 µl R10 medium. The MDCKII cells were washed 
once with PBS++ and 200 µl FcγR cells per well were added before the cells were incubated over 
night at 5 % CO2 and 37°C. Finally, ELISA plates were coated with 1 µg/ml anti-IL2 antibody in 
50 µl coating buffer overnight at 4°C. 
Figure 14: Schematic representation of the experimental protocol of the influenza virus infection-based FcγR assay 
as described in section 3.8.7; modified from (378). 
The next day, 100 µl PBS with 0.1 % Tween-20 and 5 % FBS were added to the MDCKII / FcγR co-
culture and cells were resuspended 5 times in order to lyse the cells and release the IL-2. ELISA 
coating buffer was aspirated and plates were blocked with PBST with 10 % FBS at room 
temperature for 1 h. 150 µl of the MDCKII / FcγR co-culture supernatant were transferred to the 
ELISA plates before they were incubated at room temperature for 1-2 h. After washing the plates 
three times with PBST, 50 µl of 1 µg/ml biotinylated anti-IL2 antibody were added to each well 
and the plates were incubated at room temperature for 1 h. 50 µl per well HRP-conjugated 
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streptavidin was added in a 1:1000 dilution after washing the plates three times with PBST. After 
30 min incubation at room temperature the plates were washes again three times with PBST and 
50 µl of ELISA substrate were added. After color development the reaction was stopped with 50 µl 
1 M sulfuric acid and OD was red at 450 nm. FcγR activation was calculated by subtracting the 
mean of the mock infected or transfected wells (i.e. background) from the infected or transfected 
wells.  
 MICE 3.9.
6 - 8 week old female C57BL/6NCrl mice were purchased from Charles River. The animals were 
allowed to acclimate to the housing conditions for one week prior to any experiment. Mice were 
kept in a 12/12 h light-dark cycle at 22°C, with an air exchange rate of 10 – 12 times per day in 
groups of 5 animals per cage containing enrichment. 
All experiments were performed in accordance with protocols approved by the Landesamt für 
Gesundheit und Soziales (LAGeSo) Berlin (reference numbers G 0256/14, G 254/15, G 0255/16). 
 IMMUNIZATION 3.9.1.
Animals were anesthetized with Isofluran and immunized either intramuscularly or intranasally 
with the respective vaccines (Table 10) in a volume of 50 µl PBS which was evenly distributed to 
both posterior limbs and nostrils, respectively. 
Table 10: Doses of vaccines used for mouse immunization studies 
Vaccine Immunization route Dose per mouse 
AAV intramuscular 1 x10
10 vg 
intranasal 1 x1011 vg 
WIV intramuscular/intranasal 20 µg 
 INFECTION 3.9.2.
Animals were anesthetized with Isofluran and infected intranasally with a lethal dose of influenza 
virus (Table 11) in a volume of 50 µl PBS which was evenly distributed to both nostrils. Mice were 
monitored daily for survival and weight loss and general signs of disease until day 14 where they 
were anesthetized and sacrificed and lungs were harvested (see 3.9.4). Animals that lost more than 
20 % of their initial weight or reached another humane endpoint were euthanized immediately. 
Table 11: Lethal doses of influenza viruses used for mouse infection studies 
Virus TCID50 / mouse 
A/California/7/09 (H1N1)pdm 7.94 x103 
A/Puerto Rico/8/34 (H1N1) – low dose 2.51 x104 
A/Puerto Rico/8/34 (H1N1) – high dose 5.01 x104 
X31 (H3N2) 1.00 x105 
 BLOOD COLLECTION AND SERUM PREPARATION 3.9.3.
Blood sampling was done before each immunization and before the challenge infection of the 
mice. Animals were anesthetized with Isofluran and blood was drawn from the retrobulbar plexus 
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and left at room temperature for ca. 30 min. The coagulated blood samples were centrifuges at 
2500 RCF for 30 min and the supernatant, i. e. the serum, was harvested and stored at -80°C. 
 LUNG HOMOGENIZATION 3.9.4.
Lungs of mice were harvested and stored at -80°C. Subsequently, all organs were thawed on ice 
and lung tissue was weighted. The lungs were transferred into FastPrep® Lysing Matrix D tubs 
(MP Biomedicals) and 1 ml cold PBS was added before the tissue was homogenized in a FastPrep-
24™ apparatus at 6 m/sec for 40 sec. Afterwards, FastPrep® tubes were centrifuged at 4000 RPM 
and 8°C for 5 min and supernatant was transferred into fresh 1.5 ml-tubes which were centrifuged 
again at 10 000 RPM and 8°C for 5 min. Again, supernatant was transferred into 15 ml-tubes and 
PBS was added to reach a final volume of 10-times the lung weight (i.e. 0.1 g lung tissue – 1 ml 
PBS). The diluted lung homogenates were aliquoted and stored at -80°C. 
 FERRETS 3.10.
Experiments with ferrets were done in cooperation with the group of Prof. Dr. Veronika von 
Messling (Division of Veterinary Medicine, Paul-Ehrlich-Institut (Langen)). Daniel Demminger 
went to the PEI for the first immunization and for the complete challenge period and assisted 
during all experimental procedures except for homogenization and titration of ferret organ 
samples, titration of nasal washes and IPMA for influenza-specific ferret serum antibodies, which 
were done by Lisa Walz and Yvonne Krebs at the PEI. All other serological assays and all analyses 
were done by Daniel Demminger. (Immuno-)Histological staining and examination of ferret 
organ samples was done by Kristina Dietert from the group of Prof. Dr. Achim D. Gruber 
(Department of Veterinary Medicine, Institute of Veterinary Pathology, Freie Universität 
(Berlin)). 
 ANIMALS 3.10.1.
16 four month old male ferrets (Mustela putorius furo) were obtained from Euroferret 
(Denmark) and housed at the Paul-Ehrlich-Institut (Langen). Animals were acclimated to the 
housing conditions and sero negativity to circulating influenza viruses was confirmed by IPMA 
(data not shown). For experiments, animals were housed in groups of four. 
 IMMUNIZATION 3.10.2.
Animals were anesthetized with ketamine (100 mg/kg) and medetomidine (0.05 mg/kg), and 
immunized either intranasally with AAV-vector vaccines in a volume of 250 µl PBS which was 
evenly distributed to both nostrils, or intramuscularly with human QIV into one posterior limb 
(Table 10). 
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Table 12: Doses of vaccines used for ferret immunization studies 
Vaccine Immunization route Dose per ferret 
AAV intranasal 1.875 x1012 vg 
QIV 
Influsplit Tetra (2017/2018): 
A/Michigan/45/2015(H1N1)pdm-like 
A/Hong Kong/4801/2014(H3N2)-like 
B/Brisbane/60/2008  
B/Phuket/3073/2013 
intramuscular human dose (15 µg per HA) 
 INFECTION 3.10.3.
Animals were anesthetized with ketamine (100 mg/kg) and medetomidine (0.05 mg/kg) ,and 
infected intranasally with a sub-lethal dose of influenza virus (Table 11) in a volume of 200 µl 
Opti-MEM which was evenly distributed to both nostrils. 
Table 13: Doses of influenza viruses used for ferret infection studies 
Virus TCID50 / ferret 
A/Mexico/InDRE4487/2009 (H1N1)pdm 1 x105 
Ferrets were monitored twice daily for signs of disease using a 0-1-2 scale for activity (normal, 
calm, depressed), respiratory signs (sneezing, nose exudate and congestion) and general clinical 
signs. Zero indicates minimal deviation from the physiological state, 1 indicates moderate nasal 
discharge, congestion and/or occasional sneezing and/or calm temper while 2 indicates severe 
nasal discharge and/or labored breathing, dyspnea and frequent sneezing and/or depressed 
manner (380). Changes in body weight and body temperature were measured. Nasal washes were 
collected once a day in which virus titers were determined (see 3.10.6). On day three post 
infection, animals were exsanguinated and nasal turbinates, trachea and lung were harvested. 
Nasal turbinates and parts of the traches and the lung where stored at -80°C until further use (see 
3.10.4). Trachea and lung samples were also fixed with paraformaldehyde for histopathological 
examination (see 3.10.7). 
  SAMPLE COLLECTION (ORGAN, BLOOD, NASAL WASHES) 3.10.4.
Blood sampling was done before each immunization and before the challenge infection of the 
mice. To this end, ferrets were anesthetized with ketamine (100 mg/kg) and medetomidine (0.05 
mg/kg), and blood was drawn from the anterior vena cava with Z Serum Sep Activator tubes 
(Greiner bio-one) which were then centrifuged for 15 min at 1600 RCF before serum was 
transferred into fresh vessel and stored at -20°C until further use.  
Nasal washes where performed on the non-anesthetized animal. Approximately 500 µl of PBS was 
instilled into one nostril and expectorate was collected into a 50 ml tube. This procedure was 
repeated until a minimum volume of 400 µl was reached. Debris was removed by centrifugation 
before virus titers were determined by the TCID50 method (see 3.10.6). 
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Organ samples were thawed, weighed and homogenized in FastPrep® tissue homogenizer 
according to the manufacturer’s instructions, debris were removed by centrifugation and virus 
titers per gram tissue weight were determined by the TCID50 method (see 3.10.6). 
 DETERMINATION OF SERUM ANTIBODY TITERS 3.10.5.
Serum antibody titers against Cal/7/9 virus were determined by immuno-peroxidase monolayer 
assay (IPMA) as described before (381).  
 VIRUS TITRATION 3.10.6.
Virus titration in nasal wash samples and tissue homogenates was done as described before (381). 
 HISTOPATHOLOGY AND IMMUNOHISTOCHEMISTRY 3.10.7.
2 µm sections of hematoxylin and eosin stained organ samples were prepared and analyzed 
microscopically by the board-certified veterinary pathologists Kristina Dietert and Achim D. 
Gruber to assess character and severity of pathologic lesions using lung specific inflammation 
score parameters for quantifying influenza virus-induced pneumonia as described (382). These 
parameters included severity of (i) interstitial pneumonia with infiltration by macrophages, 
lymphocytes, neutrophils (ii) bronchitis, (iii) epithelial necrosis of bronchi, alveoli and, 
submucosal glands, (iv) perivascular lymphocytic cuffing, and (v) hyperplasia of type II 
pneumocytes. 
Also, influenza A virus antigen was detected via an goat anti-influenza A virion antibody and 
corresponding phosphatase-conjugated secondary antibody. Binding was detected with the 
chromogen triamino-tritolyl-methanechloride (Neufuchsin), and slides where counterstained 
with hematoxylin and eosin. Samples from non-influenza infected ferrets served as negative 
control for histopathological and immunohistochemical analysis. Neither one of the above 
mentioned influenza-infection specific parameter nor influenza virus antigen could be detected in 
these control samples (data not shown). 
 STATISTICS 3.11.
Statistical analyses were performed using GraphPad Prism version 7.03 for Windows (GraphPad 
Software, La Jolla California USA, www.graphpad.com). Results are presented as mean ±/+ 
standard deviation or standard error of the mean (linear scales) or as geometric mean (log scales) 
as indicated in the figure legend. ELISA results are presented as area under the curve (AUC) of the 
OD (450nm)–serum dilution curve. For comparison of two unmatched groups, a non-paired, 
non-parametric Mann-Whitney test was used. Analysis of peptide-screen data was done with one-
sample t-test (hypothetical value: 1) after normalization to control values obtained for AAV-GFP 
serum. For comparison of three or more groups a non-paired, non-parametric Kruskal-Wallis test 
was used in combination with Dunn’s posttest. Groups where either compared to a control group 
or to each other, as indicated in the figure legends. For comparison of matched data, a paired, 
non-parametric Friedman-test was used in combination with Dunn’s posttest. Groups were 
compared to their individual day sero values. Analysis of survival data was done with log rank 
Mantel-Cox test comparing treatment groups with each other or to a control group as indicated in 
the figure legend. Linear regression curves where fitted to the data using the “linear regression” 
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option. Curves are displayed with the 95% confidence band, i.e. the area that contains the true 
regression curve with 95% confidence, in the figures. The correlation coefficient (r2) is reported as 
measure of goodness-of-fit of the regression together with a p value testing the null hypothesis is 
the slope of the best fit curve zero. Nonlinear regression was performed using the “nonlinear 
regression - [Inhibitor] vs. response -- Variable slope (four parameters)” option. Default settings 
where used except for analysis of influenza microneutralization assays, where the fitting was 
constrained with the setting “Bottom: Shared value for all data set”. Correlation coefficient where 
between r2 = 0.93-0.99 for all nonlinear regressions. IC50 values are reported where indicated.
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4. RESULTS 
 AAV-VECTORS INDUCE STRONG IN VITRO ANTIGEN EXPRESSION 4.1.
AAV-vectors represent one of the most promising viral vectors not only for use in human gene 
therapy, but also as carrier for vaccines against viral pathogens including influenza viruses (361). 
Although AAV-vectors have been used for passive immunization with broadly reactive influenza-
specific antibodies, there is a lack of knowledge on the influence of AAV-vectored expression of 
influenza wildtype or broadly reactive antigens on the breadth of the immune response and on 
protection against influenza virus challenge. In this context, a direct comparison of AAV-vectored 
and inactivated vaccine is missing, too. Thus, in this thesis the immunogenicity and protective 
efficacy of AAV-vectors expressing HA, NP, chimeric HA or headless HA was evaluated in mice 
and compared to immunization with whole inactivated virus (WIV). Finally, AAV-vectored 
influenza vaccines were also evaluated in the gold-standard human influenza animal model, the 
ferret. 
Based upon the (H1N1)pdm-based AAV9-vectors described by Sipo et al., four additional 
AAV-vectors were constructed during the first phase of the project (Figure 13) (362). (H1N1)pdm 
viruses, including the prototypic A/California/7/09 (Cal/7/9), caused the most recent influenza 
pandemic and have been circulating seasonally in humans ever since with only minor antigenic 
changes. A (H1N1)pdm virus strain has thus been included in the seasonal vaccine from 2010 on 
(383). Therefore, Cal/7/9 was chosen as vaccine virus in this study. 
For the generation of an Cal/7/9-based headless HA, the region between cysteine52 and 
cysteine277 within the Cal/7/9 HA amino acid sequence, i.e. the HA-head, was replaced with a 
tetra-glycine linker as described by Steel et al. (288) (Figure 13B). In the original publication, these 
particular cysteines were chosen due to their close proximity to each other enabling their 
connection via a short flexible linker (288). Three different cHA were constructed by swapping the 
respective region in the headless HA with the exotic HA-head regions of the avian viruses H2N2 
(cHA1), H10N7 (cHA2) or H13N6 (cHA3) (Figure 13A). Thus, cHA1 and cHA3 contain a HA-
head region from group 1 influenza A viruses, while cHA2 contains a group 2 HA-head (Figure 
1). Various chimeric combinations of HA-heads and stalks were shown in other studies to behave 
comparable to their parental counterparts (271). Hence, there is apparently no predictor for the 
resulting overall HA structure. The H2, H10, and H13 HA-head regions were chosen i) based on 
availability of the parental viruses at the Robert Koch Institute and ii) because they are currently 
not circulating in humans. Therefore, little to no immunological experience in humans, i.e. 
immunological naivety, against these virus subtypes can be expected. All constructs/fragments 
were synthesized de novo and optimized to mammalian (i.e. murine) gene expression. cHA and 
headless HA were eventually inserted into the pAAV-vector plasmid from which they are 
expressed under the control of a Cytomegalovirus (CMV) promoter enabling ubiquitous tissue 
expression (362). Furthermore, the expressed proteins are tagged with a simian virus 5 epitope tag 
(V5-tag).  
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The transgene cassette is flanked by AAV2 ITR which enable transencapdsidation into the 
AAV9 capsid (Figure 13D). The constructs were named pAAV-HL, pAAV-cHA1, pAAV-cHA2 
and pAAV-cHA3. 
Figure 15: In vitro expression and HA-stalk conformation of the AAV-vectored antigens 
(A) Three dimensional structure of a trimeric HA protein (PDB: 3UBE). HA1 (black) and HA2 (grey) subunits are
indicated as well as the position of the RBS (yellow). The globular HA-head and the membrane proximal stalk domain 
are indicated. All antigens are based on sequences of A/California/7/2009 (H1N1)pdm virus. cHA1 contains the HA-
head region of the HA from an avian H2N2 virus, while cHA2 contains the HA-head from an avian H10N7 and cHA3
from an avian H13N6 virus. While the HA-head region is deleted in headless HA, mHL1 and mHL2 contain further
substitutions and/or deletion (yellow) to stabilize the conformation of the HA-stalk. Initially, of each mHL a version
with (+TM) and without transmembrane domain was evaluated. All constructs carry a V5-tag at their C-terminus (V5). 
(B) Immunoblot analyses of 293T cell lysates 48 h after transfection with pAAV-vector plasmids. Expression of
antigens was detected with anti-V5-tag antibody and equal loading was confirmed with anti-GAPDH antibody. (C) 
Immunofluorescence staining of 293T cells 48 h after transfection with AAV-vector plasmids. Cells were fixed,
permeabilized and stained with the conformational HA-stalk antibody C179 or anti-V5-tag antibody and suited dye-
conjugated secondary antibody (green). Nuclei are shown in blue (DAPI) (scale bar: 20 µm) (n=3). (D) Cells were
transfected with pAAV-vector plasmids for 48 h, fixed, permeabilized and stained with C179 (filled bars) or anti-V5-tag 
(empty bars) antibody and suited dye-conjugated secondary antibody. Amount of antibody-positive cells was
quantified by flow cytometry (mean+SD, n=3). 
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With the advent of stabilized headless HA, hereafter referred to as modified headless HA 
(mHL), antigen design concepts as described by Yassine et al. (mHL1) and Impagliazzo et al. 
(mHL2) were included at a later time point in the project as well (297, 298). These mHL contain 
substitution which for instance generate additional stabilizing disulfide bridges within the HA-
trimer or remove polar and/or hydrophobic surfaces, the undesired exposure of which is 
associated with the removal of the HA-head. Furthermore, they contain stabilizing trimerization 
elements at the membrane proximal or distal part of the HA-stalk (297, 298). 
In this thesis, the sequence alterations described in the aforementioned publications were 
adapted to the Cal/7/9 HA sequence. In contrast to the unmodified headless HA described by 
Steel et al., Gen6 (Yassine et al.) is stabilized by several amino acid substitutions and deletions 
within the HA-stalk region, as well as fusion to a nanoparticle carrier, which maintains a native 
protein fold as shown in the original publication by binding to the conformational HA-stalk 
antibody CR6261 (198, 297). The construct #4900 (Impagliazzo et al.) contains a trimerization 
motif also at the membrane distal end of the HA-stalk in addition to other substitution which 
increase its stability (288). A native protein fold was assessed with the conformational antibodies 
CR6261 and CR9114 in the original publication (198, 202, 298). Due to the high conservation of 
the amino acids between the parental HA of Gen6 (A/New Caledonia/20/1999 (H1N1)) and #4900 
(A/Brisbane/57/2007 (H1N1) and A/California/4/2009 (H1N1)pdm) and the Cal/7/9 HA, it was 
expected that the adaptation of the respective alterations to the Cal/7/9 HA would result in 
comparable antigen structures (297, 298). While the antigens described in the original 
publications represent secreted protein (coupled to a nanoparticle carrier in case of Gen6) a 
version of each mHL with and without the original Cal/7/9 HA transmembrane domain (TM) was 
generated (mHL+TM or mHL+TM). As with the antigens mentioned above, mHL were optimized 
to mammalian gene expression, synthesized de novo and inserted into the pAAV-vector (Figure 
13C; Figure 15A). These constructs were designated pAAV-mHL1, pAAV-mHL1+TM, pAAV-
mHL2 and pAAV-mHL2+TM. 
High transgene expression could be verified for each antigen after transfection of cells with the 
pAAV-vector plasmids (Figure 15B). However, wildtype antigens HA and NP as well as mHL1 
and mHL2 showed a somewhat higher expression level compared to the cHA, headless HA, 
mHL1+TM and mHL2+TM (Figure 15B). As mentioned in section 1.3.2, several HA-stalk 
binding antibodies, such as the prototypic C179, recognize conformational epitopes (193). 
Therefore, C179 was used to approximate whether the HA-stalk domain is folded correctly 
(Figure 15, C and D). Interestingly, apart from wildtype HA, only cHA3 and mHL1+TM were 
recognized by C179 comparable to the level of recognition seen with V5-tag antibody (Figure 15, 
C and D). While cHA1 and mHL1 showed reduced reactivity, the C179 epitope seems not to be 
intact in cHA2, headless HA, mHL2 and mHL2+TM (Figure 15D). Since mHL1+TM and 
mHL2+TM did show decreased in vitro antigen expression compared to their counterparts 
without TM, only mHL1 and mHL2 were pursued. 
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Initially, production of AAV-vector stocks was performed in suspension cells grown in spinner 
bottles (not shown). Although AAV-vector stocks produced that way were successfully used in the 
experiments outlined in Figure 17 to Figure 19, inter-stock variability prompted further 
optimization of the production and purification methodology. Finally, a streamlined purification 
protocol as depicted in Figure 12 was established, with which AAV-vector stocks could be 
reproducibly produced that contain high amounts of encapsidated viral genomes (vg) (Figure 16, 
A to D). Particle morphology and integrity of the preparations was assessed by electron 
microscopy (EM) as well as ELISA with the antibody ADK9, which is specific for intact AAV9 
capsids (Figure 16, A and C) (374). All preparations contained nearly only intact AAV9 particles 
in the characteristical icosahedral shape. EM also revealed a high grade of dispersion within the 
preparation and a medium to high full to empty particle ratio, which will likely positively 
influence infectivity and immunogenicity (Figure 16, A and B). Coomassie staining of 
electrophoretically separated AAV-vector preparations together with EM data also indicated high 
purity of the preparation, while all three AAV capsid proteins (VP1, 2 and 3) could be clearly 
identified (Figure 16D). As expected, the AAV-vector preparations where highly infective in vitro 
and induced strong antigen expression (Figure 16, E and F). High infectivity and strong transgene 
expression in vitro suggested their suitability for vaccination of animals. 
Figure 16: Quality analysis of AAV-vector stocks used for animal trials 
(A) AAV-vector preparations were analyzed under a transmission electron microscope for impurities, particle
dispersion and morphology (shown here: AAV-HA). qPCR titration of AAV-vector stocks yielded titers in the range of
1010 vg/µl. (B) Full and empty AAV particles were counted on the electron micrographs and a ratio was calculated
(min. five pictures; mean±SD). (C) 2-fold serial dilutions of AAV-vector stocks were coated on ELISA plates. Intact
particles were detected with the conformational AAV9-antibody ADK9 and suited secondary antibody (mean±SD of
tech. duplicates, representative result). (D) 10 µl of each AAV-vector preparation were separated on SDS-PAGE and
proteins were stained with coomassie. The position of the three AAV proteins (VP1, VP2, VP3) is indicated
(representative result). (E) Immunoblot analyses of 293T cell lysates 72 h after infection with AAV-vectors at an MOI of
106. Expression of antigens was detected with anti-V5-tag antibody and equal loading was confirmed with anti-
GAPDH antibody (n=3). (F) Cells were infected with AAV-vectors at an MOI of 106 for 72 h, fixed, permeabilized and
stained with anti-V5-tag antibody and suited dye-conjugated secondary antibody. Amount of antibody-positive cells
was quantified by flow cytometry (mean+SD, n=2 in tech. duplicates). 
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 AAV-HA AND AAV-CHA ARE IMMUNOGENIC IN MICE AFTER INTRAMUSCULAR APPLICATION 4.2.
To assess immunogenicity of AAV-HA, AAV-cHA and AAV-HL in mice, groups of three to 
five animals were immunized intramuscularly (i.m.) in three week intervals with 1x1010 vg 
according to the scheme depicted in Figure 17A. Different vaccination regimens were tested to 
evaluate the influence of antigen combinations on broadly reactive HA-stalk antibody responses 
(Figure 17B): Animals either received AAV-cHA (groups 1 & 2), AAV-HL (groups 7 to 9) or 
combinations thereof (groups 3 to 6). Additionally, groups of mice were immunized with AAV-
HA (group 10) or AAV-GFP (group 11), the latter of which expresses the green fluorescent 
protein (GFP) and served as non-influenza related negative control antigen. 
Figure 17: AAV-HA and AAV-cHA, but not AAV-HL is immunogenic in mice after intramuscular application 
(A) 3 – 6 mice per group were immunized intramuscularly three times in three week intervals. Before the first (pre-
serum) and after the last (immune-serum) immunization blood samples were drawn from the animals. (B) 
Immunization groups included in the study (C) AAV9-specifc total serum antibody ELISA titers expressed as area
under the curve (AUC) (symbols: individual animals; bars: mean ± SD). (D) Correlation of AAV9-specific total antibody
titers with number of received immunization (symbols: individual animals; line: linear regression curve, dotted lines:
95 % CI band) (E to J) ELISA titers of serum antibodies against the influenza virus indicated above each panel
(symbols: individual animals; bars: mean ± SD). *p<0.05; **p<0.01 (in comparison to AAV-GFP) 
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Notably, although other studies suggest that the influence of an incorrectly folded HA-stalk 
domain on the immune response is negligible (289), cHA2 was placed at the end of the 
immunization schedule as this construct showed the least C179-binding (Figure 17B). Before the 
first (pre-serum) and after the last (immune-serum) immunization serum was obtained from the 
animals in which AAV9-specific total as well as influenza-specific total and neutralizing antibody 
titers were determined (Figure 17A). 
As expected, all animals developed AAV9-specific serum antibodies which increased with the 
number of immunization (Figure 17, C and D). Furthermore, a significant increase of 
homologous Cal/7/9-specific antibodies were detectable in the groups immunized three times 
with AAV-cHA or AAV-HA (Figure 17E). All other groups remained Cal/7/9-negative, including 
those receiving only AAV-HL. Interestingly, AAV-cHA but not AAV-HA did also induce 
antibodies against PR8 and the parental viruses H2N3 and H13N6 (Figure 17F). However, no 
reactivity was seen against the H3N2 subtype viruses X31 and H10N7, indicating that the AAV-
cHA induced broadly reactive antibodies are restricted to group 1 influenza A viruses (Figure 17, 
G and J). Intriguingly, an increase in antibody titers against H2N3 virus not only in the groups 
1 & 2 but also in the groups 3 & 4, which received only a single immunization with AAV-cHA1 
indicated that a one-shot vaccination with AAV-vectors might suffice to induce an at least virus-
strain specific antibody response (Figure 17H). 
No induction of broadly neutralizing serum antibodies against the aforementioned influenza 
viruses was seen in the groups receiving three AAV-vector immunizations (group 2, 9, 10, 11) 
(Figure 18). AAV-HA induced Cal/7/9-specific neutralizing antibodies, while AAV-cHA induced 
H2N3-specific neutralizing antibodies. Thus, neutralization was restricted to the virus whose HA-
head was included in the prime immunization of the respective group (Figure 18). These results 
Figure 18: Intramuscular immunization induces strain specific neutralizing antibodies 
2-fold serial dilutions of pooled serum were incubated with the virus indicated above each panel for 1 h and added to 
MDCKII cells for 1 h before cells were washed and fresh serum dilutions were added to capture putative post-
attachment effects of serum antibodies as well. After 24 h, influenza virus antigen was detected by immuno-
peroxidase staining. Inhibition was calculated, whereas a value of 1 means complete absence of infection. The MN50 
value, i.e. the reciprocal serum dilution yielding 50 % inhibition, is indicated (mean ± SD, n=3; curve: non-linear 
regression curve). 
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indicated that i.m. immunization with AAV-HA and AAV-cHA induces a humoral response in 
mice while AAV-HL seems not to be immunogenic. Moreover, although AAV-cHA induced a 
more cross-reactive response, no cross-neutralization of multiple influenza virus subtypes was 
apparent, which was also the case for AAV-HA. 
 INTRANASAL IMMUNIZATION WITH AAV-VECTORS IS EFFECTIVE IN BOOSTING ANTIBODY RESPONSE 4.3.
IN MICE BEING NON-NAÏVE FOR AAV9 
In an attempt to investigate the protective efficacy of the AAV-vectored vaccines against 
influenza virus challenge, another set of mice was immunized i.m. three times in three week 
intervals with 1x1010 vg of AAV-HA, AAV-cHA or AAV-HL (Figure 19A). The sequence of the 
AAV-cHA was changed to completely resemble the pattern of C179-binding to the respective 
cHA, i.e. AAV-cHA3 – AAV-cHA1 – AAV-cHA2 (Figure 15D). Unexpectedly, and in contrast to 
AAV-HA, after three i.m. immunizations during this trial no increase of influenza-specific 
antibody titers against Cal/7/9 was seen for the AAV-cHA and AAV-HL immunized groups 
(Figure 19B). 
Figure 19: Intranasal application can boost antibodies in AAV-non-naive mice 
(A) 10 mice per group were immunized intramuscularly three times in three week intervals. Before the first and after
the last immunization blood samples were drawn from the animals. Since animals receiving AAV-cHA or AAV-HL were 
seronegative at this time point, animals were not challenged but further intranasal immunizations were given to
these groups. During this period, too, blood samples were collected. After two additional intranasal immunizations,
all animals were challenged with a lethal dose of Cal/7/9 and survival and weight loss was monitored. On day 2, day 7 
or at the individual humane endpoint, lungs were collected and virus titers were determined. (B) Cal/7/9-specific total
antibody ELISA titers (symbols: individual animals; bars: mean ± SD) (C) Lung virus titers as determined by plaque
assay at the indicated time points (line: geometric mean; n.d.: not determined). (D) Kaplan-Meier plot of survival data. 
(E) Relative weight loss during challenge period (mean ± SEM). *p<0.05; **p<0.01; ***p<0.001; ****p<0.0001 
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Apparently, a peculiarity of AAV9 is its ability to be re-administrable to the respiratory tract 
even in the presence of high titers of AAV9 serum neutralizing antibodies that would otherwise 
preclude repetitive transduction with the AAV-vector (369). Thus, AAV-cHA and AAV-HL 
immunized mice were given two additional intranasal (i.n.) boosts containing the same amount of 
AAV-vector as before (1x1010 vg) (Figure 19A). In fact, a boosting effect was seen in AAV-cHA 
immunized mice after the first i.n. immunization which resulted in a significant increase of 
Cal/7/9-specific antibody titers after the second boost (Figure 19B). No significant boosting effect 
was seen with AAV-HL. Interestingly, although AAV-HA immunized mice did not receive further 
immunizations, Cal/7/9-specific antibody titers were nearly unaffected by the longer time interval 
until challenge (about six month), underlining the beneficial effect of the durable AAV-mediated 
transgene expression on longevity of the immune response (Figure 19B). 
At the end of the immunization period, mice were i.n. challenged with Cal/7/9 
(102.9 TCID50/mouse in 50 µl). At day two and seven post infection subsets of mice were 
euthanized and lung virus titers were determined (Figure 19C). Remaining animals were 
monitored for 14 days for survival and weight loss as this represents the main criteria for severity 
of influenza disease in mice (384). Lungs were harvested after a mouse reached a humane 
endpoint or at day 14 post infection and virus titers were determined. As indicated in Figure 19D, 
the challenge virus dose was only sub-lethal and led to 20 % survival in the AAV-GFP immunized 
animals. However, a significant protective effect was seen with AAV-HA immunization (100 % 
survival) which was associated with complete lack of weight loss in these animals (Figure 19, D 
and E). Correspondingly, except for one animal that had an above baseline lung virus titers at day 
two, all animals were negative for influenza virus already from day two on (Figure 19C). This 
sterile immunity is most likely induced by neutralizing antibodies against Cal/7/9 in AAV-HA 
immunized mice (data not shown). Reflecting the magnitude of influenza-specific antibody titers, 
AAV-cHA immunization induced partial protection which was also associated with a significantly 
reduced lung virus titer at day 14 (Figure 19, C to E). However, no sterile immunity was induced 
in these animals (Figure 19C). In contrast to that, no protection was seen with AAV-HL (Figure 
19, D and E). These results indicated that i.n. application might be favorable over i.m. 
administration to induced protective antibody titers with AAV-cHA. 
 INTRANASAL AAV-VECTOR IMMUNIZATION INDUCE BROADLY REACTIVE ANTIBODIES AGAINST 4.4.
INFLUENZA 
Although the headless HA described by Steel et al. induced broadly protective immunity when 
it was applied as DNA/VLP-vaccine or protein antigen as described in the original studies, AAV-
HL appeared completely non-immunogenic (see 4.2, 4.3) (288, 289). Recent reports by Yassine et 
al. and Impagliazzo et al. further underlined the great potential of the headless HA approach for 
the induction of a broadly protective immunity (297, 298). Their advantage over the headless HA 
described by Steel et al. might in part be the more native-like conformation of the HA-stalk (288). 
Hence, it was evaluated whether one of the modified headless HA would be immunogenic in the 
AAV-vector background. 
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AAV-vectors expressing Cal/7/9-adpated versions of the headless HA by Yassine et al. (Gen6; 
mHL1) and Impagliazzo et al. (#4900; mHL2) were constructed and their immunogenicity was 
evaluated and compared to AAV-HL in mice (297, 298). A lack of immunogenicity of a headless 
HA antigen has also been described in a MVA-vector background (315). Interestingly, in the 
respective study MVA-vectored expression of the headless HA together with NP did induce an 
immune response superior to the immune response seen with MVA-vectored NP alone, 
indicating a synergistic effect (315). To evaluate whether also the combination of AAV-vectored 
headless HA and NP would induce a synergistic effect, another experimental group receiving a 
bivalent AAV-mHL1 + AAV-NP (AAV-mHL1+NP) vaccine was included besides a group 
receiving monovalent AAV-NP (Figure 20). 
Based on the results described in section 4.3, i.n. immunization was used in all following 
experiments. Mice were i.n. immunized in three week intervals with 1x1011 vg of AAV-vectors as 
outlined in Figure 20. Aside from groups receiving three times immunization with AAV-HA, 
AAV-cHA, AAV-mHL1+NP or AAV-NP, one group was vaccinated two times with Cal/7/9 
whole inactivated virus vaccine (WIV), while animals receiving three times AAV-GFP served as 
negative control group. Though cHA require more than one immunization to refocus the immune 
response from the HA-head to the stalk domain, headless HA were shown to induce HA-stalk 
antibodies even after one immunization (Figure 10) (298). To evaluate whether this is possible 
with the AAV-vectored vaccines, AAV-HL, AAV-mHL1 or AAV-mHL2 groups received either 
one or three immunizations (Figure 20).  
Before each and after the last immunization blood was taken from the animals (pre-serum; 
immune-serum 1, 2, and pre-challenge serum). Different parameters of humoral immunity as 
Figure 20: Immunization scheme for intranasal AAV-vector vaccination and challenge trial 
Mice were intranasally immunized three times in three week intervals according the scheme depicted in the table. 
Before each and after the last immunization, blood samples were drawn from the animals which where pooled per 
group and time point for serological analysis. Three weeks after the last immunization, mice were challenge with 
Cal/7/9, PR8 or X31. During this time period, survival and weight loss was monitored. 
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specified in the sections below were determined. Three weeks after immunization #3 mice were 
challenged with homologous Cal/7/9 (H1N1)pdm, with heterologous PR8 (H1N1) or with 
heterosubtypic X31 (H3N2) virus (Figure 20). 
As in the aforementioned experiment (see 4.2), all animals immunized with AAV-vectors 
developed high AAV9-specific serum antibody titers, which increased over time (Figure 21A). 
This was not the case in the WIV immunized group. AAV9-neutralizing serum antibody titers did 
correlate with total AAV9 antibody titers (Figure 21, B and C). In comparison to the groups 
receiving only one AAV-vector immunization, a boosting effect of AAV9 antibodies was apparent 
in groups receiving three immunizations (Figure 21A). This indicates that serum neutralizing 
antibodies did not preclude intranasal re-administration of the AAV-vector. 
Influenza virus-specific total serum antibody binding was analyzed against a panel of ten 
viruses from both antigenic groups including viruses from subtypes circulating in humans (H1N1, 
H3N2), pandemic viruses ((H1N1)pdm from 2009 and 1918) and viruses bearing zoonotic 
potential (H7N9, H5N1) (Figure 22A). As expected, AAV-HA and AAV-NP showed the strongest 
increase and induced the highest endpoint total antibody titers against the homologous Cal/7/9-
virus (Figure 22, B and C). Also, AAV-cHA and WIV induced significantly higher antibody titers 
against this virus compared to the AAV-GFP immunized control group (Figure 22B).  
Figure 21: AAV total and neutralizing antibodies correlate with each other 
(A) AAV9-specific total serum antibody ELISA titers in pooled sera at indicated time points. (B) Correlation of AAV9-
specific total serum antibody ELISA titers and AAV9-specific neutralizing antibody titers (line: linear regression curve, 
dotted lines: 95 % CI band). (C) As indicated in the cartoon, AAV-GFP particles were incubated with serial dilutions of 
pooled pre-challenge serum for 1 h before they were added to 293T. After 48 h the number of GFP-positive cells was 
quantified by flow cytometry (mean ± SD of tech. duplicate, representative result). MN50 titers were determined as
reciprocal serum dilution yielding 50 % inhibition. 
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Surprisingly, none of the groups immunized one or three times with AAV-HL, AAV-mHL or 
AAV-mHL2 mounted antibody titers against the homologous or any other virus (Figure 22B). 
Also, contrasting the report by Hessel et al., the combination of AAV-mHL1 + AAV-NP did only 
induce antibodies specific for NP but had otherwise no synergistic effect on the antibody response 
(Figure 22H). It appears that there might be a general barrier to an AAV-based immunization 
strategy employing headless HA. Thus, AAV-HL, AAV-mHL1, AAV-mHL2 and AAV-
mHL1+NP were not included in the analysis described in the following sections. 
As shown in Figure 22, D to G, AAV-HA, AAV-NP, AAV-cHA and WIV induced broadly 
reactive antibodies. AAV-HA induced antibodies reacted strongest with viruses from the H1N1 
subtype, including the pandemic virus from 1918, and was otherwise restricted to group 1 
influenza A virus subtypes, e.g. H5N1 (Figure 22D). 
Figure 22: AAV-HA, AAV-cHA, AAV-NP and WIV induced broadly reactive antibodies 
(A) Phylogenetic tree of influenza viruses used for serological analysis. (B) Cal/7/9-specific total antibody ELISA titers
in pooled pre-challenge sera (mean ± SD of tech. replicate). (C) Cal/7/9-specific total antibody ELISA titers in pooled
serum over time (mean ± SD of tech. replicate). (D to G) Total antibody ELISA titers in pooled pre-challenge sera
against the influenza viruses indicated at the end of each axis of the web-diagram (colored area: specific reactivity of 
the immune serum indicated above each web-diagram; white area in center: background sero-reactivity of AAV-GFP 
group). (H) Immunofluorescence staining of MDCKII cells 48 h after transfection with the plasmids expressing the
antigen indicated above each panel. Cells were fixed, permeabilized and incubated with pooled pre-challenge serum 
of AAV-NP or AAV-mHL+NP immunized animals and suited secondary antibody (green) (n=2) (I and J) Cal/7/9- (I) or
PR8-specific IgA antibody ELISA titers in pooled pre-challenge sera (mean ± SD of tech. replicate). *p<0.05 (in
comparison to AAV-GFP) 
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The AAV-cHA induced antibodies, though binding less strongly to viruses from the H1N1 
subtype compared to AAV-HA, showed overall a stronger binding intensity to all other group 1 
viruses (Figure 22E). However, both AAV-cHA and AAV-HA induced antibodies did not react 
with group 2 viruses. Interestingly, AAV-NP and WIV induced antibodies reacted with all tested 
influenza viruses including H3N2 and H7N9 viruses (Figure 22, F and G). However, binding 
intensity was weaker for the WIV compared to the AAV-NP immunized group.  
IgA antibodies were shown to confer potent protection against respiratory pathogens due to 
their transudation into the respiratory mucosa (125). Here, serum IgA levels were analyzed, which 
can serve as a crude estimator for mucosal IgA levels, which might in fact be even higher. 
Interestingly, Cal/7/9-specific serum IgA were only found in animals immunized with AAV-HA 
or AAV-NP, whereas broadly reactive IgA against PR8 were only detected in AAV-NP 
immunized animals (Figure 22, I and J).  
In summary, these results indicate that i.n. immunization with AAV-vectors efficiently 
induced influenza-specific immune responses even in the presence of high titers of AAV9-
neutralizing serum antibodies. Intriguingly, binding breadth of the antibodies varied depending 
on the antigen used for immunization. 
 BROADLY REACTIVE ANTIBODIES ARE NON-NEUTRALIZING IN VITRO 4.5.
To analyze the functionality of the antibody response, several serological analyses were 
performed, which are described in the following sections. 
First, hemagglutination inhibition (HAI) and neutralizing antibody titers in the sera were 
determined. HAIpos antibodies, which block the RBS and interfere with attachment, currently 
represent the gold standard for evaluation of influenza vaccine immunogenicity. Neutralizing 
antibodies, however, do not necessarily bind to the RBS, but might inhibit later steps of the viral 
replication cycle as well (208). To measure effects on the late replication cycle, a modified version 
of a classical microneutralization (MN) assay was performed (375).  
Figure 23: MN-positive and HAI-positive 
antibodies act virus strain specific 
(A and B) 2-fold serial dilutions of pooled 
pre-challenge sera were incubated with 
Cal/7/9 (A) or H13N6 (B) virus for 1 h and 
added to MDCKII cells for 1 h, before cells 
were washed and fresh serum dilutions 
were added. After 24 h, Influenza virus 
antigen was detected by immuno-
peroxidase staining. Inhibition was 
calculated and the MN50 value is indicated 
(mean ± SD of tech. replicate; curve: non-
linear regression curve). (C) Mean HAI and 
MN50 titers (n=2-3 in tech. duplicates) in 
pooled pre-challenge sera against the 
indicated viruses. 
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Here, serum antibodies are not only present during attachment, but constantly throughout the 
viral replicative cycle. HAIpos and MNpos antibodies against Cal/7/9 could only be detected in sera 
of mice immunized with AAV-HA (Figure 23, A and C). However, these antibodies were strain 
specific and no other tested viruses from the H1N1 (PR8), H3N2 (X31) or H13N6 subtype could 
be inhibited or neutralized (Figure 23C). Sera from AAV-cHA immunized mice were HAIpos and 
MNpos against H13N6, but negative towards all other tested viruses (Figure 23, B and C). Notably, 
as the H13 HA-head domain is included in cHA3, the AAV-cHA immunized group encounters 
the H13 HA-head domain during their prime immunization (Figure 20A). Unexpectedly, WIV 
did not induce any HAIpos or MNpos antibodies. AAV-NP and AAV-GFP were negative in these 
assays (Figure 23C). Thus, HAIpos and MNpos antibodies seem to be specific for the HA-head 
domain of the virus which is encountered during the first immunization, resembling data 
obtained in the first immunogenicity study (Figure 18, Figure 23). 
 AAV-HA AND AAV-CHA INDUCE ANTIBODIES AGAINST THE HA-HEAD AND HA-STALK DOMAIN 4.6.
Induction of antibodies against the HA-head and HA-stalk domain. 
The absence of broadly reactive HAIpos and MNpos serum antibodies suggested the presence of 
other antibody specificities against regions apart from the RBS or classical antigenic sites within 
the HA-head region (see 1.2.4). Therefore, the binding specificities of the AAV-vector vaccine 
induced HA-specific serum antibodies were determined in more detail. 
First, differences in binding of the serum antibodies to the HA1 and HA2 subunit of four 
different viruses from the H1N1 subtype spanning more than 90 years of influenza virus evolution 
were analyzed via immunoblots (Figure 24A). HA1 contains the HA-head domain, whereas most 
of the stalk is contained within HA2. Beforehand, the input virus amount loaded on the SDS-
PAGE was adjusted to yield equal intensities of HA2 after detection with a commercially available 
HA2-specific antibody (Figure 24B; anti-HA2 (ctrl.)). Notably, all sera were tested in the same 
dilution (1:500) allowing comparison of the relative abundance of the respective antibodies 
recognizing HA1 and HA2 between the vaccine groups. AAV-HA induced sera detected the HA1 
subunit of Cal/7/9 (pdm2009) and of A/Brevig Mission/1/1918 (pdm1918), but not of PR8 (1934) 
and another seasonal H1N1 virus, A/Brisbane/59/2007 (2007) (Figure 24B). This differential 
binding pattern to HA1 reflects the closer phylogenetic relationship between the amino acid 
sequences of both the complete HA proteins and the HA1 subunit of the pandemic viruses from 
2009 and 1918 compared to the viruses from 1934 and 2007 (Figure 24, A and C). In contrast to 
that, the highly conserved HA2 domain of all four H1N1 viruses could be detected by antibodies 
in the AAV-HA induced sera (Figure 24, B and C). 
The presence of antibodies against HA1 and HA2 in the AAV-HA sera could also be verified in 
an epitope screen with overlapping 15-mer peptides of the Cal/7/9 HA (Figure 24, E to G). Five 
surface exposed peptides were identified which reacted significantly stronger with AAV-HA 
serum compared to AAV-GFP serum (Figure 24G).  
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Figure 24: Induction of distinct antibody binding specificities 
(A) Phylogenetic tree with sequence identities of the complete HA sequences of the H1N1 viruses used for
immunoblot analysis. (B) Immunoblot analysis of purified H1N1 viruses separated under denaturing conditions.
Uncleaved HA0 and the cleavage products HA1 and HA2 were detected with 1:500 diltuion of pooled pre-challenge 
serum indicated above each panel. Beforhand, loading was normalized to yield comparable signals with an
commercial anti-HA2 antibody (n=3). (C) Sequence identity of HA1 and HA2 of the indicated viruses compared to
Cal/7/9. (D) Immunoblot analysis as shown in (B). NP was detected with AAV-NP pooled pre-challenge serum. AAV-
GFP pooled pre-challenge serum served as negative control (n=3). (E) Significant peptides identified with the epitope 
screen with AAV-HA pooled pre-challenge sera were mapped onto HA1 (red) and HA2 (blue) of the trimeric HA (PDB: 
3UBE). The position of the RBS (yellow) and the C179 epitope (dashed line) is indicated. (F) Epitopes #39, #41 which
were identified in the epitope screen with AAV-HA are located at the upper end of the alpha-helices, while epitope
#48 is located at the membrane proximal end (blue). Upon conformational changes of HA2, the alpha-helical 
structure of peptide #41 and #48 seems to be maintained. (G) Results of the 15-mer Cal/7/9 peptide screen with AAV-
HA pooled pre-challenge serum. Data is shown as fold change over AAV-GFP signal (n=3 in tech. duplicates). *p<0.05. 
Floating bars represent mean and range. (H) Amino acids at the positions identified in the peptide screen with AAV-
HA serum in the HA sequence of the influenza viruses used for serological assays. The amino acid identity to the
Cal/7/9 sequence of the peptides in the HA-stalk compared to Cal/7/9 sequence is indicated. (I and J) Results of the
15-mer Cal/7/9 peptide screen with AAV-cHA or WIV pooled pre-challenge serum. Arrow points at the stronger but
non-significant binding peptide #44 (I). 
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Mapping of those peptides onto the three dimensional structure of H1N1 HA revealed that the 
identified epitopes include the RBS (HA1; peptide #16; amino acid positions 168-182), an epitope 
at the lateral site of the head locate in a cleft between two HA monomers (HA1 + HA2; peptides 
#30 and #39/#41; amino acid positions 308-322, 398-412, and 418-432), and one epitope at the 
membrane proximal end of the HA-stalk domain (HA2; peptide #48, amino acid positions 488-
502) (Figure 24E). Apparently, upon structural changes of HA2 as consequence of a pH change,
only the conformation of peptide #39 seems to change, while peptides #41 and #48 remain in their
alpha helical structure (Figure 24E) (see below). Furthermore, the amino acid positions in the HA-
stalk identified in the epitope screen appeared to be more conserved among group 1 influenza A
viruses with which AAV-HA induced serum reacted in the aforementioned ELISA analyses
compared to group 2 viruses (Figure 24H, Figure 22). This might explain the limitation of
reactivity towards group 1 influenza A viruses seen with the AAV-HA induced sera (Figure 22).
As expected, AAV-cHA induced very strong HA2-specific antibodies that reacted with all four 
viruses in the immunoblot analysis (Figure 24B). Interestingly, also WIV induced an HA2-specific 
antibody response which, however, was weaker compared to AAV-cHA. No significantly binding 
peptides could be identified in the epitope screen with these sera, which might reflect lower overall 
antibody titers in the AAV-cHA and WIV sera (Figure 24, I and J). However, with AAV-cHA sera 
one non-surface exposed peptide (#44) appeared to show a trend towards increased binding 
compared to AAV-GFP control group (1.8-fold increase, p-value: 0.128, Figure 24I). 
Figure 25: AAV-HA but not AAV-cHA or WIV induced 
antibodies dependent on the correct folding of the HA-
stalk 
(A) Binding of the conformational antibody C179 or pooled
mouse pre-challenge sera to wildtype HA expressed in
MDCKII cells quantified by In-cell ELISA or shown as
immunofluorescence staining. (B) Binding of the
conformational antibody C179 or pooled mouse pre-
challenge sera to a stalk-only HA showing the correct HA-
stalk conformation as assessed by C179 staining (mHL1,
C179-positive). (C) Binding of the conformational antibody 
C179 or pooled mouse pre-challenge sera to a stalk-only HA 
not showing the correct HA-stalk conformation (headless 
HA, C179-negative) (mean + SD, n=3 in tech. duplicates) 
(scale bar: 20 µm). *p<0.05; ***p<0.01, ****p<0.001 
Results 
70 
Dependence on conformation of the HA-stalk domain on antibody binding 
Several HA-stalk reactive antibodies, such as the prototypic C179, recognize conformational 
epitopes (193). To assess the influence of conformation of the HA-stalk on serum antibody 
reactivity binding was assessed by immunofluorescence and quantified via in-cell ELISA to 
different HA-antigens either showing the correct HA-stalk conformation (wildtype HA and 
mHL1) or not (headless HA) as indicated by C179-binding (Figure 15, Figure 25, A to C). 
Interestingly, AAV-HA sera resembled the binding profile of C179, as binding was only apparent 
to the correctly folded stalk (Figure 25). However, results from the immunoblot analyses shown in 
Figure 24B, which was done under denaturing conditions indicate that in polyclonal context of 
the serum also non-conformational antibodies must be present. In addition to the results shown 
in Figure 24 binding to mHL1 lacking the H1 head region further validates that AAV-HA 
immunization in fact induced HA-stalk reactive antibodies (Figure 25, B and C). 
AAV-cHA induced sera reacted with all tested antigens irrespective of the conformation of the 
HA-stalk (Figure 25). WIV induced sera behaved comparable to AAV-cHA induced sera, with the 
only difference that no binding to the truncated mHL1 was detectable, indicating that mHL1 
might lack the major epitope recognized by antibodies in WIV induced sera (Figure 25, A to C). 
Influence of pH-dependent conformational changes on antibody binding 
Upon acidification of the endosome HA needs to undergo a major conformational change 
which eventually results in fusion of the viral and endosomal membrane and release of the viral 
genome into the cytoplasm (Figure 5). 
Figure 26: AAV-HA and AAV-cHA induced sera bind differentially to the pre- and post-fusion HA-stalk 
(A to E) Binding of C179 (A) or AAV-HA (B), AAV-cHA (C), WIV (D) or AAV-NP (E) pooled pre-challenge sera to Cal/7/9 or 
PR8 virus particles which were pre-incubated at pH=7.2, 5.8, 5.4, 5.0, 4.4 or 4.4 + DTT, to induced pH-dependent 
conformational changes in HA or to remove the HA1 subunit (+DTT) (mean + SD, n=3 in tech. duplicates). (F) 
Schematic principle of the experiment. Upon acidification conformational changes are induced in HA2 which lead to 
the exposition of the fusion peptide. By the addition of the reducing agent DTT disulfide bonds between HA1 and 
HA2 are solved and HA1 can be removed from the system by washing. Conformational antibodies such as C179 do 
not recognize the low pH form of HA (A). *p<0.05, **p<0.01 (in comparison to pH=7.2) 
Results 
71 
As mechanism to inhibit viral replication, some HA-stalk specific antibodies were shown to 
interfere with theses conformational changes (see 1.3.3) (200). To execute this effect, HA-stalk 
reactive antibodies require to recognize the HA pre-fusion conformation are required. Thus, 
binding of mouse sera to HA at a pH-range from neutral (7.2) to acidic (4.4) was analyzed to 
determine the presence of antibodies binding to the pre- and/or post-fusion HA-stalk region. 
Additionally, the reducing agent DTT was added at acidic pH to remove the HA1 subunit from 
the HA protein (Figure 26F). 
As expected, already at a slightly acidic pH=5.4 binding of C179 to HA of Cal/7/9 or PR8 virus 
particles was reduced and the removal of HA1 (+DTT) had no further effect (Figure 26A). Sera 
induced by AAV-HA bound to Cal/7/9 HA unless HA1 subdomain was removed, indicating that 
binding to the homologous HA is mediated mainly by antibodies directed against the HA-head 
domain (Figure 26B). Removal of HA1 had, however, no effect on AAV-HA induced serum 
binding to PR8 (Figure 26B). This further supported the findings from the immunoblot analysis, 
which already indicated that binding to PR8 by AAV-HA induced sera is mainly mediated by 
antibodies against HA2 (Figure 24). Interestingly, AAV-HA induced stalk antibodies did, unlike 
C179, bind also to the low pH conformation of HA (Figure 25, A and B). This corroborates the 
aforementioned findings from the immunoblot analysis that AAV-HA induced sera contain non-
conformational antibodies which apparently recognize epitopes that appear not to be largely 
restructured upon acid induced conformational changes of HA (Figure 24F). 
Intriguingly, AAV-cHA induced sera reacted even stronger with the low pH conformation of 
HA, indicating that some otherwise buried epitopes might become more accessible upon 
conformational change (Figure 26C). In fact, peptide #44, which showed increase reactivity in the 
epitope screen with AAV-cHA induced serum, is not exposed on the surface of HA, but located at 
the interior of the trimeric HA-stalk (data not shown). Hence, it might become more accessible 
during conformational change of the HA resulting in increased reactivity (Figure 26C). WIV 
induced antibody binding did not vary with pH or after the addition of DTT which was also the 
case for AAV-NP sera (Figure 26, D and E). 
These results showed that AAV-HA was the only vaccine to induce antibodies against the HA-
head and –stalk of H1N1 viruses including those used for the challenge infections, while AAV-
cHA and unexpectedly WIV did induce stalk antibodies. 
 NON-NEUTRALIZING ANTIBODIES ACTIVATE FC-GAMMA RECEPTORS 4.7.
As shown in section 4.5, MNpos and HAIpos antibodies could be detected in AAV-HA and 
AAV-cHA immunized mice. These antibodies, however, reacted virus strain-specific (Figure 23). 
Broadly binding to non-homologous virus strains thus seems to be mediated by HAIneg and MNneg 
antibodies. These antibodies might execute their protective effect via different mechanisms such 
as FcR-mediated effector functions, including ADCC or ADP (95, 96, 223). Therefore, it was 
analyzed whether the influenza-specific serum antibodies could activate FcγR employing a 
recently developed reporter assay which allows for separate measurement of the activation of the 
four murine FcγRI, IIB, III and IV (225) (Figure 27A, see 3.8.7). As shown in Figure 27B, all 
vaccines induced Cal/7/9-specific antibodies that could activate all four murine FcγR.  
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However, AAV-HA, AAV-NP and AAV-cHA led to an overall stronger activation compared 
to WIV. On the contrary, only the AAV-vectored vaccines but not WIV did induce PR8-specific 
FcγR-activating antibodies (Figure 27C). Notably, PR8 FcγR-activating antibody and total 
antibody titers did not correlate (Figure 27D). Thus, AAV-HA and AAV-cHA vaccination 
Figure 27: AAV-vectored but not inactivated vaccines broadly activate FcγR 
(A) Schematic drawing of the principle of the different settings of the FcγR-assay. MDCKII cells were either infected
with influenza viruses (left), which allows measurement of FcγR-activating antibodies against any viral protein, or
transfected with full length HA (middle), which allows measurement of HA-specific antibodies against the head and
the stalk, or transfected with a stalk-only HA (right), which allows measurement of HA-specific antibodies against the
stalk. FcγR-cells and read-out of the assay (IL-2 ELISA) is the same with each setup. (B) Cal/7/9 virus-specific activation 
of murine FcγRI, FcγRIIB, FcγRIII or FcγRIV by antibodies in pooled pre-challenge sera. (C) PR8 virus-specific activation
of murine FcγRI, FcγRIIB, FcγRIII or FcγRIV by antibodies in pooled pre-challenge sera. (mean ± SEM, n=3 in tech.
duplicates) (D) Linear regression between serum ELISA titer and FcγR assay titer against the influenza virus indicated 
above each panel. (E) Activation of FcγR-IV by antibodies against the full-length HA or a stalk-only HA in the pooled
pre-challenge sera indicated above each panel. (mean ± SEM, n=2 in tech. duplicates) 
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induced higher amounts of broadly-reactive FcγR-activating antibodies in proportion to total 
antibodies than WIV vaccination (Figure 27D). Interestingly, AAV-NP vaccination induced 
antibodies showed unexpectedly potent FcγR-activation against Cal/7/9 and PR8 and also 
appeared to activate the inhibitory FcγRIIB more potently compared to the HA-antibodies 
induced by AAV-HA and AAV-cHA (Figure 27, B and C). 
Initially it was proposed in the literature that only HA-stalk antibodies rely on activation of 
FcγR to execute their protective effect. However, this view has recently been changed and now 
acknowledges that apparently all broadly reactive antibodies require activation of FcγR to mediate 
protection (223). To dissect HA-head and -stalk specific FcγR-activating antibody activities, the 
experimental setup of the FcγR-assay was modified. In contrast to the setup described above, in 
which MDCK cells where infected with influenza viruses and, thus, express all influenza proteins, 
uninfected MCDK cells were transfected either with full length HA (pAAV-HA) or a stalk-only 
construct lacking the HA-head (pAAV-mHL1+TM) (Figure 27A). Since the HA-stalk domain is 
present in both setups serum-specific differences in the activation of the FcγR-assay are likely due 
to the presence of additional non-stalk-binding FcγR-activating antibodies. In fact, in the sera of 
AAV-HA immunized mice a signal increase was apparent when the FcγR assay was performed 
with full length HA compared to the stalk-only construct, indicating that antibodies against sites 
that are only present in the context of the full length HA, e.g. the HA-head, can activate FcγR, too 
(Figure 27E). In contrast to that, AAV-cHA sera, which contain only HA-stalk antibodies, yielded 
comparable signals under both experimental conditions. WIV induced signals were barely above 
background level.  
These results indicate that vaccination with AAV-HA, AAV-cHA and AAV-NP leads to a 
more potent induction of broadly reactive FcγR-activating antibodies compared to WIV. 
Furthermore, AAV-HA, unlike AAV-cHA, induced FcγR-activating antibodies against the HA-
head and -stalk domain of H1N1 viruses.  
 AAV-HA, AAV-CHA AND AAV-NP BUT NOT WIV INDUCE BROADLY PROTECTIVE IMMUNITY 4.8.
To evaluate the extent and breadth of protection of the AAV-vectored vaccines, immunized 
mice were infected with lethal doses of homologous Cal/7/9, heterologous PR8 or heterosubtypic 
X-31 (H3N2) viruses. Survival and weight loss was monitored during a 14 days period. Mice
reaching 20 % weight loss were euthanized and lungs were collected to determine the virus load by
plaque assay. Eventually, surviving mice were euthanized at 14 days post infection and lungs were
harvested, too.
After challenge with Cal/7/9, 100 % of AAV-HA, AAV-NP and AAV-mHL1+NP immunized 
mice were protected, while all mice of the negative control (AAV-GFP) succumbed to the 
infection by day eight (Figure 28A). AAV-cHA and WIV immunized animals were partially 
protected (80 %; 4/5). Interestingly, whereas animals of all other groups showed a mean maximum 
weight loss of up to 10 %, AAV-HA immunized animals did not lose weight (Figure 28, B and C). 
This is most likely due to the presence of neutralizing antibodies conferring sterile immunity only 
in these animals (Figure 23C). However, as expected, all animals surviving the challenge period 
were able to eventually clear the virus from their lungs (Figure 28D).  
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Figure 28: AAV-HA, AAV-cHA and AAV-NP protect against homologous and heterologous challenge 
(A to D) Kaplan-Meier plots (A), relative weight loss (B), maximum weight loss (C) and lung virus titers at the individual 
endpoint or at 14 days post infection (D) of mice infected with Cal/7/9. (E to H) Kaplan-Meier plots (E), relative weight 
loss (F), maximum weight loss (G) and lung virus titers at the individual endpoint or at 14 days post infection (H) of 
mice infected with the lower dose of PR8. (I to L) Kaplan-Meier plots (I), relative weight loss (J), maximum weight loss 
(K) and lung virus titers at day 3 post infection, the individual endpoint or at 14 days post infection (L) of AAV-HA, 
AAV-cHA, WIV or AAV-GFP immunized mice infected with the higher dose of PR8. (M to P) Kaplan-Meier plots (M), 
relative weight loss (N), maximum weight loss (O) and lung virus titers at the individual endpoint or at 14 days post 
infection (P) of AAV-HL, AAV-mHL1, AAV-mHL2 or AAV-GFP immunized mice infected with the higher dose of PR8. (Q 
to T) Kaplan-Meier plots (Q), relative weight loss (R), maximum weight loss (S) and lung virus titers at the individual
endpoint or at 14 days post infection (T) of mice infected with X31. (weight curves: mean ± SEM, max. weight loss
bars: mean, lung virus titers lines: geometric mean). nsp≥0.05, *p<0.05, **p<0.01, ***p<0.001 (in comparison to AAV-
GFP, or as indicated) 
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Next, heterologous protection against another H1N1 strain, PR8, was evaluated. Although 
being 100 % lethal for AAV-GFP immunized mice, this first challenge with a lower dose of PR8 
did not reveal any differences regarding survival of the vaccinated groups (Figure 28E). However, 
WIV vaccinated animals did show an increased mean maximum weight loss of up to 10 %, while 
all AAV-vector immunized animals did show an only moderate mean maximum weight loss of 
about 3 - 4.5 %, which was significantly less compared to the AAV-GFP group (21 %) (Figure 28, 
F and G). As seen for the Cal/7/9 challenge, all surviving animals were eventually able to clear the 
virus also in the absence of neutralizing antibodies against PR8 (Figure 28H, Figure 23C).  
To evaluate the influence of HA-specific non-neutralizing antibodies on survival, the 
heterologous PR8 challenge was repeated with a higher virus dose. Here, the majority (71 %; 5/7) 
of the AAV-HA and AAV-cHA immunized animals were protected from the infection (Figure 
28I). This was also reflected by less mean maximum weight loss of only up to 10 % seen in 
surviving animals from these groups (Figure 28, J and K). In contrast, all AAV-GFP immunized 
animals had to be euthanized and only one WIV immunized animal survived the challenge with 
the higher PR8 dose, with both groups showing increased mean maximum weight loss of about 
18-19 % (Figure 28, I to K). Notably, a single AAV-GFP immunized animal survived the PR8
challenge without weight loss and any sign of disease, and furthermore remained PR8
seronegative (data not shown), suggesting a failure during inoculation of the challenge virus. This
one animal was therefore excluded from the analyses. During the second PR8 challenge a subset of
animals was sacrificed on day three post infection to analyze the course of viral replication during
the challenge period. Interestingly, all animals showed comparable virus titers in their lungs at this
early time point, indicating that due to the lack of PR8-specific neutralizing antibodies no sterile
immunity was achieved (Figure 28L). However, at the end of the challenge period, only AAV-HA
and AAV-cHA immunization led to significantly reduced virus titers in the lungs of the mice
compared to AAV-GFP (Figure 28L). AAV-HL, AAV-mHL1 and AAV-mHL2 immunized groups
were challenged with the higher dose of PR8, too. As expected, due to the complete lack of a
vaccine induced influenza-specific immune response, none of the animals was protected, which
was associated with severe weight loss and uncontrolled virus replication in the lungs (Figure 28,
M to P).
Finally, a heterosubtypic challenge infection with X31 was performed. Unfortunately, the used 
challenge dose was set too low and induced only 17 % lethality in the negative control group 
(AAV-GFP, 1/6) (Figure 28Q). In fact, lethality was more pronounced in the WIV immunized 
animals (50 %, 3/6). 100 % of the AAV-HA, AAV-NP and AAV-mHL1+NP immunized mice 
were protected while AAV-cHA immunization protected 83 % (5/6). Interestingly, AAV-NP 
immunized animals did show very little mean maximum weight loss compared to the other 
groups, indicating a protective effect which is however concealed by the too low challenge dose 
(Figure 28, R and S). Correspondingly, virus replication was not detectable in animals surviving 
the challenge (Figure 28T).  
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In summary, these results show that AAV-HA, AAV-cHA and AAV-NP immunization 
reduced symptom severity and showed superior protective effect against homologous and 
heterologous challenge compared to vaccination with the inactivated virus vaccine. 
 AAV-VECTOR IMMUNIZATION HAS A PROTECTIVE EFFECT IN FERRETS 4.9.
Ferrets have become the gold standard animal model for research on influenza, as they are 
naturally susceptible to the virus, and the clinical course of infection resembles aspects of the 
human disease including fever, lethargy, as well as signs of upper and lower respiratory tract 
infection (385). This is in part due to the comparable distribution of the influenza virus receptors 
in the respiratory tract of ferrets and humans. 
Consequently, the ferret model has not only been used to assess virulence of emerging 
pandemic strains, which is of high public health relevance, but also to evaluate a series of avant-
garde vaccines including approaches using different kinds of broadly reactive antigens and/or 
virus vectors (276, 278, 281, 297, 366) (see 1.3.7). However, so far an active vaccination strategy 
employing AAV-vectors in ferrets has not been described in the literature. 
Thus, to evaluate whether AAV-vectored vaccines expressing HA are immunogenic and 
protective in ferrets, groups of four ferrets were immunized intranasally three times in four week 
intervals with 1.875x1012 vg of AAV-HA, AAV-cHA or AAV-GFP (Figure 29A). As a control, one 
group received twice an intramuscular application of the human seasonal quadrivalent inactivated 
vaccine (QIV) of season 2017/2018 (Influsplit Tetra). Notably, the H1N1 component of the 
seasonal vaccine has been changed from Cal/7/9 to A/Michigan/45/2015 (H1N1)pdm. However, 
ferret convalescent sera raised against Cal/7/9 reacted undistinguishably also with 
Michigan/45/2015 (386). Before each and after the last immunization, serum samples were 
obtained from the animals. Animals were challenged with a non-lethal dose of the early 
(H1N1)pdm isolate A/Mexico/InDRE4487/2009 which has been shown to be highly virulent in 
ferrets (387). During the following three days, ferrets were monitored daily for clinical signs of 
influenza including changes in activity and respiratory signs. Also, temperature and body weight 
were measured daily and nasal wash samples were obtained in which virus titers were determined. 
At day three post infection animals were sacrificed and nasal turbinates, trachea and lungs were 
collected and either processed for titration of virus or histological examination (Figure 29A). 
Interestingly, not only the QIV immunized but also some of the animals which were 
immunized with AAV-HA or AAV-cHA remained AAV9 seronegative throughout the 
vaccination period (Figure 29B). Nevertheless, all ferrets of the aforementioned groups mounted 
robust total antibody titers against Cal/7/9, which constantly and significantly increased over time 
only in AAV-HA immunized animals (Figure 29C). Resembling data obtained in mice only AAV-
HA vaccination induced HAIpos and MNpos antibodies against Cal/7/9, which could also cross-
neutralize A/Michigan/45/2015 (Figure 29D). 
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Upon challenge with influenza virus, all animals rapidly developed signs of influenza, 
including serous nasal exudation, congestion, frequent sneezing and wheezing and depression 
(Figure 29G). However, only AAV-GFP (2 and 3 dpi) and QIV (3 dpi) immunized animals 
showed a significant increase of clinical score over time (Figure 29G). From day two on, AAV-HA 
and AAV-cHA immunized animals started to recover as evidenced by a regain of normal activity 
Figure 29: AAV-HA and AAV-cHA 
show symptomatic protection in 
ferrets 
(A) Four ferrets per group were
intranasally immunized three times in
four week intervals with AAV-HA, 
AAV-cHA or AAV-GFP. A control group 
was intramuscularly immunized two
times with the inactivated influenza
vaccine of season 2017/18 (Influsplit 
tetra) (QIV). Before each and after the
last immunization, serum was
obtained from the animals in which
serological parameters were analyzed. 
All ferrets were challenged with 105 
TCID50 an (H1N1)pdm virus. During
the three days challenge period
clinical signs, body temperature and
weight was measured. Nasal washes
were performed daily. At day three
post infection all animals were
sacrificed and nasal turbinates,
trachea and lung was harvested. (B) 
AAV9-specific antibody response in
individual ferret sera over time (black
lines: individual animals, green lines:
mean). (C) Cal/7/9-specific antibody
response in individual ferret sera over
time (black lines: individual animals,
red: mean). (D) HAI and MN50 titers of
individual ferrets against the virus
indicated above the panels (line:
geometric mean). (E) Correlation of
HAI or MN50 titer with day 3 clinical
score of AAV-HA immunized animals.
The coefficient of correlation (r2) and
p-value is indicated to the right. (F) 
Correlation of HAI or MN50 titer with
virus titers in nasal turbinates (NT) of
AAV-HA immunized animals. (G) 
Mean clinical signs as expressed by a
clinical score over time (mean ± SD).
AAV-GFP: $p<0.05, $$p<0.01; QIV:
*p<0.01 (compared to day 0). (H) 
Mean body temperature over time
(mean ± SD). AAV-HA: ##p<0.01; AAV-
cHA: §§p<0.01; AAV-GFP: $p<0.05; QIV:
*p<0.05 (compared to day 0). (I) Mean 
relative weight loss over time (mean ± 
SD). QIV: *p<0.05 (compared to day 0). 
(J) Virus titers in nasal washes over
time (mean ± SD). (K) Virus titers at
day three post infection in
homogenates of nasal turbinates (NT), 
trachea and lung as determined by
TCID50 assay (line: geometric mean).
*p<0.05, **p>0.01 
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and improvement of respiratory signs (Figure 29G). With AAV-HA immunized animals, higher 
MNpos or HAIpos serum antibody titers were associated with lower clinical scores (Figure 29E). 
Upon infection, all animals lost weight irrespective of the immunization (Figure 29H). 
However, only QIV immunized animals showed a significant weight loss over time (about 10 % at 
3 dpi) (Figure 29H). Weight loss in AAV-HA and AAV-cHA immunized was more moderate 
(about 6 %), and unexpectedly AAV-GFP immunized animals lost least weight (3 %) (Figure 
29H). Fever peaked in all animals at day two post infection (Figure 29I). While the body 
temperature was no longer increased statistically significant at 3 dpi compared to the initial value 
in AAV-HA, AAV-cHA and AAV-GFP immunized animals, QIV immunized animals still had 
significantly higher temperature at this time point (Figure 29I). Prominent virus replication in the 
respiratory tract was apparent in all animals, corresponding to the fact that clinical signs of 
influenza were seen in all animals, too. Nasal wash titers peaked on 2 dpi in all groups but 
otherwise revealed no marked differences between the groups (Figure 29J). Nevertheless, AAV-
HA immunized ferrets showed reduced virus titers in tissue homogenates of the nasal turbinates, 
trachea and lung, while all other groups showed comparable and high virus titers (Figure 29K). In 
fact, reduced virus replication in the upper respiratory tract (i.e. nasal turbinates) was associated 
with higher MNpos or HAIpos serum antibody titers in AAV-HA immunized ferrets (Figure 29F).  
Immuno-histochemical staining of influenza virus antigen revealed, too, that none of the 
animals was completely negative for virus replication (Figure 30, A to D). However, influenza 
virus antigen was detectable in lower amounts in the submucosal glands and the bronchi of AAV-
HA immunized animals compared to all other groups (Figure 30, A, B, D). Interestingly, AAV-
cHA immunized animals showed slightly increased antigen detection in these tissues compared to 
QIV and/or AAV-GFP (Figure 30, A, B, D). Lungs of AAV-HA immunized animals did show 
reduced virus antigen detection compared to animals from AAV-cHA or QIV groups. 
Unexpectedly, the lungs of AAV-GFP immunized animals seemed to be spared from influenza 
virus replication (Figure 30, C and D). 
Also, histopathological changes were analyzed and scored. All ferrets developed typical signs of 
an influenza virus induced bronchio-interstitial pneumonia at varying degrees of severity. 
Damage of bronchi and bronchiols was most pronounced in AAV-GFP immunized animals, 
while lesions of lung interstitium as well as submucosal glands were more severe in AAV-cHA 
and QIV immunized animals (Figure 30E). Ferrets receiving AAV-HA appeared to show less 
severe lesions of the conducting airways and the lung compared to animals from the other groups. 
Furthermore, more prominent hyperplasia of type II pneumocytes was apparent in AAV-cHA 
and QIV vaccinated groups resulting in increased surfactant production and immigration of 
alveolar macrophages (Figure 30F). Interestingly, although the induction of bronchus-associated 
lymphoid tissue (BALT) could be observed in AAV-cHA and QIV immunized animals to a high 
extent, AAV-HA immunized animals only showed moderate BALT formation and it was 
completely absent in AAV-GFP immunized animals (Figure 30G). 
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BALT formation can be induced upon immunologic stimulation, e.g. after infection or 
vaccination (388, 389). This ectopic lymphoid tissue represents sites of local initiation and 
maintenance of a protective and regulatory adaptive immune response in the lung (390). In 
contrast to AAV-HA immunized ferrets, prominent perivascular lymphocyte cuffing was 
Figure 30: Immuno-histochemical and pathological examination of ferret respiratory tissue 
(A to C) Immuno-histochemical staining of submucosal glands (SMG, bar 100 µm) (A), bronchi (bar 100 µm) (B) and 
lung parenchyme (bar 100 µm) (C) with anti-influenza antibody (red) and nuclei (blue). (D) Scoring of degree of 
infetion with influenza virus in the respective section of the respiratory tract (mean + SD). **p>0.01. (E to H) H&E 
staining showing inflammation in bronchial tissue (arrow heads, bar 100 µm) (E), damage of alveolar epethelial cells 
(AEC) (arrows, bar 50 µm) (F), BALT formation (asterisc, bar 200 µm) (G) and areas of lymphocyte cuffing (white arrow 
head, bar 100 µm) (H). Sample preparation and analysis (qualitative and quantitative) was done by K. Dietert and A. D. 
Gruber. 
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observed in AAV-cHA, QIV and AAV-GFP immunized animals, indicating extensive recruitment 
of immune cells (Figure 30H). Taken together, these results indicated that AAV-HA and AAV-
cHA have a protective effect in ferrets as both reduced severity of clinical signs. This, however, 
was associated with reduced virus replication in the respiratory tract and less pronounced 
pathology only in AAV-HA immunized ferrets. 
81 
5. DISCUSSION
Influenza remains to be a severe threat to public health. Currently, the only efficient 
prophylaxis is seasonal vaccination. The inactivated seasonal influenza vaccine induces antibodies 
mainly against highly variable regions in the head domain of the viral surface glycoprotein HA. 
Although these are neutralizing antibodies which can confer sterile immunity, their binding 
breath is very narrow and restricted to only a few strains of one influenza virus subtype. Since 
influenza viruses evolve quickly, the composition of the vaccine has to be adapted frequently to 
match circulating strains. This, however, can lead to vaccine mismatch when vaccine strains and 
circulating strains do not match. Under these circumstances, vaccine effectiveness can 
dramatically drop. Furthermore, even in years with good match with the circulating strains, 
vaccine effectiveness is only at about 60 % in healthy adults, while it is likely lower in groups being 
at high risk for influenza complications, such as the elderly (183). Also, the current seasonal 
vaccine does not provide protection against zoonotic or emerging pandemic strains. The urgent 
need for a broadly protective and long lasting vaccine has recently been acknowledged by public 
health authorities (190, 191). As a result, the National Institute of Allergy and Infectious Diseases 
(NIAID, USA) has released a ‘strategic plan’ for the development of a universal vaccine (190). 
According to this, improved understanding of influenza virus pathogenesis and of the immunity 
induced by the virus will help to define new correlates of protection (besides HAI titers) and aid 
rational vaccine design (190). Basic criteria of a universal vaccine were set up by the NIAID 
(Figure 31). Also, the WHO developed 
‘preferred product characteristics for 
next-generation influenza vaccines’, 
which basically include the NIAID 
criteria, and also emphasize the need for 
new correlates of protection, including 
cell-mediated and FcγR-mediated 
immunity (191). 
Consequently, research has been 
(re)focusing on the topic intensively during the last decade with the goal of developing a vaccine 
which induces broadly reactive humoral and/or cellular immunity. With the discovery of broadly 
reactive antibodies against conserved regions in the HA protein, such as the HA-stalk domain, 
research on rationally designed antigens has been propelled. These antigens, including chimeric 
HA or headless HA, should allow circumvention of the immunodominance of the strain specific 
epitopes in the HA-head region. Also, other influenza virus proteins have gained interest as 
potential broadly reactive antigen candidates, such as NP, the extracellular domain of M2, and NA 
(190).  
Although a growing body of work underlines the great potential of rationally designed broadly 
reactive antigen candidates, research on innovative vaccine delivery platforms such as viral vectors 
Figure 31: Criteria for a universal influenza vaccine 
adapted from Erbelding et al., J Infect Dis (2018) 
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and their influence on the immune response is considered important as well (391). With viral 
vector-based vaccination not only the transgene but also the vector itself shapes the immune 
response through its interaction with components of innate and adaptive immunity (392). 
Moreover, viral vectors enable targeting of the antigen to particular antigen processing pathways 
and/or compartments (e.g. mucosa) and thus activation of different arms of the immune system, 
which might not be activated by ‘conventional’ vaccines. Also, the stimulation of the immune 
system by components of the vector, and long persistence of vector and antigen can obviate the 
need for adjuvants (392). Most viral vectors can be produced in cell culture and do not rely on 
production in embryonated chicken eggs, a process which is not only costly and time consuming 
but also not ethically sound. However, viral vectors widely being used, such as Pox virus or 
Adenovirus vectors express viral gene products and induce strong inflammatory responses 
themselves, which might represent a safety risk. Moreover, they have to compete with high pre-
existing immunity in the human population (361). In contrast to that, AAV-vector are ‘gutless’, 
meaning they only express the transgene product (361). AAV-vectors appear to induce less strong 
inflammatory responses upon administration which might be linked to their apparent inability to 
efficiently infect APC (393). This amounts to weaker activation of CTL and neutralizing antibody 
responses against the vector capsid, enabling stable and durable expression of the transgene (394). 
Hence, induction of strong immune responses against antigens from several pathogens has been 
reported using AAV-vectors (361). Although pre-existing immunity is an issue with some AAV 
serotypes, others, including AAV9, show low sero prevalence of neutralizing factors in the human 
population (319). Furthermore, AAV-vectors are environmentally stable and can be freeze dried 
(371). This, together with the opportunity for intranasal administration will likely ease the 
formulation and application of a vaccine based on AAV-vectors. Importantly, AAV-vectors are 
the first viral vectors to be licensed in Europe and the USA for use as gene therapy vectors (395). 
Thus, they represent a highly promising candidate for clinical evaluation as a virus vector-based 
vaccine carrier against influenza. 
 AAV-vectors have demonstrated in several in vivo studies their suitability as expression 
vectors for broadly reactive antibodies (365-367). However, these studies focused on the 
expression of monoclonal antibodies, whereas the polyclonality of a humoral immune response 
was shown to enhance the potency of HA-stalk antibodies (264). Development of active 
immunization strategies, which can induce polyclonal responses, is thus of high relevance. 
However, so far only very few studies focused on AAV-vectors as carriers for an active influenza 
vaccine, none of which had the goal of a broadly reactive vaccine (362-364). Therefore, in this 
study the potential of AAV-vectors as carriers for a broadly reactive influenza vaccine was 
evaluated in mice, and for the first time in ferrets. 
Antigens and vectors 
All antigens used in this study are based on Cal/7/9 virus, a prototype of (H1N1)pdm viruses, 
which caused the most recent pandemic in 2009 and which have been circulating since 2010 in 
humans. Only recently the Cal/7/9 component of the seasonal vaccine was replaced by the closely 
 
Discussion 
 
83 
related (H1N1)pdm-like virus A/Michigan/45/2015. The Cal/7/9 HA itself seems to show some 
peculiarities compared to other contemporary H1 HA, as it appears to be less stable and less 
glycosylated, thus resembling rather the HA of viruses which circulated before 1947, including the 
HA of the 1918 pandemic H1N1 virus (396-398). This might influence immunogenicity, given 
that heavy glycosylation can shield epitopes within HA from recognition by the immune system 
(397). 
Initially, it appeared that the induction of antibodies against conserved epitopes in HA, i.e. the 
stalk, requires antigens such as cHA or headless HA. These antigens have been shown in several 
studies to be immunogenic when applied as protein antigen (273-275, 277, 280, 288, 289, 297, 
298), as inactivated or life attenuated influenza virus vaccine (281), or viral (276, 278, 279) and 
DNA vector (274, 275, 277, 280). Thus, besides wildtype antigens (HA, NP) also three different 
cHA and three different headless HA were evaluated in this thesis, which all contained the HA-
stalk of Cal/7/9. 
Several HA-stalk reactive antibodies have been described to bind conformational epitopes, 
including the prototypic C179 (194). The chimeric HA constructs cHA1 (H2 head – H1 stalk) and 
cHA2 (H10 head – H1 stalk) have in contrast to cHA3 (H13 head – H1 stalk) not been described 
before (271). While it could be shown here that cHA3 contains the intact C179 epitope, it was 
partially misfolded in cHA1 and cHA2. Notably, although giving a first impression of the 
conformation of distinct epitopes, binding of a single antibody might not allow inference of the 
conformation of the complete HA-stalk, as for example the cHA3-like construct described in the 
aforementioned publication was not bound by another conformational antibody, 6F12 (271). 
Furthermore, different previously published headless HA design concepts were adapted in this 
thesis to the Cal/7/9 HA sequence. Interestingly, although key residues used for the design of the 
different headless HA antigens were conserved between the influenza strains used in the original 
publications and Cal/7/9, some differences were observed between the Cal/7/9-based constructs 
generated in this thesis and the headless HA antigens described in the original publications. The 
PR8-based headless HA, which was initially described by Steel et al. (288), was shown to display a 
misfolded HA-stalk conformation, based on the finding that several conformational antibodies 
did not bind to the construct (289). This was also true for the Cal/7/9-based headless HA 
generated in this thesis, which displayed an incorrectly folded HA-stalk as indicated by the lack of 
C179 binding. In contrast to the construct described by Steel et al., the three-dimensional 
structures of the modified headless HA construct #4900 (Impagliazzo et al.) and an intermediate 
design step of Gen6 (i.e. Gen3, Yassine et al.), each obtained after co-crystallization with a 
conformational antibody, align almost perfectly to each other, and the HA2 domain of Cal/7/9 
HA, strongly indicating their overall correct conformation (Figure 32). Unfortunately, the three-
dimensional structure of the Steel et al. headless HA has never been resolved. Of note, both 
modified headless HA construct described in the original publications lack the cognate HA TM 
region, as construct #4900 (mHL2) is a secreted protein, and Gen6 (mHL2) is fused to a carrier 
particle (297, 298). However, as the Steel et al.-like headless HA used herein does contain the TM 
region, also mHL1 and mHL2 versions were constructed and analyzed containing the Cal/7/9 TM 
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region. In contrast to results described for construct #4900, mHL2 and mHL2+TM did not seem 
to show a correctly folded stalk region, or at least not the correctly folded C179 epitope (298). 
mHL1, which is based on construct Gen6, could to some extent be detected with C179, whereas 
the addition of a TM region to this construct further appeared to stabilize the correct 
conformation of the HA-stalk. This effect has also been described by Yassine et al. after fusion of 
construct Gen6 to a carrier protein, thereby replacing the TM region (297). Notably, Impagliazzo 
et al. used two other conformational antibodies, CR6261 and CR9114, to assess and select for the 
correct conformation of construct #4900 during their design process (298). In contrast, as 
mentioned above, Yassine et al. co-crystalized construct Gen3 with C179 (Figure 32), and found 
the epitope of the antibody to be intact (297). Thus, inference of the correct conformation of the 
HA-stalk solely based on C179 binding might be biased in this case. Nevertheless, mHL1 and 
mHL2 appear to show greater differences regarding the conformation of the HA-stalk as would 
have been expected by the almost perfectly aligning structures of the parental constructs (Figure 
32). Nevertheless, misfolded HA-stalk antigens were shown to induce antibodies against the 
native HA protein conformation (289). 
Figure 32: Alignment of Cal/7/9-derived headless HA constructs 
Top: Amino acid alignment of headless HA, mHL1 and mHL2. Amino acid 
positions of mHL1 (Yassine et al.) and mHL2 (Impagliazzo et al.) that differ 
from the unmodified headless HA described by Steel et al. are marked in red. 
Basic structural features of the headless HA including linkers and motifs are 
indicated. The residues of the conformational C179 epitopes are shown as 
green boxes, as is the position of HA1 (red bar), HA2 (blue bar), 
transmembrane region (grey bar) and cleavage site. Bottom: alignment of 
3D-structures of Gen3 (red, PDB: 5C0R), #4900 (blue, PDB: 5CJQ) and the 
Cal/7/9 HA2 (grey, PDB: 3UBE). Relative position of C179 that was co-
crystalized with Gen3 towards the HA-stalk is shown (green). Although, the 
structures of the parental constructs almost perfectly align, differences 
regarding C179 binding were apparent for mHL1 and mHL2. 
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Hence, to which extent the conformation of the antigen will influence immunogenicity of HA-
stalk epitopes remains elusive, especially in the context of AAV-vectored expression of the antigen 
from inside the cell, involving presentation of peptide and not protein antigen on MHC 
molecules. Thus, eventually this can only be assessed in vivo. 
There were only minor differences regarding expression levels of the constructs. Whereas the 
cHA, headless HA, mHL1+TM and mHL2+TM showed a somewhat lower expression level, 
wildtype antigens (HA, NP) and mHL without TM (mHL1, mHL2) were expressed at higher 
levels. This might relate to the closer-to-optimum sequence of the latter constructs due to natural 
evolution (wildtype antigens) or design steps (mHL) enabling higher expression levels. Strong 
expression of the antigen from AAV-vectors in peripheral tissue was shown to be a prerequisite 
for efficient cross-presentation to the immune system and induction of a transgene-specific 
immune response (399). Moreover, shedding of antigen from AAV-vector transduced cells, as it 
occurred from in vitro cell cultures to high levels with the mHL proteins without TM (data not 
shown), was shown for other antigens to increase immunogenicity (400). Therefore, expression 
level and secretion was judged more important than correct conformation of the HA-stalk which 
is why mHL without TM region (i.e. mHL1 and mHL2) were used in the mouse study.  
The purified AAV-vector stocks were highly infective and expression of all transgenes was 
confirmed in vitro. Furthermore, with the finally established purification protocol high quality 
AAV-vector preparations could be reproducibly produced. However, the aforementioned 
differences observed for each antigen on plasmid DNA-level were also apparent on the AAV-
vector-level. This underlines the importance of a rigid assessment of quality of each vector to 
assure sufficient antigen production prior to experiments in vivo on both, plasmid DNA- and 
AAV-particle-level.  
Intranasal application is advantageous over intramuscular immunization 
In the first immunogenicity study in mice, different combinations of cHA and headless HA 
were applied intramuscularly (i.m.) to investigate, which vaccine regimen would induce the most 
potent HA-stalk-specific antibody response. I.m. immunization was used to allow better 
comparability and transferability of the results to preceding studies performed at the Robert Koch 
Institute (362, 371). Immunization with AAV-cHA induced broadly reactive antibodies against 
viruses from the H1N1 subtype, which were, however, non-neutralizing against Cal/7/9 virus, 
suggesting that these antibodies are directed towards non-classical antigenic sites, including the 
HA-stalk. These results are in line with other reports using cHA antigens (274, 275, 278). 
Interestingly, i.m. immunization with AAV-HA induced only Cal/7/9-specific antibodies during 
this initial immunogenicity study. This, however, was not corroborated by subsequent challenge 
studies, in which intranasal (i.n.) vaccination was used. Here, also AAV-HA immunization 
induced broadly reactive antibodies. This clearly underlines the impact of immunization route on 
the breadth and quality of the immune response, which needs to be distinguished more closely in 
follow up studies. 
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Notably, during the first immunogenicity study, only animals receiving three AAV-cHA 
immunizations mounted significant influenza virus-specific antibody titers. However, since 
immune responses were assessed three weeks after each immunization, animals receiving two 
immunizations were sacrificed at the time point when the other groups received their third 
immunization. Thus, it remains elusive, whether the third immunization was actually required to 
induce these antibody levels, or whether merely a longer time interval from the second 
immunization until sacrification of the animals would have sufficed. Furthermore, it became 
apparent that further refinements of the AAV-vector preparations and/or the administration 
process were required, as high variability was seen for antibody responses of individual animals 
and the antibody titers were overall relatively low.  
Unexpectedly, in the first immunogenicity study, AAV-HL seemed to be completely non-
immunogenic when given alone one to three times, or in combination with AAV-cHA. Also, 
priming with AAV-HL obviated the immunogenicity of subsequently applied AAV-cHA. This 
was most likely due to AAV9-specific serum neutralizing antibodies induced after prime 
immunization with AAV-HL, which might have prevented successful transduction with AAV-
cHA. This is in stark contrast to other studies using headless HA (288, 289). In these studies, 
however, the headless HA was based on the more stable PR8 HA, or further stabilized by addition 
of a C-terminal trimerization domain. Moreover, the antigen was administered as combination of 
a DNA-vaccine (prime/boost) with a virus-like particle-vaccine (boost) (288), or as adjuvanted 
protein antigen (prime/boost) (289). Both studies report the induction of broadly reactive 
antibodies which, however, only provided partial homologous protection. This indicates that the 
headless HA itself is generally a suboptimal inducer of a de novo antibody response. Only after 
priming with a chimeric HA-DNA-vaccine (H9 head – H1 stalk), headless HA protein antigens 
induced complete homologous protection (289). However, this could not be recapitulated in the 
first immunogenicity study, in which no elevated antibody responses were triggered by AAV-cHA 
prime followed by AAV-HL immunization. Expression of foreign transgenes by AAV-vectors has 
been shown to occasionally induce immune tolerance towards the transgene (400). Apparently, 
this strongly depends on the administration route and the sub-cellular localization of the antigen 
(400). However, surface expressed wildtype HA has been shown in this thesis and by others to be 
immunogenic after transduction of muscle cells (362, 393). As the headless HA used herein is 
correctly targeted to the surface of the cell (data not shown), the lack of immunogenicity is more 
likely either associated with i) suboptimal amounts of in vivo produced transgene, which might 
lead to the induction of immune tolerance, or ii) the false conformation or lack of 
immunodominant epitopes in the headless HA protein, which furthermore might be outcompeted 
by the strongly immunogenic epitopes within the AAV-vector capsid (401, 402). To assess reasons 
for the failure of AAV-HL to induce influenza-specific antibodies, further experiments with 
modified headless HA were performed (see below). 
The second mouse study was conducted to assess the protective efficacy of AAV-HA, AAV-
cHA and AAV-HL against influenza virus challenge. Surprisingly, and in contrast to the 
aforementioned immunogenicity study, in this experiment mice remained influenza virus sero-
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negative even after three immunizations with AAV-cHA. On the contrary, AAV-HA induced 
high Cal/7/9-specific neutralizing antibody titers comparable to those in the first study, which 
completely protected all animals against homologous challenge with Cal/7/9. It was hypothesized 
that the transgene expression in the murine muscle cells might have been too low as a 
consequence of low titers of infectious AAV-vector particles in the particular AAV-cHA 
preparations used for this study. Consequently, the production and purification methodology was 
further refined prior to the following studies to reproducibly yield high quality AAV-vector 
stocks. Another possibility is that AAV9-specific neutralizing serum antibodies interfered with 
transduction of the muscle cells. It has been shown before that AAV9-vectors can be re-
administered into the respiratory tract even in the presence of AAV9-specific serum neutralizing 
antibodies (369). Thus, to circumvent AAV-vector neutralization by serum antibodies, mice 
received two additional i.n. immunizations. In fact, after these i.n. immunizations antibody titers 
could be induced in the AAV-cHA immunized group, which partially protected the animals from 
homologous challenge. At this stage of the project it was hypothesized that i.n. vaccination con 
not only circumvent neutralization of the vector by serum antibodies by might also lead to the 
induction of a stronger and/or broader immune response, because it resembles natural infection 
and activates canonical antigen processing pathways. This effect has also been shown for 
vaccination with LAIV in comparison to inactivated vaccine (166). Therefore, i.n. immunization 
was used for all subsequent studies in mice and ferrets. 
Headless HA proteins appear to be generally non-immunogenic in the AAV-vector context 
AAV-HL was completely non-immunogenic in the first two mouse studies, and also additional 
i.n. immunizations did not have the effect which was seen for the additional in AAV-cHA
immunized mice, and thus mice were not protected against Cal/7/9 challenge during the challenge
study. Nevertheless, the headless HA approach is appealing, because of its simplicity of just
excluding all ‘unwanted’ epitopes from the antigen. Thus, the modified headless HA constructs
were evaluated. Based on the results obtained with AAV-HL so far, reasons which could account
for the lack of immunogenicity appeared to be either i) the amount of in vivo produced antigen, ii)
its cellular localization and/or iii) the false conformation or lack of dominant epitopes in the HA-
stalk. To assess these possible reasons, during the third study mice were i.n. immunized with
AAV-HL, AAV-mHL1 or AAV-mHL2. As mentioned above, both mHL1 and mHL2 are strongly
expressed in vitro and secreted from the cell. However, only AAV-mHL1 carries the at least
partially correctly folded C179 epitope. Unexpectedly, not only all mice immunized with AAV-
HL, but also all mice immunized with AAV-mHL1 and AAV-mHL2 remained sero-negative for
influenza virus-specific antibodies after three immunizations. Thus, it seems unlikely that
expression level, localization or conformation of the antigen account for the lack of
immunogenicity of the AAV-vectored headless HA. Interestingly, the same phenomenon has been
described before by Hessel et al., using MVA-vectors expressing a headless HA based on A/Viet
Nam/1203/2004 (H5N1) (MVA-hlHA) (315). MVA-hlHA would not induce protective immunity
against homologous and heterologous challenge unless NP was co-expressed from the same vector
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(MVA-hlHA-NP) (315). Herein, however, the combination of AAV-mHL1 + AAV-NP did not 
have this kind of effect. Comparable to immunization with AAV-NP alone, merely NP-specific 
immunity was induced by AAV-mHL1 + AAV-NP. Since headless HA and NP are co-expressed 
from the MVA-vector, each MVA-vector transduced cell will likely express both proteins at a time 
(315). In this case, NP-specific B-cells, which are likely not as rare as HA-stalk-specific B-cells, 
might pick up headless HA protein as well during antigen uptake from dying cells resulting in the 
presentation of headless HA-derived peptides on MHCII molecules. This could lead to the more 
efficient activation of headless HA-specific T-cells and, thus, could accelerate antibody responses 
towards headless HA, which might not be efficiently activated by solitary expressed headless HA. 
In fact, Hessel et al. described absence of influenza-specific CD4+ T-cells when mice were 
vaccinated with MVA-hlHA alone, supporting such a scenario (315). Unfortunately, they did not 
differentiate between HA- and NP-specific cellular and humoral responses in their study (315). 
Here, due to the constrained coding capacity of the AAV-vector genome (ca. 4.7 kb max. vector 
size, (403)), mHL1 and NP had to be expressed separately from two AAV-vectors. This might 
have resulted in a too low number of cells expressing both antigens for this intermolecular help to 
happen. This hypothesis comes with the caveat that HA (and thus most likely also mHL1) and NP 
do not interact with each other, which should decrease the likelihood for concomitant uptake by a 
B-cell, especially when one of the proteins is secreted from the transduced cell as it is the case with
mHL1 (404). The success of other headless HA-based vaccines might therefore also be connected
to their ability to activate B-cells in a T-cell-independent manner through cross-linking of the B-
cell receptors, as antigens are for example displayed in high density on carrier particles (288, 297).
However, headless HA which completely lack dominant HA epitopes appear to be poor inducers
of immune responses, especially in the presence of other immunodominant epitopes for instance
from the AAV-vector capsid. Thus, a virus vectored approach solely based on headless HA does
currently not seem to be feasible.
AAV-vectored antigen expression mitigates antibody immunodominance 
In the third study in mice, AAV-HA, AAV-cHA and AAV-NP induced high homologous 
antibody titers after i.n. immunization. Also, variability among animals from each immunization 
group could be minimized (data not shown), which was either related to the higher quality of the 
AAV-vector preparations used for this study, or was a consequence of the i.n. immunization itself, 
which enabled a more controlled administration and uptake of the vaccine. During the third 
study, AAV-vectored vaccines were also for the first time compared to i.n. immunization with 
WIV. 
Although high titers of AAV9-specific neutralizing serum antibodies were induced, a strong 
increase of homologous Cal/7/9-specific antibody titers over the complete immunization period 
was seen, especially with AAV-HA vaccination. Notably, AAV-HA immunization rather led to a 
constant Cal/7/9-specific antibody titer increase over the immunization period, whereas no clear 
boosting effect of immunizations #2 and #3 was seen. Thus, it remains elusive whether the second 
and third immunization were required, or whether a single immunization would have sufficed to 
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induce protective influenza-specific antibody titers with AAV-HA. As vaccination with the cHA is 
commonly done with a sequential regimen comprising three immunizations (274, 275, 278), 
AAV-HA was applied three times to allow for direct comparison with the AAV-cHA vaccine. 
Therefore, the option of a ‘one-shot’ vaccine has not been evaluated yet, and requires further 
investigation. As mentioned above, studies regarding the minimum required number of AAV-
vectored cHA to induce broadly reactive HA-stalk antibodies would also be informative. Due to 
the long-lasting AAV-vector-mediated transgene expression, a vaccine requiring only one 
immunization seems feasible and would be most convenient regarding implementation in 
humans as well (332). 
Interestingly, in the third study in mice, i.n. immunization with AAV-HA induced broadly 
reactive antibodies against several group 1 influenza A viruses, including the 1918 pandemic 
H1N1 and H5N1. As mentioned above, this was not the case after i.m. vaccination in the first 
immunogenicity study. Compared to the i.m. or parenteral administration route, mucosal 
immunization has been shown before to induce more broadly reactive antibodies also after 
immunization with inactivated or live attenuated vaccines (166, 405). 
As expected, AAV-HA induced MNpos and HAIpos antibodies, which were, however, Cal/7/9-
specific and did not bind to the PR8 HA. The amino acid sequence of the PR8 and Cal/7/9 HA1 
subunits are only distantly related and diverge from each other by about 25 %. Also, IgA 
antibodies triggered by AAV-HA immunization were Cal/7/9-specific. IgA antibodies were shown 
to play an important role during protection from influenza virus infection due to their high local 
abundance within the respiratory tract (125). Notably, serum IgA was measured, which can 
however serve as surrogate for mucosal IgA, the 
concentration of which might even be higher in the lung 
compared to the serum (125). However, antibody 
responses against PR8 lacked detectable amounts of IgA, 
indicating that broadly reactive antibodies against this and 
likely other viruses rather belong to other Ig isotypes, such 
as IgG. 
HA conformational change ELISA indicated that 
binding of AAV-HA induced sera to the homologous 
Cal/7/9 virus was largely mediated by HA-head antibodies, 
as removal of the Cal/7/9 HA1 subunit by DTT treatment 
led to an almost complete loss of reactivity. However, 
AAV-HA induced sera also appeared to contain a large 
proportion of broadly reactive antibodies towards the HA-
stalk, as removal of the PR8 HA1 subunit would not lead 
to a loss of reactivity. This finding was somewhat 
surprising, since the induction of antibodies against the 
HA-stalk domain was only expected for immunization 
with cHA. In fact, immunization with AAV-cHA triggered 
Figure 33: Footprints of well 
characterized broadly reactive 
antibodies overlap with epitopes 
recognized by AAV-HA induced 
antibodies 
Peptides identified in the peptide screen 
with AAV-HA induced serum were 
mapped on the 3D-structure of HA as in 
Figure 24E. Additionally, structures of 
broadly reactive antibodies S-139 (PDB: 
4GMS), CR8071 (PDB: 4FQJ) and C179 
(PDB: 4HLZ) were aligned to the HA 
structure. 
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high levels of HA-stalk antibodies, which recapitulated findings from other studies using cHA 
protein antigens (274, 275). 
Unlike C179, AAV-HA induced antibodies also strongly bound to PR8 HA at post fusion pH. 
Judged by the three-dimensional structures of the pre- and post-fusion HA, the conformation of 
some of the epitopes identified in the peptide screen (peptide #39, #41, #48) with AAV-HA 
induced sera seems to be largely maintained upon conformational changes of the HA-stalk. 
Though located in close proximity, the C179 epitope, i.e. the N-terminal part of a short-alpha 
helix in the HA-stalk extending to the fusion peptide, is completely restructured upon 
conformational change, which might explain the difference seen for C179 and the AAV-HA 
induced antibodies (194). The presence of both strain-specific antibodies against the HA-head and 
broadly reactive HA-stalk antibodies could also be confirmed with the immunoblot analysis. Here, 
AAV-HA induced sera could detect HA1 and HA2 subunit of two closely related H1N1 viruses, 
whereas binding to the more distantly related H1N1 viruses, such as PR8, was mediated by HA2 
antibodies. Furthermore, the peptide screen revealed that AAV-HA induced antibodies not only 
bind to residues in HA1, e.g. the RBS (positions 168-182), but also to the lateral part of the HA-
head domain (positions 308-322), and the membrane proximal part of the stalk domain (positions 
389-412 and 418-432), thus including amino acid residues in HA1 and HA2. Moreover, the
identified sites were in close proximity or overlapped with the footprints of well described broadly
reactive HA-specific antibodies against the head and the stalk, such as S-139 (RBS) (204), CR8071
(lateral head) (202), or C179 (membrane proximal stalk) (194) (Figure 33).
Interestingly, the above mentioned results indicated that AAV-HA induced sera contain non-
conformational stalk antibodies, which were able to bind to denatured antigen in conformational 
change ELISA and immunoblot analysis or to peptides. Results from in-cell ELISA, however, 
indicated that AAV-HA induced sera also contain a substantial proportion of conformational 
HA-stalk antibodies. Here, AAV-HA induced antibodies behaved comparable to the prototypic 
conformational HA-stalk antibody C179, and bound HA-stalk constructs only when they 
displayed the correctly folded C179 epitope. Interestingly, the difference in reactivity between 
AAV-HA and AAV-cHA induced sera towards the natively folded antigen as measured by in-cell 
ELISA was not as pronounced as against the denatured antigen in the immunoblot analysis, which 
further supports the idea that AAV-HA sera contain a considerable proportion of conformational 
HA-stalk antibodies, whereas AAV-cHA induced antibodies seemed to be largely non-
conformational (see below). Further experiments assessing the prevalence of different antibody 
specificities after AAV-HA immunization in more detail (e.g. on a monoclonal antibody or B-cell 
level) would be highly informative. 
The HA-stalk antibodies induced by AAV-cHA and AAV-HA showed quite different binding 
characteristics. Unlike AAV-HA, AAV-cHA induced antibodies bound the HA-stalk irrespective 
of the presence or absence of the correctly folded C179-epitope in the in-cell ELISA. Also, AAV-
cHA induced antibodies showed stronger binding to denatured antigen in the immunoblot 
analysis compared to AAV-HA. Possibly, the at least partially misfolded conformation of the HA-
stalk of cHA1 and cHA2, which were used for immunization #2 and #3, influenced the antibody 
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response and led to these findings. Intriguingly, these antibodies bound even stronger to the post 
fusion HA conformation at low pH in the conformational change ELISA. Cryo-electron 
microscopy structures of a representative chimeric HA (H5 head – H1 stalk) revealed that it 
adopts a more open HA-head and a tilted stalk domain configuration (406). The authors argued 
that the functionality of the cHA is unaltered by this non-naturally occurring conformation (406). 
However, this might as well change immunogenicity of the antigen, since otherwise buried 
epitopes within the HA-stalk could become more recognizable by the immune system. In fact, 
antibodies could be detected in AAV-cHA induced sera, which showed a trend towards increased 
binding to a peptide (#44) which is located at the inside of the trimeric HA-stalk. Thus, also the 
cHA used in this thesis might exhibit a more open conformation influencing the immune 
response. Although the AAV-cHA induced antibodies bind the post fusion conformation of HA 
the extent of their contribution to protection is questionable, since the post-fusion conformation 
of HA is present only during late attachment steps in the acidified endosome. Unfortunately, the 
epitope screen did not reveal further significantly binding peptides with AAV-cHA and WIV 
induced sera. In contrast to AAV-HA, AAV-cHA and WIV immunization induced lower 
antibody titers against Cal/7/9. These might have been too low to detect significant binders with 
the screening protocol used here.  
AAV-cHA induced MNpos and HAIpos antibodies, which were specific for the head of the H13 
HA which was included in cHA3 and thus used for prime immunization of these animals. The 
lack of MNpos and HAIpos antibodies against other influenza viruses, including the parental viruses 
of the cHA which were used for immunization #2 and #3, recapitulates findings from other 
studies (278) and is in accordance with the hypothesized mode of action of the cHA: Upon 
sequential immunization with different cHA, re-focusing of the immune-response from dominant 
neutralizing epitopes in the HA-head to non-neutralizing epitopes in the stalk occurs (278). 
Although in the challenge studies described in this thesis the neutralizing antibodies against the 
‘irrelevant’ exotic H13 HA-head did likely not provide protection against the infection with H1N1 
viruses, they might become advantageous in a real-world setting when the head region of the cHA 
happens to match the HA of a newly emerging virus. The cHA-head used for vaccination would 
then have to be chosen appropriately to match for instance strains with high zoonotic potential, 
e.g. H5N1. 
In conclusion, AAV-vectored immunization seemed to mitigate the immunodominance of 
variable epitopes in the HA-head, allowing induction of antibodies against subdominant epitopes 
as well. Hence, not only AAV-vectored vaccination with a sequence of cHA could induce HA-
stalk antibodies, but also immunization with wildtype HA. Important factors leading to this effect 
were most likely continuous generation of antigen by respiratory cells after mucosal 
immunization, and the lung-specific environment, which influences processing and presentation 
of antigen to cells of the adaptive immune system. This possibly resulted in more effective priming 
of rare B-cells recognizing conserved epitopes in the HA-stalk. Further experiments for example 
comparing different administration routes (i.n. versus i.m.) and antigen forms (AAV-vectored 
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versus protein antigen) will be required to evaluate the exact reason for the mitigation of the 
immunodominance. 
Both AAV-HA and AAV-cHA induced antibody responses were restricted in their reactivity to 
group 1 influenza A viruses. This restriction seems to represent a major hurdle for the 
development of a universal influenza vaccine and has thus been reported in several studies before 
(268, 274). Eventually, further studies need to be conducted to expand protection to both 
antigenic groups, for example by the inclusion of another vaccine component from antigenic 
group 2, such as H3, or use of an inter-group-stalk consensus construct. 
Unexpectedly, also WIV vaccination induced HA-stalk antibodies, which showed 
exceptionally broad reactivity against all tested influenza A viruses. WIV-induced sera, however, 
appeared completely negative in the MN and HAI assays. Product batch-specific difference in the 
HA1 and HA2 content of the inactivated virus preparation could account for the peculiar breadth 
and specificity of the immune response (192), though the batch’s HA content, i.e. HA1 and HA2, 
was analyzed and confirmed by the supplier, i.e. the NIBSC. Thus, this seems rather unlikely. 
However, it was shown that the i.n. route in contrast to parenteral vaccination is able to induce a 
broadened immunity, which might also have been the case here (405). Interestingly, the binding 
of WIV induced antibodies was independent of the conformation of the HA-stalk in the 
immunoblot analysis and independent of the pH-induced conformational changes in ELISA. 
However, in the in-cell ELISA binding to the extensively truncated mHL1 was completely absent. 
This indicates that the dominant epitope recognized by WIV induced antibodies is likely located 
in the upper part of the HA (-stalk). 
Finally, AAV-NP induced a remarkably potent broadly reactive antibody response covering all 
tested virus from both antigenic groups of influenza A viruses. This reactivity breadth is most 
likely associated with the high conservation of the NP proteins of the tested viruses. In contrast to 
AAV-HA and AAV-cHA, this response included broadly reactive IgA. However, rather than 
being specifically induced to higher relative amounts by AAV-NP immunization, the higher levels 
of PR8-specific IgA most likely resulted from higher absolute overall serum antibody levels against 
PR8 in these animals. There is increasing evidence that NP-specific antibodies play an important 
role during protection from unmatched influenza viruses (143, 233). Since NP is the major 
stimulus for the induction of protective CTL responses, NP-specific T-cells likely play a major role 
during protection as well (362, 371). These were not analyzed in this project since the main focus 
was on HA-mediated immunity, which is mainly mediated by humoral immune responses. 
Notably, a similar project performed at the Robert Koch Institute focused on AAV-NP-induced 
cellular immunity (371). In the respective study, however, though strong NP-specific CTL 
responses could be measured in AAV-NP immunized mice, cell mediated immunity was not able 
to protect against heterologous challenge with a PR8 virus. In fact, the CTL were unable to 
efficiently execute cytotoxic effector functions in vivo (371). This might have resulted from a ca. 
10-fold lower dose of AAV-vector or the i.m. route which was used for immunization (371),
which was in this thesis shown to result in weaker immune responses compared to i.n.
immunization. Further studies including measurement of AAV-NP induced cell mediated
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immunity in the context of broad protection will be required to analyze the impact of antibody 
mediated versus cell mediated immunity against the internal viral NP.  
AAV-HA, AAV-cHA and AAV-NP mediated protection is associated with increased capacity to induce 
FcγR-activating antibodies 
Several studies described that non-neutralizing antibodies confer protection via interference 
with later steps of the viral life cycle. These include inhibition of the conformational changes of 
HA, which are required for fusion of the viral and cellular membrane, or prevention of release of 
progeny virus from infected cells (208, 223, 224, 229). The MN-assay which was performed herein 
not only allowed for measurement of inhibitory effects on attachment and/or fusion, but also on 
release and maturation of the virions, since serum was constantly present throughout multicycle 
replication of the virus (375). However, no influence on infectivity of the viruses or interference 
with their release into the supernatant (data not shown) by cross-reactive antibodies could be 
found in AAV-vector immunized animals. Though the polyclonality of the mouse sera might 
conceal effects of some minor antibody specificities, it appears that inhibition of steps in the viral 
replicative cycle thus seems not to account for broad protection seen with the AAV-vectored 
vaccines. 
Activation of FcγR by broadly reactive antibodies was shown to play an important role for 
protection in the mouse model (201, 222). The presence of FcγR- or ADCC-activating antibodies 
has also been shown in humans (213, 407). Furthermore, these human antibodies conferred 
protection after passive serum transfer into mice (408). Although there is growing evidence that 
high ADCC-activating antibody titers are associated with low viral replication and less severe 
disease, pre-existing immunity in humans hampers research, which could ultimately prove 
functionality and relevance of FcγR-activating antibody-mediated protection (218, 232, 409). 
ADCC-activating antibodies are induced early in life, and their titers increase over a lifetime (213, 
410, 411). In fact, repetitive natural infection and vaccination with inactivated vaccine was shown 
to boost ADCC-activating antibodies in children and adults (218-221, 411-414). However, an 
inactivated vaccine failed to induce ADCC-activating antibodies in influenza-naïve macaques 
(216). Only infection with influenza virus mounted ADCC-activating antibodies in these animals 
(216). Also, H7N9 LAIV vaccination of H7N9-HAIneg human subjects did not mount detectable 
ADCC-activating antibodies levels until subjects received a booster vaccination with inactivated 
vaccine (221), while children receiving booster vaccination with LAIV after LAIV priming did not 
mount ADCC-activating antibodies (218). The authors argue that the latter finding might be due 
to suboptimal antigen production by LAIV in the respective study (218). This indicates that 
broadly reactive FcγR-activating antibodies are not readily induced in humans by currently 
licensed vaccines, but seem to require innovative vaccine approaches including adjuvants, 
heterologous prime-boost regimens, or viral vector-vaccines (415). 
Here, a recently developed reporter assay was used which allows for the measurement of 
influenza virus-specific activation of each of the four murine type I FcγR (I to IV) by serum from 
AAV-vector or WIV vaccinated mice (225). Interestingly, AAV-HA, AAV-cHA and AAV-NP 
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vaccination induced high Cal/7/9-specific FcγR-activating antibody titers, while WIV vaccination 
only induced marginal reactivity. Even more striking, PR8-specific FcγR-activation was not 
detected in WIV-induced sera. In contrast, AAV-HA, AAV-cHA and AAV-NP vaccination 
induced broadly reactive FcγR-activating antibodies against PR8. Notably, this was not due to the 
lack of binding antibodies in the WIV immunization group, as all vaccines induced high titers of 
Cal/7/9- and PR8-specific antibodies. Potent activation of FcγR and requirement on the FcγR-
activated effector mechanisms to mediate protection was in particular shown for broadly reactive 
antibodies against the HA-stalk (222). Interestingly, in contrast to the HA-stalk antibodies 
induced by AAV-HA and AAV-cHA immunization, stalk antibodies induced by WIV could not 
potently activate FcγR. As mentioned above, the failure of inactivated vaccine to induce ADCC-
activating antibodies has been shown before in macaques while only influenza virus infection 
could induce/boost a functional antibody response in this study (216). Thus, the AAV-vectored 
vaccines seem to be able to activated cognate antigen processing pathways, which would also 
become active during natural infection and, thus, induce and boost superior functional FcγR-
activating antibody response compared to WIV. 
Activating and inhibitory type I FcγR are (co-)expressed on most immune cell types (120). 
Thus, the response of a particular cell is modulated depending on the relative abundance of each 
receptor (416). Also, relative abundance of antibodies activating one particular FcγR influences 
regulation of the immune response (120). With AAV-HA and AAV-cHA induced sera, however, 
only modest differences were apparent with respect to the activation of the individual four murine 
FcγR: FcγRIIB seemed to be less strongly activated by Cal/7/9-specific antibodies in the sera of 
AAV-HA and AAV-cHA immunized mice, and FcγRIV less strongly by PR8-specific antibodies 
compared to the respective other receptors. The induction of such a potent homologous and 
heterologous FcγR-activating antibody response by AAV-NP was unexpected. In fact, AAV-NP 
was the only vaccine which also showed a protective effect towards the heterosubtypic X31, which 
might also be conferred by FcγR-activating antibodies. Notably, the internal viral protein NP 
seems to be expressed also on the surface of cells (114, 234). Furthermore, an AAV-NP transduced 
293T cell culture released NP into the cell culture supernatant (data not shown), increasing the 
likelihood for interaction of the antibody molecule with the otherwise internal viral protein. In 
humans, broadly reactive NP-specific antibodies were shown to mediate protection via ADCC 
(233, 417). Aside from activation of ADCC, NP-specific FcγR-activating antibodies might also be 
involved in regulation of the immune response, as the inhibitory FcγRIIB seems to be more 
potently activated by AAV-NP induced sera compared to other vaccines (against Cal/7/9) or FcγR 
(against PR8). Activation of FcγRIIB can for example regulate the B-cell repertoire and lead to 
survival of higher affinity B-cells (135). However, as mentioned above, the true impact of FcγR-
mediated protection and the underlying effector mechanisms, as well as the influence of T-cell-
mediated immunity on protection needs to be defined in more detail in additional studies in 
immunocompromised FcyR-KO (e.g. Fcer1g KO mouse) or CTL-deficient (e.g. CD8 KO mouse) 
mice. In addition, further experiments in FcγR-class-specific KO mice (e.g. FcgγRIIb– mouse) 
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could reveal the influence of the slightly differential activation of the individual FcγR by AAV-HA, 
AAV-cHA and AAV-NP vaccines on regulation of the immune response. 
AAV-cHA seemed to induce lower FcγR-activating titers compared to AAV-HA. In AAV-HA 
immunized mice, the higher amount of total antibodies against Cal/7/9 might as well include a 
higher absolute amount of FcγR-activating antibodies against this virus. In fact, Cal/7/9-specific 
total and FcγR-activating antibody titers in the vaccine groups were proportional to each other. 
Against PR8, however, AAV-HA immunization also induced slightly higher titers of FcγR-
activating antibodies, though less total antibody titers were induced compared to AAV-cHA. 
Thus, AAV-HA immunization seems to induce a greater fraction of FcγR-activating antibodies. 
Amount of antigen, as well as conformation of the HA-stalk was shown to influence the induction 
of broadly reactive antibodies (297, 298). Since AAV-HA is expressed to high amounts and 
displays the native HA conformation, this might positively influence the functional antibody 
response. Besides FcγR-activating antibodies against the HA-stalk, also broadly reactive non-RBS 
binding antibodies against the head were shown to activate FcγR (223). These might complement 
the potency of FcγR-activation of the HA-stalk antibodies, resulting in increased overall FcγR-
activation. In fact, by measuring the induction of FcγR by antibodies which bind either to the 
complete HA or a truncated stalk-only construct, it could be shown that AAV-HA but not AAV-
cHA induced FcγR-activating antibodies against epitopes present only in the context of the full 
length HA, such as the HA-head. Data obtained with the peptide screen suggested that these 
antibodies bind to the epitope at the lateral side of HA-head, which includes amino acid in HA1 
(positions 308-322), and HA2 (positions 389-412 and 418-432). As the cHA contain exotic HA-
head domains, the immune responses evoked by AAV-cHA immunization will likely lack 
antibodies against these epitopes in the H1 HA-head domain. Thus, with respect to the potent 
induction of FcγR-activating antibodies against H1N1 viruses, AAV-HA seems to be 
advantageous over AAV-cHA. 
During homologous challenge infection with Cal/7/9, sterile immunity was achieved in AAV-
HA immunized mice, which was most likely mediated by neutralizing antibodies against this 
virus. The absence of neutralizing antibodies in AAV-cHA and WIV immunized mice suggests 
that FcγR-activating antibodies accounted for the observed partial homologous protection, given 
that the relatively low titers of FcγR-activating antibodies in WIV immunized mice were high 
enough to mediate protection. In fact, already low concentrations of FcγR-activating antibodies 
can confer protection (222). AAV-NP immunized mice, which also lacked neutralizing antibodies, 
might as well be protected through FcγR-mediated effector mechanisms. However, T-cell 
mediated effector mechanisms likely also play a role during homologues protection (362, 371). 
Further experiments in immuno-compromised mice (B-cell (e.g. muMt– mouse) or CTL-deficient 
(e.g. CD8 KO mouse)) could, therefore, help to unravel the involved arms of the immune 
response and mediators of protection. 
During heterologous challenge infection with PR8, high FcγR-activating antibody titers in 
AAV-HA, AAV-cHA and AAV-NP immunized mice were associated with increased survival 
and/or less severe weight loss. As mentioned above, in another study T-cells induced by AAV-NP 
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immunization were shown to be non-functional in vivo against PR8 infection, suggesting that 
FcγR-mediated effector mechanisms could account for the AAV-NP-mediated heterologous 
protection seen in this thesis (371). Notably, in the respective study different immunization 
conditions were used, which might limit comparability to the results described in this thesis. WIV 
immunized animals lacking broadly reactive FcγR-activating antibodies were not protected 
against heterologous challenge. Protection of the AAV-vector immunized groups was associated 
with clearance of virus in the lung at the end of the challenge period (day 14). Although initial 
infection of the respiratory tissue could not be prevented due to the absence of pre-existing 
neutralizing antibodies, FcγR-mediated effector mechanism seem to become active later on, which 
eventually mediate clearance of the virus infection. 
Induction of antibody-dependent enhancement of disease (ADE) during infection with several 
viruses including influenza virus has been shown (238, 239). Hereby, concomitant binding of a 
non-neutralizing antibody to the virus and the FcγR may result in enhanced uptake of viruses into 
the FcγR bearing cells and thus increased replication (238, 239). However, no signs for ADE were 
apparent in any of the AAV-vector immunized mice. 
Jegaskanda et al. illustrated the putative role of neutralizing and non-neutralizing but FcγR-
activating antibodies as shown in Figure 34 (418). According to this, in case of infection with a 
matched influenza virus, neutralizing antibodies can confer sterile immunity and prevent 
infection completely. 
Figure 34: Protection against homologous and drifted influenza virus strains is conferred by neutralizing and non-
neutralizing antibodies 
In case of an infection with homologous influenza virus, matched neutralizing and HAIpos antibodies (blue) confer 
sterile immunity and prevent infection (blue cells). Non-neutralizing antibodies (green) presumably play a minor role 
during infection with homologous viruses. Strain-specific, neutralizing antibodies are limited with respect to their 
binding breadth, and might not completely prevent infection with a drifted virus variant. However, broadly reactive, 
non-neutralizing antibodies help to rapidly limit and clear infection through activation of FcγR-mediated 
mechanisms, such as ADCC, thereby reducing disease severity (light red cells). Without any antibody, no control and 
clearance of virus infection can of course be mediated (dark red cells). (adapted from Jegaskanda et al., Hum Vacc 
Immunother (2017)) 
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However, with increased antigenic distance to the homologous strain, protection is mediated 
by broadly-reactive, non-neutralizing antibodies which are able to activate FcγR (418). In 
conclusion, the aforementioned findings indicate that AAV-HA is able to induce both 
neutralizing antibodies that confer sterile immunity against a homologous strain, and broadly 
protective antibodies against heterologous viruses, which confer protection via FcγR-mediated 
effector functions.  
In conclusion, AAV-vectored vaccines, particularly AAV-HA and AAV-NP, induced and 
boosted superior FcγR-activating antibody responses compared to WIV, which were associated 
with homologous and heterologous protection. Thus, AAV-vectors could potentially be used in 
humans as stand-alone vaccine to induce, boost, and maintain robust broadly protective 
functional antibody responses. In this respect, and as criteria set by health authorities require the 
protection of a universal vaccine to last for a minimum of one year (Figure 31), longevity of AAV-
vector vaccine induced immunity is of high importance and should be assessed in follow-up 
studies. Furthermore, AAV-vector vaccines could also act as primer-vaccine to induce broad basal 
immunity, which could be expanded in case of an unforeseen pandemic by, for example, 
immunization with a non-perfectly matching inactivated vaccine. This would help to bridge time 
until better matched vaccines are available. However, the interplay of AAV-vector and inactivated 
vaccine has not yet been analyzed, and further experiments are required to gain understanding of 
the requirements for optimal induction of a broadly protective immune response. 
AAV-HA and AAV-cHA show a protective effect in ferrets 
Since the first isolation of influenza A virus, ferrets have represented the gold-standard animal 
model for influenza in humans (152). The main reasons for this are their natural susceptibility to 
most human influenza viruses and the close resemblance of human influenza in ferrets (385). 
Hence, while focusing on HA-mediated immunity, the protective efficacy of i.n. immunization 
with AAV-HA and AAV-cHA was evaluated in ferrets, and compared to i.m. immunization with 
human QIV of the season 2017/18. The latter represents the vaccination recommendation for 
influenza virus naïve individuals by the STIKO (160). 
Interestingly, during the complete immunization period, some of the ferrets receiving AAV-
HA and AAV-cHA remained AAV9 sero-negative, although all of these animals developed 
Cal/7/9-specific total antibody titers. Several factors might influence the extent of immunity 
against the AAV-vector capsid including route of administration, vector purity, vector dose, and 
AAV serotype, as well as peculiarities of the transgene. Unfortunately, data from another ferret 
study using AAV9 did not include information about capsid-specific antibodies (366). It is, 
however, unlikely that AAV9-specific antibody titers were below the detection limit of the ELISA 
(i.e. a serum dilution of 1:100), since administration of AAV-vectors usually readily induces 
relatively high titers of AAV-specific antibodies in mice and larger animals including humans 
(359). Thus, reason and relevance of this finding remain elusive.  
Most likely due to the strong and long-lasting transgene expression, immunization with AAV-
HA led to a stronger induction of antibody titers against Cal/7/9 compared to immunization with 
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QIV. As for results obtained in the mouse studies, it would be highly interesting to investigate in 
ferrets whether even a single immunization with AAV-HA would have sufficed to induce 
protective antibody titers. In congruence with results obtained in mice, only AAV-HA but not 
AAV-cHA induced MNpos and HAIpos antibodies against Cal/7/9. Unexpectedly, QIV induced 
total antibodies but no neutralizing antibodies. However, this has also been observed in other 
ferret studies, indicating that the human vaccine has a rather low immunogenicity in these 
animals (281). 
AAV-HA immunized ferrets were partially protected against signs of disease and showed less 
virus replication in the respiratory tract compared to the other groups. Moreover, MNpos antibody 
titers correlated inversely with virus titers in nasal turbinates, suggesting that robust local 
protective immunity was induced at the side of administration of the AAV-HA vector. In fact, the 
highest expression of transgene was shown directly at the site of administration of AAV-vectors 
expressing reporter genes in the nostrils of ferrets (366). Since the nasal mucosa is the first site in 
contact with intruding respiratory pathogens, the establishment of local immunity by direct 
targeting of the antigen to the mucosa could enhance the protective efficacy of a vaccine (419). 
Notably, viral titers in trachea and lung of AAV-HA immunized animals were also reduced 
compared to the other groups, but did not differ enough from each other within the AAV-HA 
group to reveal any correlation with MNpos antibody titers. 
The induction of bronchus-associated lymphoid tissue (BALT) has been implicated in the 
initiation and maintenance of an adaptive mucosal immune response (390, 420). Viral infection-
induced BALT was also shown in ferrets challenged with A/Mexico/InDRE4487/2009 
(H1N1)pdm at seven days post infection, and even earlier post infection in mice (three days) (421, 
422). However, the lack of BALT in AAV-GFP immunized ferrets indicates that its formation in 
the other vaccine groups is rather associated with the immunization and not a consequence of the 
challenge infection itself. The induction of BALT was shown after intranasal and intravenous 
immunization with inactivated vaccine (389, 423). In the ferret study described in this thesis, it 
appears that also i.m. immunization with QIV could induce BALT. Interestingly, less distinct 
formation of BALT was seen in AAV-HA compared to AAV-cHA and QIV immunized ferrets. 
Influenza virus infection was shown to result in enlargement of pre-existing BALT structures 
(424). The lower virus load, which was associated with the presence of neutralizing antibodies in 
AAV-HA immunized ferrets, might have led to a less pronounced stimulation of immune cells 
migrating into BALT and, thus, less enlarged BALT structures. This might, however, be an 
advantage, since less marked influx of immune cells might also diminish the risk for tissue damage 
in AAV-HA immunized animals (425). Further analyses of the immunological mechanisms 
involved in establishment of AAV-vector induced influenza immunity in ferrets will be required. 
AAV-cHA immunized ferrets were partially protected against signs of disease but did not show 
reduced viral replication in the respiratory tract. Most likely other protective mechanisms apart 
from neutralization, such as FcγR-mediated effector mechanisms, account for the observed 
symptomatic protection. Unfortunately, measurement of FcγR-activating antibodies in ferret sera 
was not possible with the murine FcγR-receptor reporter assay (data not shown). However, it was 
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shown that a human-specific FcγRIV assay shows some cross-reactivity with ferret sera, which 
would allow at least an approximation of the amount of FcγR-activating antibodies (278). The 
impact of FcγR-receptor mediated immunity for protection in the ferret model needs to be 
addressed in further studies. 
Unexpectedly, QIV immunized animals were not protected against disease and developed 
symptoms comparable to the AAV-GFP immunized negative control group. As the time interval 
between vaccination and challenge could influence the protective efficacy of a vaccine, it might be 
argued that vaccination with QIV closer to the time point of challenge infection would have 
induced a more effective protection. However, also vaccination with TIV four weeks (and not 
eight weeks as in the study presented in this thesis) in advance to challenge infection did not 
provide protection in another study, in which inactivated vaccine also showed low efficacy (281). 
Therefore, timing might not be as relevant, but a low immunogenicity of the inactivated vaccine in 
ferrets seems to account for the low efficacy. 
A more widespread infection also to the lower respiratory tract was shown for (H1N1)pdm 
virus compared to seasonal strains, which are normally restricted to infection of the upper 
respiratory tract and the trachea (387, 426). Unexpectedly, AAV-GFP immunized animals seemed 
to be free from influenza replication in the lung as indicated by immunohistochemistry (IHC). 
Notably, this not necessarily contradicts findings from the virus titration of lung homogenates, in 
which AAV-GFP immunized ferrets shows comparably high virus titers as AAV-cHA and QIV 
immunized animals. As homogenates contain lung lobes as well as bronchi, this might conceal a 
more distinct spatial distribution of virus replication within the respective tissue compartments, 
which can only be resolved with IHC. In fact, the overall IHC-score of the lungs reflected data of 
the homogenate virus titration quite well (not shown). Infection of the lower respiratory tract was 
shown to result in more severe disease (426). The presence of neutralizing antibodies against 
(H1N1)pdm in AAV-HA immunized animals likely led to the reduction of virus replication in the 
complete respiratory tract, which ameliorated inflammation and severity of disease in these 
animals. In AAV-GFP immunized animals, however, virus apparently did just not reach the 
alveoli and, therefore, did not cause as severe alveolar damage as in the AAV-cHA and QIV 
immunized groups. This might also explain why AAV-GFP immunized animals lost least weight. 
Correspondingly, also no hyperplasia of type II pneumocytes was seen in AAV-GFP immunized 
mice. Nevertheless, AAV-GFP immunized animals showed a more severe infection and 
inflammation of the upper respiratory tract compared to the other vaccine groups, and these 
animals were not symptomatically protected. It can only be speculated on the reason for this 
phenomenon, but it was shown that immune pressure, imposed for instance by the presence of 
antibodies in the upper respiratory tract, can force a change of tropism of the virus, which might 
have occurred here (427). However, variability introduced by the low animal number, 
experimental variance and the outbred genetic background of the ferrets might also account for 
some differences. Thus, further experiments will be required to define the exact mechanism 
behind and the relevance of this phenomenon. 
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Interestingly, AAV-cHA immunized ferrets seemed to show slightly increased tissue 
inflammation. Non-neutralizing antibodies have been shown to occasionally enhance virus uptake 
and disease (235, 238, 239). This effect could have also played a role in the study described here. 
However, due to the low number of animals and the high variability associated with the 
outbreeding of the ferrets, it might be premature to speak of antibody-dependent enhancement of 
disease. As mentioned above, such an effect has not been observed with AAV-cHA in mice. This 
has, however, to be considered cautiously and requires further attention.  
Nevertheless, a protective effect of AAV-HA and AAV-cHA was demonstrated for the first time 
in a sub-lethal ferret infection model. However, only AAV-HA immunized ferrets showed 
reduced virus replication and tissue damage. Symptomatic protection would already have a huge 
impact on public health, since most influenza infections progress without need for medical 
attendance or even hospitalization, which is, however, causing high costs for health systems, too 
(190). Further experiments in ferrets are warranted to explore the protective efficacy of AAV-
vectored vaccines against heterologous virus infections. 
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Perspective 
AAV-vectors expressing influenza virus antigens were shown in this thesis to induce superior 
broadly protective immunity in mice compared to an inactivated vaccine. The protective 
mechanism likely includes the activation of FcγR-mediated cytotoxic or regulatory effector 
functions. Interestingly, vaccination with AAV-vectors appears to mitigate the 
immunodominance of virus-specific epitopes in the HA-head, focusing the immune response to 
epitopes within the conserved HA-stalk. Furthermore, for the first time an active AAV-vectored 
vaccine was shown to be protective in ferrets against homologous challenge in direct comparison 
to the gold-standard human inactivated vaccine, which had little to no effect. 
As discussed above, further studies will be required to further develop the AAV-vectors as 
carriers for broadly reactive influence vaccines according to the criteria set up by health 
authorities (Figure 31). The 75 % efficacy criterion against symptomatic influenza could already 
be met. Further studies should include on the one hand the assessment of the exact mechanisms 
by which AAV-vectored vaccines mediate protection, which likely includes FcγR-activated 
mechanisms. On the other hand further immunization regimens should be assessed to extent the 
protective breadth to both antigenic groups of influenza a viruses. This could be achieved by 
combination of different AAV-vectored HA components (e.g. H1 and H3), or by combination of 
these with AAV-NP. Furthermore, also evaluation of AAV-vectored expression of other 
promising broadly reactive antigen candidates such as the viral neuraminidase would be highly 
interesting.  
Due to the aforementioned advantageous of AAV-vectors, including their excellent safety 
profile, their licensure for use in humans and clinical grade manufacturability, AAV-vectors 
belong to the best suited candidates among viral vectors for clinical evaluation as influenza 
vaccine carriers. Taken together, findings from both animal models justify progression to clinical 
evaluation of the AAV-vectored vaccine, in particular of the most promising candidates AAV-HA 
and AAV-NP. Thus, AAV-vectors might eventually be useable in a naïve human population to 
efficiently prime a broadly reactive immunity, or to boost and maintain such a response in 
influenza experienced individuals. Influenza remains to be a disease with extreme impact on 
public health, not least due to the low efficacy of current vaccines. In this thesis, the beneficial 
influence of AAV-vectors on the immunogenicity of influenza virus antigens could be 
demonstrated, which might help to develop a more effective and broadly reactive influenza 
vaccine. 
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